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Abstract 
 
Photobiomodulation refers to low-intensity light therapy (LILT) in the far-red to 
near-infrared (IR) region of the spectrum (630-1000nm). A peak wavelength, 
1072nm (IR1072), in the IR transmission spectrum has been previously 
shown to have protective effects against UVA toxicity in human lymphocytes 
and beneficial effects on working memory in IR-treated 12 month old CD-1 
mice. The aim of this investigation was to establish the beneficial effects of 
IR1072 in the murine mammalian CNS utilising a range of in vivo and in vitro 
model systems. Acute treatment of primary rat neuronal cultures with IR1072 
endowed an insult severity-dependent protective effect; the less severe the 
insult the more profound the protection. An age-dependent (3 month to 12 
month) reduction in brain derived neurotrophic factor (BDNF) and heat shock 
protein HSP27, and HSP40 and HSP90 was observed in both CD-1 and 
TASTPM Alzheimer disease mice, which may underlie the severe learning 
deficits seen in these mice. Acute whole body treatments of CD-1 mice in vivo 
comprising ten consecutive daily 6 minute sessions of IR1072 elicited 
increased mitochondrial complex II enzyme activity. Long-term chronic in vivo 
IR1072 treatments in CD-1 mice, consisting of biweekly 6 minutes sessions 
spanning a 5 month period, increased expression of selective HSPs, notably 
HSP27 in cortical and hippocampal regions. Following chronic IR1072 
treatment, a profound reduction of AMPA receptor binding sites in CD-1 mice, 
and reduced total Aβ1-42 expression and small amyloid plaque counts (in 
cortex and dentate gyrus) in TASTPM mice, was observed. Overall, this thesis 
reveals new mechanisms of photobiomodulation with IR1072 which involves 
restoring cellular homeostasis for optimal functional operation of a neuron.  
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Chapter 1: Literature Review and aims 
 
 
1.1 Photobiomodulation 
 
 
1.1.1 EM spectrum 
 
Electromagnetic (EM) waves are photons of light that exhibit electrical and 
magnetic properties that vibrate at different rates resulting in differing photon 
energy and wavelengths (Enwemeka, 2004). The EM spectrum includes radio 
waves, infrared (IR) radiation, visible light, ultraviolet rays, x-rays, gamma 
rays, and cosmic radiation.  
 
 
Figure 1-1: Electromagnetic spectrum of light. Abbreviations: UV, Ultraviolet. 
 
As photons of differing regions in the EM spectrum possess varying energy 
and wavelengths, they have been shown to produce varying effects in cells 
e.g. Gamma rays, X-rays, and UV rays are high energy photons with short 
wavelengths and produce ionising damage in tissue, whereas radio waves are 
fairly low energy photons with long wavelengths and are relatively harmless 
(Enwemeka, 2004). Near-IR and visible light are in between these two 
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opposing ends of the spectrum. Evidence shows that red and IR light have 
therapeutic benefits, where research to characterise the effects of unique 
wavelengths in these regions of the EM spectrum are plenteous. The 
development of single colour (monochromatic) light sources occurred in 1960 
when Theodore Maiman developed a device that produced red light at a 
unique wavelength (Maiman, 1960; Enwemeka, 2004). The device was called 
a Light Amplification by Stimulated Emission of Radiation or LASER, which 
led to early research focused on high powered laser techniques and 
therapies, where later in the decade an accidental discovery by a Hungarian 
physician, Endre Mester, paved the way for research into low-powered or low-
intensity light therapy (LILT) (Enwemeka, 2004).  
 
1.1.2 Photobiomodulation 
 
Photobiomodulation refers to LILT in the far-red to near-IR region of the 
spectrum (630-1000nm), which modulates numerous cellular functions in 
various in vitro and in vivo models (Eells et al., 2004; Barolet, 2008). As early 
as 1968, Endre Mester was studying the stimulating effects of 
photobiomodulation on biological systems (Mester et al., 1968). Mester 
hypothesised that “high power” lasers could be used to destroy tumours, 
where he irradiated tumours implanted into rats with a customized ruby laser 
thought to be high powered, but was later discovered to be a low powered red 
light. Mester's experiments showed that tumour cells were not destroyed by 
this red light but, however, observed the skin incisions he made had appeared 
to heal faster in treated animals compared control animals (Mester et al., 
1968; Enwemeka, 2004). These findings led Mester to conduct further 
experiments using this LILT on skin defects, burns, and human cases of 
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ulcers arising from diabetes, venous insufficiency, infected wounds, and 
bedsores, where the LILT appeared to aid the healing process in all groups 
compared to controls (Enwemeka, 2004).  
 
These pioneering experiments by Mester led to an array of fascinating in vitro 
and in vivo research on photobiomodulation, mostly by using laser therapy. 
Lasers have some limitations when used in a clinical environmental, including 
exact wavelength capabilities and beam width, production of multiple 
wavelengths optimal for wound healing, treatment area i.e. excessive 
hardware and bulky equipment are needed for large area wounds, heat 
production from the laser light causing tissue damage, and retinal damage if 
inadvertently exposed to the laser beam (Whelan et al., 2001; Eells et al., 
2004; Brawn and Kwong-Hing, 2007). Light Emmiting Diodes (LED) have 
become a favourable and effective alternative to lasers, as they can be 
configured to produce single or multiple wavelengths with a narrow 
bandwidth, require smaller hardware packages, can be arranged in large 
arrays allowing treatment of large areas and do not produce heat as they 
have a lower energy density and therefore reduced risk of eye damage 
compared to laser light (Whelan et al., 2001; Eells et al., 2004; Brawn and 
Kwong-Hing, 2007), where experiments at the cellular level have provided 
evidence that laser and LED, or coherent and non-coherent light, respectively, 
with the same wavelength, intensity, and irradiation time provide the same 
biological effect (Karu, 2003). LEDs also have the Food and Drug 
Administration (FDA) approval for light therapy, as they are deemed as a non-
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significant risk in humans (Whelan et al., 2001; Eells et al., 2004; Brawn and 
Kwong-Hing, 2007).  
 
Tissue penetration using red to near- IR light is an issue that should be 
brought to attention when dealing with LILT. Spectra from photons at the red 
to near-IR 630–800 nm wavelengths have been shown to travel approximately 
23 cm through the skin surface (light input) and muscle of wrist flexor muscles 
in the forearm and muscles in the calf of the leg (Whelan et al., 2001). Young 
et al. (2000) conducted a study to determine the near-IR transmission in the 
human head. Sterile probes for emitting and detecting IR light at a fixed 
separation of 40 mm were placed in turn on intact skin, skull, dura and 
cerebral cortex of patients undergoing elective neurosurgery, where the 
detecting probe was moved through successive extracereberal layers with the 
emitter (776.5, 819, 871 or 909nm wavelength) on the skin surface, or vice 
versa (Young et al., 2000). They found that removal of bone and dura from 
the light path caused a 14-fold significant reduction in detected intensity, 
therefore suggesting the skull and/or its interface with other layers may act as 
an optical 'channel', distorting the behaviour of near-IR light (Young et al., 
2000). These results show that photons in the red to near-IR can travel 
distances in the brain and other tissue, therefore photobiological effects of 
wavelengths in these regions are plausible. 
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1.2 Therapeutic effects of photobiomodulation 
 
1.2.1 General 
Various effects of LED and laser LILT have been reported, some of which 
confirm Mester's evidence of improved wound healing (Mester et al., 1971; 
Deriabin, 1997; Yu et al., 1997b; Schaffer et al., 2000a; Pugliese et al., 2003; 
Byrnes et al., 2004), show increases in mitochondrial respiration or adenosine 
triphosphate (ATP) synthesis (Passarella et al., 1984; Morimoto et al., 1994; 
Karu et al., 1995; Yu et al., 1997a; Wilden and Karthein, 1998; Mochizuki-Oda 
et al., 2002) and promotion of cell proliferation and cell survival (Yu et al., 
1997a; Carnevalli et al., 2003; Brondon et al., 2005; Hawkins and Abrahamse, 
2006). 
 
Reports detailing the beneficial effects of various wavelengths and treatment 
protocols of LILT on wound types are plentiful and show improved healing 
time, stimulated re-epithelialization, granulation tissue and collagen fibre 
deposition, local microcirculation and decreased inflammation and edema in 
the early phases of the wound healing using laser LILT in the 630nm-690nm 
(Yu et al., 1997b; Pugliese et al., 2003; Medrado et al., 2008; Meireles et al., 
2008; Meirelles et al., 2008; Oliveira et al., 2008; Chung et al., 2009; Freddo 
et al., 2009; Gonzaga Ribeiro et al., 2009; Santos et al., 2009), 780nm-790nm 
(Schaffer et al., 2000b; Oliveira et al., 2008; Santos et al., 2009), and 830nm 
(Freddo et al., 2009) wavelength range. Using LED LILT, Deriabin et al. 
(1997) showed a decrease in inflammation at the injured site of mandilar bone 
defects in rabbits following LILT at 890nm compared to sham controls. 
Interestingly, Whelan et al. (2001) studied LED LILT at combined wavelengths 
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(670nm, 728nm & 880nm) in in vitro and in vivo models and showed an 
increase of cell growth of 140-200% in mouse-derived fibroblasts, rat-derived 
osteoblasts, and rat-derived skeletal muscle cells, and increases in growth of 
155-171% in normal human epithelial cells. In the same study, LILT in 
conjunction with hyperbaric oxygen, showed wound size was decreased by 
36% in an in vivo ischemic rat model and in clinical studies, LILT showed 
greater than 40% improvement of in musculoskeletal training injuries and 
decreased wound healing time in Navy sea, air and land (SEAL) team 
members, suggesting the combined wavelengths in this range may be optimal 
for accelerated wound healing using LED LILT.  
 
Dentistry has also used low-power lasers in the treatment of dentin 
hypersensitivity, gingivitis, periodontitis, and oral ulcers (Pereira et al., 2002). 
Whelan et al. (2002) treated bone marrow transplant patients, who are 
susceptible to oral mucositis following chemotherapy, with daily 670nm LED 
LILT to the left extraoral epithelium and found ulcerated oral mucositis to be 
decreased compared to the sham (right extraoral epithelium), where left and 
right buccal pain was also improved (Whelan et al., 2002). Also, LILT reduced 
pain by 47% in children suffering from oral mucositis suggesting that LILT, 
overall improves the wound healing process (Whelan et al., 2001).  
 
Laser LILT has been shown to increase bone resorption and formation at 
660nm (Nicola et al., 2003), 685nm (Freddo et al., 2009), and 830nm (Blaya 
et al., 2008; Gerbi et al., 2008), to increase calcium and phosphorus 
mineralisation and percentage crystallinity at 830nm (Hubler et al., 2009) as 
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well as to increase calcium and alkaline phosphotase in osteoblastic cell lines 
at 632.8nm and 830nm, respectively (Yamada, 1991; Ueda and Shimizu, 
2003).  Brawn and Kwong-Hing (2007) grafted sockets, created from tooth 
extraction, with hydroxyapatite, a calcium phosphate ceramic, and used LED 
LILT 605nm-631nm for 21 days post-extraction, and found increased bone 
formation and particle resorption compared to the non-LILT treated socket. A 
similar study in rabbit dental implants confirmed increased calcium 
hydroxyapatite following laser LILT at 880nm (Lopes et al., 2007).  
 
LILT research has been used for various other applications, in order to try and 
elucidate any therapeutic benefits. Further other effects using laser LILT have 
included decreased myocardial tissue loss in rats following myocardial 
infarction at 804nm (Ad and Oron, 2001), preventing signs of brain damage in 
mannitol-induced blood brain barrier breakdown in rats receiving 770nm, 
850nm or 905nm laser treatments (Keller et al., 2002), preventing tumour 
growth acceleration and increasing life span in tumour-bearing mice using 
chronic 632.8nm laser treatments (Glushkov et al., 2006), selective nanoshell-
assisted thermal ablation of tumour cells in mice using a 808nm laser 
(Schwartz et al., 2009), and increasing axonal number and distance of 
regrowth, suppressing immune cell activation and decreasing 
cytokine/chemokine expression in rats during spinal cord injury using an 
810nm laser (Byrnes et al., 2005a). Barolet et al. (2009) demonstrated that 
LED 660nm LILT reduced rhytid depth and surface roughness in 90% of 
individuals taking part in a split-face single blinded study. Furthermore, his 
study showed LED LILT reversed age-related collagen downregulation and 
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matrix metalloproteinase-1 upregulation (an enzyme involved in the 
breakdown of interstitial collagens) compared to sham controls using human 
reconstructed skin (Barolet et al., 2009).  Yeager and colleagues conducted a 
series of experiments using LED 670nm LILT in fertile chicken eggs to 
demonstrate the effect on embryonic mortality, as well as various other 
parameters. Yeager et al. (2005) showed that treatments on embryonic days 
0-20 decreased mortality rates, increased body weight, crown-rump length 
and liver weight in hatchlings (Yeager et al., 2005). Upon injection with a sub-
lethal dose of toxin 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) at 200ppt, 
Yeager showed that LILT attenuated the toxic effects of TCDD by increasing 
hatchling size and weight, decreasing hepatic oxidised:reduced glutathione 
ratio and hepatic glutathione and catalase, therefore restoring hepatic enzyme 
activities to control levels (Yeager et al., 2006a; Yeager et al., 2006b; Yeager 
et al., 2006c). Eells et al. (2003) showed that LED LILT at 670nm wavelength 
reduced the methanol-derived formate, a mitochondrial toxin formed following 
methanol intoxication. Significant recovery of rod- and cone-mediated function 
was also determined using an electroretinogram as a sensitive indicator of 
retinal function (Eells et al., 2003) 
 
Overall, these results demonstrate that photobiomodulation in the red to near-
IR spectrum changes recovery pathways to promote cellular proliferation and 
restore cellular function following injury. This present study focuses on LED 
photobiomodulation at the infra-red wavelength 1072nm (IR1072).  
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1.2.2 Infrared 1072nm 
 
Most of the published work to date to establish the therapeutic effects and 
mechanisms underpinning photobiomodulation has centred around the 600-
900nm wavelength range. Much work using 1064nm wavelength lasers have 
been used mainly for skin resurfacing (Trelles and Allones, 2006; Berlin et al., 
2007), dental cavities or decay (Harazaki et al., 2001; Zezell et al., 2009) and 
wrinkle treatment (Karabudak et al., 2008).  
 
The narrow waveband of IR light centred at 1072 nm (IR1072) is a peak 
wavelength in the transmission spectrum through water (Figure 1-2) therefore 
it has been reasoned that tissue penetration would be influenced by light 
transmitted by water, which represents the major component of the human 
body (Dougal and Kelly, 2001). LED IR1072 LILT has been previously 
reported to show an improved healing time of Herpes labialis (Dougal and 
Kelly, 2001), had protective effects against UVA toxicity in human 
lymphocytes (Bradford et al., 2005) and beneficial effects on the acquisition of 
working memory in IR-treated 12 month old CD-1 mice (Michalikova et al., 
2008).  
 
Bradford et al. (2005) examined the effects of various protocols and 
wavelength in the red to near-IR spectrum (660nm, 880nm, 950nm, 1072nm 
and 1267nm) on human lymphocytes and found cell viability to be highest for 
the 1072nm wavelength-treated cells compared to other wavelengths and the 
untreated controls. These findings correlate data reported from other red to IR 
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wavelengths of light, therefore the establishment of any further beneficial 
effects following IR1072 treatment in vivo and in vitro was essential.  
 
Figure 1-2: Percentage transmission of IR through pure water (Figure based on Bradford et 
al., 2005). 
 
1.3 Molecular Mechanisms of Photobiomodulation 
 
LED and laser LILT in the red to near-IR spectrum appear to have beneficial 
effects in diverse range of in vitro and in vivo experimental models. 
Increased cellular proliferation has been a common reported effect of LILT in 
multiple cell culture systems, including; fibroblasts at 570nm LED (Vinck et al., 
2003) 632.8nm laser (Hawkins and Abrahamse, 2006) 660-670nm laser 
(Taniguchi et al., 2009) and LED (Vinck et al., 2003; Brondon et al., 2005), 
900-950nm laser (Pereira et al., 2002) and LED (Vinck et al., 2003); 
osteoblast cells at 800-830nm (Kreisler et al., 2003a; Ueda and Shimizu, 
2003; Pires Oliveira et al., 2008); olfactory ensheathing cells at 810nm 
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(Byrnes et al., 2005b), human larynx carcinoma cells at 808nm (Kreisler et al., 
2003b); CHO K-1 cells at 830nm (Carnevalli et al., 2003); and rabbit aortic 
endothelial cells at 685nm (Ricci et al., 2009). These findings show that 
wavelengths in the red to near-IR region have an effect on cellular 
proliferation, although the energy density and treatment regime may be 
important in eliciting these effects (Hawkins and Abrahamse, 2006; Pinheiro 
and Gerbi, 2006). It has been postulated that many of the therapeutic effects 
seen with LILT i.e. tissue repair, is due to an increase in cellular proliferation 
following red to IR irradiation. 
 
Oxidative phosphorylation in mitochondria is the main process by which ATP 
is produced in excitable and non-excitable mammalian tissue, whereby 
hydrolysis of ATP drives cellular processes such as protein synthesis, 
DNA/RNA synthesis, ion (Na+, K+, Ca2+) transport through the cell membrane, 
gluconeogenesis, ureagenesis, relative movement of myosin and actin 
filaments during muscle contraction (Korzeniewski, 2001). In 1960, Gordon & 
Surrey investigated the effect of red light in isolated rat liver mitochondria and 
found that red light at 670nm reversed far red light (725nm)-induced ATP 
reduction. Over 20 years later, Passarella et al. (1984) irradiated isolated rat 
liver mitochondria with a low-powered 632.8nm laser, and found an increase 
in mitochondrial membrane potential, proton gradient and an increase in ATP. 
They correlated this effect to the mitochondrial ETC, as complex chain 
inhibitors appeared to block the effects elicited by LILT, and suggested that 
the increase in ATP synthesis is due to a laser-induced increase in proton-
motive force, where the electrochemical potential is discharged through ATP 
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synthesis (Passarella et al., 1984). Supporting evidence show rises in ATP 
levels following LILT, some of which include 602nm lasers (Vekshin and 
Mironov, 1982) 632.8nm lasers (Karu et al., 1995; Zungu et al., 2009) and 
830nm lasers (Mochizuki-Oda et al., 2002). These findings have become the 
basis for continuing research on LILT-induced ATP synthesis, and has led to 
the idea that the mitochondrial ETC is the primary photoacceptor for LILT 
resulting in a cascade of signalling events, proposed as secondary 
mechanisms, involved in promoting cellular proliferation and cytoprotection 
(Eells et al., 2004; Gao and Xing, 2009). 
 
 
Figure 1-3: Cascade of events proposed to be elicited by LILT Abbreviations: LILT, Low 
Intensity Light Therapy; ATP, Adenosine Triphosphate; DNA, Deoxyribonucleic Acid; RNA, 
Ribonucleic Acid; ERK1/2, Extracellular Signal-regulated Kinase 1 and 2 (Figure based on 
Enwemeka, 2004). 
Absorption in mitochondria  
by photoreceptors 
↑ ATP synthesis 
Formation of low amounts of ROS 
DNA & RNA synthesis 
Protein synthesis 
Therapeutic Effects 
Cell signalling i.e ERK1/2 
LILT 
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1.3.1 Photoreceptors for red to near-IR light 
All photoreceptors known to date consist of the following: A protein moiety 
and one or several chromophores which are covalently or non-covalently 
bound to the protein (Batschauer, 2003). Light in the visible region of the 
spectrum requires a chromophore in order to absorb light, thus if additional 
photoreceptors are identified in the future, it is unlikely that they will divert 
from this rule, however bare in mind the same may not be true of light in other 
regions of the spectrum i.e. IR (Batschauer, 2003). The chromophore, with its 
conjugated π electron system, can be excited with photons of longer 
wavelengths and lower energy, such as those present in the red to near-IR 
region (600-1000 nm) where photon absorption causes a shift in the 
molecular configuration of the protein moiety that is required to transduce the 
primary light signal to downstream components (Batschauer, 2003; Gao and 
Xing, 2009). Photoreceptors are present on the most metabolically active cells 
in the body, and the energy required for phototransduction is derived primarily 
from oxidative metabolism (Eells et al., 2003).  
 
A growing body of evidence suggests cytochrome c oxidase, the terminal 
enzyme of the electron transport chain (ETC), to be the key photoacceptor of 
light in the far red to near-IR spectral range (Karu, 1999; Eells et al., 2004; 
Barolet, 2008; Gao and Xing, 2009). It has been generally accepted that 
cytochrome c oxidase acts as the primary mechanism for red to near-IR 
photobiomodulation and subsequent signalling is the secondary mechanism 
of LILT, however some other photoacceptors have been suggested. Complex 
II and IV activity of the ETC has been shown to be increased following LILT 
  24 
using 904nm wavelength laser suggesting a possible photoacceptor of IR light 
(Silveira et al., 2007) and phosphorylation of tyrosine protein kinase receptor 
(TPKR) following LILT using 632.8nm laser has been shown also (Shefer et 
al., 2001), suggesting the receptor to be in the "right energetic state" to accept 
laser energy and autophosphorylate to activate signalling pathways such as 
the ERK1/2 pathway, which in turn promote cell proliferation and 
cytoprotection in cells (Gao and Xing, 2009). Cytochrome c and Ubiquinone, 
mobile electron transporters in the electron transport chain (ETC), have also 
been suggested as possible photoacceptors.  
 
These would be interesting alternate photoacceptors, however more evidence 
is required in order to define the possible role of these photoacceptors, albeit 
to establish whether these are wavelength-specific photoacceptors or possess 
combined photoabsorbing activity - either way evidence for cytochrome c 
oxidase to be the primary photoacceptor is compelling and confirms a likely 
role for this enzyme upon red to IR photobiomodulation. 
 
1.4 Mitochondria: Primary mechanism 
 
Mitochondria are organelles found in the cytoplasm of most eukaryotic cells. 
They are spherical or elliptical in shape, with general dimensions of 1-2μm in 
length by 0.5-1μm in width (Scheffler, 2001; Burroughs and French, 2007). 
Structurally, mitochondria are bound by two membranes that create two 
distinct compartments separated by an intermembrane space (Scheffler, 
2001; Burroughs and French, 2007). The outer membrane encloses the entire 
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organelle and is permeable to small molecules and ionic species, but recent 
studies suggest that it might form a more important and potentially regulated 
barrier via specific transporters (Duchen, 2004; Burroughs and French, 2007). 
The inner membrane forms an invaginated high surface area containing 
cristae that project into and enclose the matrix (Duchen, 2004; Burroughs and 
French, 2007).  
 
The central role of mitochondria in respiring cells of eukaryotic organisms is 
aerobic catabolism of dietary intermediates, i.e. fatty acids and amino acids, 
to the three carbon intermediate, pyruvate (Duchen, 2004; Burroughs and 
French, 2007). Pyruvate is transported into the mitochondrial matrix by 
pyruvate dehydrogenase and subsequently undergoes oxidative 
decarboxylation to the two carbon intermediate, acetyl CoA, (Duchen, 2004; 
Burroughs and French, 2007). Acetyl CoA enters the tricarboxylic acid (TCA) 
cycle and combines with oxaloacetate which is further oxidised generating 
carbon dioxide and water (Duchen, 2004; Burroughs and French, 2007). 
Oxidation of respiratory substrates, NADH to NAD+ and FADH2 to FAD
+, is 
coupled to phosphorylation of adenosine diphosphate (ADP) and inorganic 
phosphate (Pi) to ATP via the ETC (Duchen, 2004; Burroughs and French, 
2007). Anaerobic glycolysis can provide enough ATP for some cells, but 
energetically active cells such as cardiomyocytes and neurons require a more 
efficient ATP supply, which can only be provided by mitochondrial oxidative 
phosphorylation via ETC (Trounce, 2000; Burroughs and French, 2007). 
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The cristae of the inner mitochondrial membrane are the site at which the 
components of the ETC are localized (Scheffler, 2001; Duchen, 2004; 
Burroughs and French, 2007). The ETC is composed of five multi subunit 
enzyme complexes: NADH-ubiquinone reductase, (complex I), succinate-
ubiquinone reductase, (Complex II), ubiquinone-cytochrome c reductase 
(complex III), cytochrome c oxidase (Complex IV) and ATP synthase 
(complex V). The chain also includes lipid soluble mobile electron carriers: 
ubiquinone (coenzyme Q) is responsible for shuttling electrons from both 
complex I and II to complex III, whilst cytochrome c transports electrons from 
complex III to IV (Nicholls and Budd, 2000; Duchen, 2004; Burroughs and 
French, 2007).  
 
Figure 1-4: The Electron Transport Chain. NADH-ubiquinone reductase, (complex I), 
succinate-ubiquinone reductase, (Complex II), ubiquinone-cytochrome c reductase (complex 
III), cytochrome c oxidase (Complex IV) and ATP synthase (complex V). Abbreviations: FAD, 
Flavin Adenine Dinucleotide; NAD, Nicotinamide Adenine Dinucleotide ; ADP, Adenosine 
Diphosphate; ATP, Adenosine Triphosphate; e
-
, electron; H
+
, hydrogen ion (Figure based on 
Ow et al., 2008). 
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According to the chemio-osmotic principle (Mitchell, 1961), a series of 
successive exergonic (energy releasing) redox reactions transfers electrons 
through the flavin mono nucleotides (FMN) and iron-sulphur (FeS) centres 
within the ETC towards compounds with more oxidative potentials, providing 
complexes with enough energy to translocate protons from the matrix to the 
inter-membrane space (IMS) (Bratic and Trifunovic; Nicholls and Budd, 2000; 
Burroughs and French, 2007). The transfer of protons across the 
mitochondrial matrix to the inner membrane space at complexes I, III and IV 
establishes a trans-membrane electrochemical gradient of 180-220 mV 
negative to the cytosol (Bratic and Trifunovic; Bernardi et al., 1999; Nicholls 
and Budd, 2000; Duchen, 2004; Van Houten et al., 2006; Burroughs and 
French, 2007). This proton gradient drives the phosphorylation of ADP to 
ATP, whereby the extruded protons re-enter the mitochondria via the 
Complex V (ATP synthase), coupling their transfer to the synthesis of a high 
energy intermediate, ATP (Kadenbach, 2003; Murphy et al., 2005; Van 
Houten et al., 2006; Burroughs and French, 2007). The final electron acceptor 
is molecular oxygen, which is reduced through a four electron addition to 
water (Van Houten et al., 2006; Burroughs and French, 2007).  
 
Cytochrome c oxidase, (complex IV) of the electron transport chain is a large 
multicomponent membrane protein (200 kDa) in the mitochondrial electron-
transport chain and has been shown to have absorption bands in the red to 
near-IR spectrum (Huang et al., 2009). In addition to the LILT-induced ATP 
synthesis in isolated mitochondria discussed earlier (Passarella et al., 1984), 
the 660–680 nm wavelength range has been shown to increase electron 
transfer in purified cytochrome oxidase with laser LILT (Gordon and Surrey, 
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1960; Pastore et al., 2000) and to upregulate cytochrome oxidase activity in 
cultured neuronal cells with LED LILT (Wong-Riley et al., 2001). It's centre 
comprises of two heme moieties (heme a and heme a3), two redox-active 
copper sites (CuA, and CuB,), one zinc, and one magnesium, all of which 
have been suggested as possible chromophores for red to near-IR light 
(Figure 1-5) (Eells et al., 2004; Gao and Xing, 2009). 
 
 
 
 
Figure 1-5: Cytochrome c oxidase centre. Abbreviations: Cyt c, Cytochrome c; heme a and 
heme a3, heme moieties; CuA, and CuB; redox-active copper sites; Zn, Zinc; Mg, 
magnesium; e
-
, electron (Figure based on Karu et al., 1995). 
 
During respiration, the pair of CuA chromophore of cytochrome c oxidase 
accepts electrons from the cytochrome c molecule, where internal electron 
transfer between CuA, heme a, and the heme a3-CuB centre results in 
reduction of molecular oxygen via at least seven redox intermediates (Karu, 
1999; Gao and Xing, 2009). Action spectra investigations on biological 
responses following LILT on HeLa cells conducted by Karu et al. (1995) 
suggested that reduced form of CuA accepts 620nm light, oxidised CuB 
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accepts 680nm, reduced CuB accepts 760nm and oxidised CuA accepts the 
near infra red spectrum of 825nm. They further confirmed cytochrome c 
cannot be considered as a primary photoacceptor when it is in a fully oxidised 
or fully reduced state (Karu et al., 1995; Karu and Kolyakov, 2005), however it 
is still unclear which one of the cytochromes c oxidase intermediates is the 
primary photoacceptor (Gao and Xing, 2009). 
 
1.5 Cell signalling: Secondary mechanism 
 
Mitochondria are at the centre of many diverse cellular functions integrating 
signals between the organelle and the nucleus (Gao and Xing, 2009). The 
changes in pH, ATP, mitochondrial membrane potential (MMP) following LILT 
described previously (Passarella et al., 1984), can initiate mitochondrial 
retrograde signalling process, which is the communication in cells from 
mitochondria to the nucleus that influences many cellular activities under both 
physiological and pathophysiological conditions (Karu, 1999; Gao and Xing, 
2009). Mitochondrial retrograde signalling is thought to be the initiator of 
several pathways following LILT, including the Mitogen-activated protein 
kinase (MAPK) cascade and extracellular signal regulated kinase 1/2 
(ERK1/2) signalling.  
 
1.5.1 MAPK Cascade 
MAPK is one of three components that regulate a number of key intracellular 
signalling events including cell proliferation, differentiation, survival and 
apoptosis, which are activated by an enormous array of stimuli (Schmitz et al., 
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2007; May and Hill, 2008; Gao and Xing, 2009). Downstream of the activating 
stimuli, the kinases themselves may be stimulated by combinations of small G 
proteins, MAP4Ks, scaffolds, or oligomerization of the MAP3K in a pathway 
(Lawrence et al., 2008). Each of the three major mammalian MAPK pathways, 
ERK1/2, p38 and c-Jun N-terminal Kinase (JNK) pathways, contains a three-
tiered kinase cascade comprising a MAP kinase kinase kinase (MAPKKK), a 
MAP kinase kinase (MAPKK) and MAPK, which are involved in the 
phosphorylation and activation of numerous proteins, including transcription 
factors, cytoskeletal proteins, kinases and other enzymes (Schmitz et al., 
2007). The ATP site is common to all of the protein kinases and is coupled to 
their dual phosphorylation of the conserved threonine and tyrosine residues, 
which promotes a conformational change in the kinase in order to elicit 
activation of transcription factors i.e. Brain derived neurotrophic factor (BDNF) 
activation of the ERK1/2 signalling pathway can result in the phosphorylation 
and activation of cyclic adenosine monophosphate (cAMP) response element 
binding (CREB) protein (Johnson, 2009).  
 
1.5.2 ERK1/2 pathway 
 BDNF is a member of the growth factor family and is highly implicated in 
neuroprotection with a major role in cell proliferation, cell survival and 
resilience via activation of the ERK1/2 pathway (Schloesser et al., 2007). A 
study by Byrnes et al. (2005b) showed BDNF gene expression to be 
increased following IR LILT. RNA extraction and real-time poylmerase chain 
reaction (PCR) techniques were used to analyse the level of gene expression 
following 810 nm laser LILT in olfactory ensheathing cells (OEC), where 
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irradiated cells showed a significant increase in BDNF and glial derived 
neurotrophic factor (GDNF) gene expression compared to control groups. 
OEC proliferation was also significantly increased in LILT treated groups 
compared to control groups, suggesting a possible role for BDNF in IR LILT-
induced cell proliferation (Byrnes et al., 2005b).  
 
 
Figure 1-6: ERK1/2 signalling. Abbreviations: BDNF, Brain Derived Neurotrophoc Factor; 
MEK, MAPK/ERK kinase; ERK1/2, Extracellular Signal-regulated Kinase 1 or 2; Rsk90, 90 
kDa Ribosomal Protein S6 Kinases; CREB, Cyclic Adenosine Monophosphate (AMP) 
Response Element Binding; Bcl-2, B-cell CLL/lymphoma 2; BAD, Bcl-2 Associated Death 
Factor; P, Phosphate; DNA, Deoxyribonucleic Acid (Schloesser et al., 2007). 
 
BDNF binds to the high affinity tyrosine kinase B receptor (TRKB) (Huang and 
Reichardt, 2003; Charney and Manji, 2004; Markham et al., 2004; Nagappan 
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and Lu, 2005), resulting in postsynaptic rises in cyclic adenosine 
monophosphate (cAMP) concentrations that facilitate translocation of TRKB 
into the postsynaptic density (Nagappan and Lu, 2005), subsequently 
triggering autophosphorylation of tyrosine residue in its intracellular domain 
leading to downstream activation of signalling events i.e. ERK1/2 activation 
(Mattson et al., 2004a; Burroughs and French, 2007).  
 
ERK1/2 is the major signalling pathway implicated in LILT. Shefer et al (2001) 
irradiated myoblasts with laser LILT at 632.8nm used phospho-specific 
antibodies to identify an upregulation of phospho-ERK1/2 following irradiation, 
with no effect on phospho-p38 or phospho-JNK. They also showed that 
Hepatocyte growth factor receptor, a member of the TRK family, was 
phosphorylated following irradiation whereas phosphorylated TNFα receptor, 
known to activate the stress pathways p38 and JNK, was unaffected by 
irradiation, suggesting these stress pathways are not involved in LILT (Shefer 
et al., 2001; Gao and Xing, 2009). The activation of ERK1/2 pathways are 
induced by stimuli such as TRKs or G-protein coupled receptors (Lawrence et 
al., 2008) which results in the sequential phosphorylation of Ras-Raf, 
MAPK/ERK kinase (MEK) and ERK (May and Hill, 2008). Depending upon the 
intensity and duration of stimulation, ERK1/2 can activate a diverse variety of 
substrates, both directly and indirectly by including several key transcription 
factors which can result in cell proliferation and cytoprotection (Lawrence et 
al., 2008). Regulation of transcription factors indirectly can occur by 
phosphorylation of the 90 kDa ribosomal protein S6 kinases (RSK90; 
Lawrence et al., 2008). Active RSK90 can mediate the actions of the ERK1/2 
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cascade and neurotrophic factors and appears to play a major role in 
transcriptional regulation, translocation to the nucleus and phosphorylating 
transcription factors such as CREB, at Ser133 (Lawrence et al., 2008). 
 
CREB is an important regulatory transcription factor for immediate early gene 
transcription and has been implicated in cell proliferation and survival, and 
upregulates the anti-apoptotic protein B-cell Lymphoma 2 (Bcl-2) (Frödin and 
Gammeltoft, 1999). The Bcl-2 family consists of anti-apoptotic members 
(including Bcl-2 and Bcl-xL) and pro-apoptotic members (such as BAD and 
BAX) (Beere, 2004; Einat et al., 2005). Studies have shown that an 
overexpression of Bcl-2 in mitochondria of cultured cells suppresses 
apoptosis by inhibiting calcium activation of the permeability transition pore of 
mitochondria (Murphy et al., 2005) thus protecting mitochondrial membrane 
integrity and preventing the release of cytochrome c (Einat et al., 2005). The 
release of cytochrome c from the mitochondria is an essential positive signal 
engaging the last phase of apoptosis, inducing the binding of apoptotic 
protease activating factor 1 (Apaf1) to cytochrome c and dATP to form an 
apoptosome thus initiating the caspases (cysteine aspartate-specific 
proteases) cascade pathway, resulting in the proteolysis of the various protein 
substrates of caspases, subsequently leading to intrinsic apoptosis (Dubois-
Dauphin et al., 2001). 
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1.5.3 AKT signalling 
 
Phosphatidylinositol 3-kinase (PI3K) or AKT (Protein Kinase B; PKB) 
signalling is a critical pathway in cell metabolism, cell survival, motility, cell 
cycle progression and transcription survival and many stimuli, including 
neurotrophins, via TRKB receptor phosphorylation, which are reported to 
activate this pathway (Martin et al., 2001; Nakagami, 2004; Akbar et al., 2005; 
Schmitz et al., 2007; Nie et al., 2009).  
 
Figure 1-7: AKT signalling pathway. Abbreviations: AKT, Protein Kinase B; TRKs, Tyrosine 
Kinase Receptors; GPCRs, G-protein Coupled Receptors; PI3K, Phosphatidylinositol-3 
Kinase; PDK1/2, Phosphoinositide-dependent Kinase 1 and 2; ERK1/2, Extracellular Signal-
Regulated Kinase; GSK3, Glycogen Synthase Kinase; BAD, Bcl-2-associated Death 
Promoter; mTOR, Mammalian Target of Rapamycin. 
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AKT is a serine/threonine kinase and its activation is induced by 
phosphorylation mediated by the upstream localised PI3K, which is essential 
for activation of AKT, in association with TRKs (Schmitz et al., 2007).  
Activation of the PI3K pathway include stimuli such as autophosphorylation of 
receptor tyrosine kinases induced by ligands such as growth factors; 
activation of cytokine receptors; stimulation of G-Protein coupled receptors, or 
activation of integrin signaling (Schmitz et al., 2007). Upon PI3K mediated 
generation of the second messenger PTEN, AKT is translocated from the 
cytoplasm to the plasma membrane where sequential phosphorylation of AKT 
by a phosphoinositide-dependent kinase 1 and 2 (PDK1, PDK2) occurs. 
Phosphorylation of both Threonine 308 and Serine 473 residues results in full 
AKT activation leading to modulation of a variety of central cellular processes 
both in the cytoplasm and in the nucleus (Schmitz et al., 2007). AKT is 
responsible for phosphoryation of a diverse variety of substrates to inhibit 
(pro-apoptotic proteins) or activate (anti-apoptotic proteins) including 
Glycogen Synthase Kinase (GSK3) BAD, caspase 9, Mammalian Target of 
Rapamycin (mTOR) endothelial nitric oxide synthase (eNOS) and Raf protein 
kinase (Figure 1-7) (Datta et al., 1997; Beere, 2004; Schmitz et al., 2007). 
AKT also regulates transcription factors that direct the expression of several 
cell death genes. AKT-mediated phosphorylation of forkhead (FKHRL1) 
prevents its translocation to the nucleus and therefore prevents the induced 
expression of its target genes including the Fas ligand (FasL) (Beere, 2004). 
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1.6 Heat Shock Proteins 
 
 
The heat shock protein (HSP) family are molecular chaperones that function 
to prevent the misfolding of proteins by facilitating folding into the native 
conformation that are specified by their primary sequences, and by 
suppressing subsequent protein aggregation, where HSPs are also 
responsible for transportation of misfolded proteins or aggregates to the 
ubiquitin-proteasome system (UPS) for degradation (Benn and Woolf, 2004; 
Wilhelmus et al., 2007; Gao and Hu, 2008; Li et al., 2009). HSP induction is 
thought to protect cells against the harmful consequences of a diverse array 
of stresses, some of which include heat shock (Hahn and Li, 1982; Mailhos et 
al., 1993) UV irradiation (Simon et al., 1995; Trautinger et al., 1995; Zhou et 
al., 1998) polyglutamine repeat expansion (Hansson et al., 2003; Iijima-Ando 
et al., 2005; Huen et al., 2007) and tumour necrosis factor (TNF) (Mailhos et 
al., 1993; Vietor and Vilcek, 1994; Engel et al., 1995; Heimbach et al., 2001; 
Miura et al., 2003). Originally, HSPs where thought to be induced solely for 
controlling protein misfolding and aggregation as a consequence of heat 
stress, but recent evidence demonstrates HSP participation in an array of 
cellular processes, including cytoprotection, and suggest they have two main 
cellular functions: promoting the UPS function and inhibiting pro-apoptotic 
activity; where HSPs, UPS, mitochondria and other organelles may work in 
conjunction to keep the cell in a stabilized state (Yenari, 2002; Arya et al., 
2007; Luo et al., 2007). HSP are broadly categorized according to their size 
and include the HSP27, HSP40, HSP60, HSP70, HSP90 and HSP100 
families (Beere, 2004). 
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1.6.1 HSPs in the control of protein misfolding 
HSPs are normally bound to heat shock factors (HSF) but dissociate in the 
presence of denatured or misfolded proteins (MP) (Yenari, 2002). Once 
dissociated, the controlled chaperone activity of the HSPs acts via an ATP 
binding, hydrolysis and nucleotide exchange cycle which mediates rapid 
association-dissociation cycles between the HSP and its target MP (Beere, 
2004; Arya et al., 2007). The unbound HSFs are phosphorylated and trimerize 
to produce trimers that bind to heat shock elements (HSE) that are contained 
within the promoters of the HSP that lead to upregulation of HSPs (Figure 1-
8). 
 
 
Figure 1-8: Mechanism of HSP activation and protein misfolding. Abbreviations: MP, 
Misfolded Protein; HSP, Heat Shock Protein; HSF, Heat Shock Factor; HSE, Heat Shock 
Element; NP, Normal Protein; UPS, Ubiquitin-proteasome System; DNA, Deoxyribonucleic 
Acid (Figure based on Yenari, 2002). 
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1.6.2 Role of HSP in the regulation of apoptosis 
Cell death can occur by apoptosis or necrosis. Necrosis typically occurs in 
response to acute cellular dysfunction which leads to the release of 
intracellular contents into the extracellular space initiating the activation of a 
marked inflammatory response (Bree et al., 2002; Beere, 2004). Apoptosis is 
a highly regulated energy-dependent, active form of cell death that occurs 
normally during development, in the immune system and in response to injury 
(Bree et al., 2002; Beere, 2004). There are two pathways leading to 
apoptosis: the mitochondrial (intrinsic) pathway and the "death receptor" 
(extrinsic) pathway (Bree et al., 2002; Beere, 2004; Benn and Woolf, 2004; 
Arya et al., 2007). 
 
Tumour necrosis factor receptors (TNFR) are known as "death receptors" and 
are the major players in extracellular signals initiating apoptosis (Benn and 
Woolf, 2004; Andera, 2009). Receptors of this family include TNFR-1 and 
TNFR-2 and apoptosis antigen-1 (FAS) (Benn and Woolf, 2004). The FAS 
ligand (FASL) is a member of the TNF superfamily of cytokines, where FASL-
activation of the FASL/FAS pathway leads recruitment of Fas-associated 
death domain (FADD), thus promoting caspase-8 activation and subsequent 
cleavage of BID to tBID, a pro-apoptotic member of the Bcl-2 family (Bree et 
al., 2002; Benn and Woolf, 2004; Andera, 2009). Activation of tBid results in 
translocation to the mitochondrial membrane where its binds and initiates 
conformational changes and oligomerisation of BAX and BAK, resulting in 
membrane permeabilisation, promoting pore formation and releasing a 
cavalry of pro-apoptotic proteins from the mitochondrial cristae and the inter-
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membrane space, such as cytochrome c, apoptosis inducing factor (AIF) and 
Smac/DIABLO (Benn and Woolf, 2004; Andera, 2009). 
 
Tumor necrosis factor (TNF) is a multifunctional cytokine that plays important 
roles in diverse cellular events such as cell survival, proliferation, 
differentiation, and death (Wang and Lin, 2008). TNF activates the nuclear 
factor-kappaB (NF-kappaB) cellular survival pathway, or the JNK death 
pathway (Benn and Woolf, 2004; Wang and Lin, 2008). Binding of TNF results 
in trimerization of TNFR-1 and recruitment of the TNFR associated death 
domain (TADD), which promotes caspase-8 cleavage, as with FADD, but also 
leads to the recruitment of TNFR-2, where binding results in the activation of 
the JNK pathway (Benn and Woolf, 2004). JNK initiates apoptosis by 
phosphorylating (inactivating) anti-apoptotic Bcl-2 proteins, and by inducing 
and phosphorylating (activating) the expression of the pro-apoptotic BH3-only 
protein, BIM (Benn and Woolf, 2004). JNK modification of BID to jBid, results 
in jBID translocation to mitochondria to selectively release SMAC/DIABLO 
(second mitochondrial-derived activator of caspases and the Drosophila 
melanogaster homologue), a mitochondrial protein that promotes apoptosis 
(Benn and Woolf, 2004). 
 
HSP-mediated regulation of apoptotic pathways has been proposed to be a 
fundamental protective mechanism that decreases cellular sensitivity to 
damaging events to allow cells to escape the otherwise inevitable apoptotic 
pathway (Novoselova et al., 2006). The role of HSPs in the control of 
apoptosis, both extrinsic and intrinsic, include the regulation of signalling 
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pathways such as JNK and FAS/FASL pathway (preventing apoptosis) and 
AKT signalling (promoting cell survival; Beere, 2004; Gao and Hu, 2008). 
 
 
 
Figure 1-9: Some roles of HSPs in the control of apoptosis. Abbreviations: TRKs, Tyrosine 
Kinase Receptors; GPCRs, G-protein Coupled Receptors; PI3, Phosphatidylinositol 3-Kinase; 
TNF, Tumour Necrosis Factor; TNFR1 or 2, Tumour Necrosis Factor 1 or 2; JNK, c-Jun N-
terminal Kinase; BIM/jBID, BH3-only proteins; FASL, FAS ligand; BAX/BAK/BOK/tBID, Bcl-2 
family proteins; SMAC, Second Mitochondrial-derived Activator of Caspases; Cyto c; 
cytochome c; AIF, Apoptosis Inducing Factor; HSP, Heat Shock Protein; P, phosphate (Figure 
based on Beere, 2004). 
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1.6.2.1 HSP27 
The small heat shock protein HSP27, acts as an ATP-independent chaperone 
in protein-protein interactions such as folding, translocation, and prevention of 
inappropriate protein aggregation, where they undergo self-oligomerization 
and MAPK-dependant phosphorylation (activation) (Mese et al., 2002; 
Kostenko and Moens, 2009). HSP27 has been shown to form complexes with 
pathological hyperphosphorylated and paired helical filaments tau which alters 
it's conformation, degrades and dephosphorylates the protein. This complex 
formation can lead to a reduction in pathological tau levels, thus rescuing the 
cell from tau-mediated apoptosis, therefore eliciting a neuroprotective effect in 
Alzheimer's Disease (AD) and other tauopathies (Shimura et al., 2004). 
HSP27 has also been implicated in regulation and architecture of the 
cytoskeleton (Zhu et al., 1994; Schafer et al., 1999; Coss et al., 2002; Keezer 
et al., 2003; Hargis et al., 2004), cell migration (Piotrowicz et al., 1998; Rust et 
al., 1999), metabolism, cell survival (Latchman, 2005; Wang et al., 2007), cell 
differentiation (Takahashi-Horiuchi et al., 2008), mRNA stabilization (Sinsimer 
et al., 2008), and tumor progression (Lambot et al., 2000).  
 
HSP27 is involved in anti-apoptotic and cell survival pathways, including 
interacting and forming complexes with AKT to promote cell survival. 
Experiments by Konishi et al. (1997) suggested that HSP27 is involved in the 
activation process of AKT in the signal transduction pathway of various forms 
of stress (Konishi et al., 1997). Mearow et al. (2002) confirmed this by 
subjecting PC12 cells and a stable cell line overexpressing HSP27 (HSPC 
cells) to heat shock which resulted in the rapid activation of AKT followed by 
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p38 mitogen-activated protein kinase (MAPK) signalling, where HSP27 was 
phosphorylated and translocated intracellularly. HSP27 was found to form a 
complex with AKT and p38 MAPK in both heat shocked and sham control 
cells, whereby dissociation of AKT and p38 from the HSP27 occured during 
the latter. NGF differentiated cells were subjected to NGF withdrawal, where 
cell death in HSPC cells was reduced and AKT remained phosphorylated or 
activated compared to parental PC12 cells. These data suggest that HSP27 
may stabilize the AKT protein and prevent it from dephosphorylation therefore 
promoting the cell survival pathway (Mearow et al., 2002; Beere, 2004; Luo et 
al., 2007). HSP27 can also block the mitochondrial pro-apoptotic protein tBID 
from translocation in to the mitochondria, can reduce SMAC and can bind to 
cytochrome c to prevent apoptotic peptidase activating factor 1, (Apaf-1) 
oligomerization, so as to block the apoptotic process (Figure1-9) (Paul et al., 
2002; Beere, 2004; Benn and Woolf, 2004) 
 
1.6.2.2 HSP60 
HSP60 proteins are classified as chaperonins, proteins that "oligomerize to 
form large structures that can engulf their clients and function as folding 
chambers" (Calderwood et al., 2009). HSP60 resides in the mitochondrial 
matrix as a homomultimer where roles include aiding protein folding and 
transport of mitochondrial proteins, where it has been proposed to have a role 
during the late stages of apoptosis as, following mitochondrial degradation 
and cytochome c release during the late stages of apoptosis (Beere, 2004). 
Samali et al. (1999) demonstrated that recombinant HSP60 and HSP10 cells 
accelerated the activation of pro-caspase-3 by cytochrome c release in an 
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ATP-dependent manner, suggesting that the release of mitochondrial HSP60 
may act as a feed-forward mechanism to accelerate and ensure optimal 
caspase activation in the cytoplasm of cells (Figure 1-9) (Samali et al., 1999; 
Beere, 2004). 
 
1.6.2.3 HSP40 and HSP70 
HSP40 protein functions as a pair with HSP70 protein to promote protein 
folding, protein transport and degradation (Li et al., 2009). Gotoh et al. (2004) 
showed that macrophages stably co-expressing HSP40 and 70 prevented 
NO-mediated apoptosis and pro-apoptotic mitochondrial protein BAX 
translocation from the cytosol to the mitochondria compared to wild-type 
control cells, suggesting that this co-chaperone anti-apoptotic action is 
through prevention of BAX translocation to the mitochondria (Beere, 2004; 
Gotoh et al., 2004). 
 
Gabai et al. (2000a) showed, using an in vitro model of myocardial ischemia, 
transient energy deprivation of H9c2 myogenic cells, that HSP72 specifically 
down-regulates JNK activity by accelerating its dephosphorylation properties, 
and that UV- or TNF-induced JNK activation was suppressed by HSP72 
accumulation (Gabai et al., 2000a; Gabai et al., 2000b). Park et al (2001) 
correlated this by demonstrating that overexpression of HSP72 in NIH3T3 
cells suppresses UV-induced JNK activity, where in vitro binding and kinase 
studies suggested HSP72 binds to JNK to elicit this effect (Park et al., 2001). 
Gabai et al. (2002) showed that HSP72 blocked TNF-activation of the JNK 
pathway which temporarily blocked Bid activation and the subsequent 
apoptotic events, suggesting in TNF-induced apoptosis, HSP72 specifically 
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interferes with the Bid-dependent apoptotic pathway via inhibition of JNK 
(Gabai et al., 2002). HSP70, and its co-chaperone HSP40 partner, also inhibit 
JNK-mediated apoptosis by direct protein–protein interactions, which result in 
prevention of cleavage and activation of BID to tBID (Figure 1-9) (Benn and 
Woolf, 2004). 
 
HSP70 prevents nuclear import of apoptosis inducing factor (AIF) following its 
release from mitochondria and, as a consequence, neutralizes its death 
inducing activity in Apaf-1-null cells (Beere, 2004; Benn and Woolf, 2004). In a 
study by Novoselova et al. (2006), macrophages and splenic lymphocytes 
irradiated with 632.8nm laser increased HSP70, but reduced HSP90 
expression (Novoselova et al., 2006), providing preliminary evidence that 
HSP, 70 and 90 at least, may be involved in the neuroprotective effects seen 
with LILT. 
 
1.6.2.4 HSP90 
HSP90 play an important role in conformational protein regulation and cell 
signalling (Beere, 2004; Benn and Woolf, 2004). Sato et al. (2000) 
constructed deletion mutants and identified that amino acid residues 229-309 
of AKT were involved in the binding to HSP90 and amino acid residues 327-
340 of HSP90β were involved in the binding to AKT, whereby inhibition of 
these binding residues resulted in dephosphorylation and inactivation of AKT, 
indicating that HSP90 plays an important role in maintaining AKT kinase 
activity by preventing the dephosphorylation of AKT (Figure 1-9) (Sato et al., 
2000; Beere, 2004; Benn and Woolf, 2004). Furthermore, HSP90 has also 
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been reported to prevent Apaf-1 oligomerization by directly associating with 
Apaf-1 (Beere, 2004) 
 
1.6.2.5 HSP105 
HSP105 is constitutively expressed and concentrated in the brain whereby 
synthesis is enhanced by the various stress stimuli, suggesting a specific role 
for HSP105 in stress responses within the nervous system (Wang and Bag, 
2008). HSP105 is essential for cell survival in eukaryotes, however over-
expression of HSP105 has been shown to have an anti-apoptotic effect in 
cultured neuronal PC12 cells (Hatayama et al., 2001). Ishihara et al. (2003) 
showed that HSP105 suppresses apoptosis in a cell culture model of 
polyglutamine disease, a neurodegenerative disease caused by the toxicity 
that is derived from a misfolded mutant protein. These findings suggest that 
overexpression of HSP105α suppresses cell death caused by expansion of 
the polyglutamine tract without chaperone activity, and the enhanced 
expression of the essential domains of HSP105α in brain may provide an 
effective therapeutic approach for CAG repeat diseases (Yamashita et al., 
2007). HSP105 has also been shown to prevent caspase-activation induced 
by proteasomal inhibition with lactacystin in neuroblastoma cell line (Ishihara 
et al., 2003).  
 
1.7 Ageing and signalling deficits 
 
Ageing is a complex process by which organisms undergo cell deterioration 
within vital organs and is associated with alterations in skeletal, muscular, 
gastrointestinal, neuronal and metabolic processes (Harrison and 
  46 
Pierzynowski, 2008; Calderwood et al., 2009). Mitochondrial dysfunction and 
decreased levels of neurotrophic factors and HSP that occur during the 
ageing process can result in decreased anti-apoptotic factor upregulation and 
disregulation of misfolded proteins that may contribute towards the neuronal 
loss which occurs in the ageing organism. 
 
A proton leak, or mitochondrial uncoupling, occurs when protons re-enter into 
the mitochondrial matrix without contributing towards ATP synthesis, where 
the energy of the proton electrochemical gradient is released as heat, 
consequently leading to low ATP production associated with high levels of 
electron transfer and respiration (Bratic and Trifunovic).  
 
Figure 1-10: Proton leak during ageing Abbreviations: UCP, Uncoupling Protein; ANT, 
Adenine Nucleotide Translocator (Figure based on Conley et al., 2007). 
 
This uncoupling can result in the reduction of oxygen production and the 
formation of reactive oxygen species (ROS), thus producing free radicals that 
cause oxidative damage (Bratic and Trifunovic). In 1956, Denham Harman 
proposed what is now known as the "free radical theory of ageing", proposing 
that oxidative damage accumulates in tissues over time which contributes to 
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the decline of physiological function in cells with age, and has become the 
most prevalent theories in ageing research to date (Harman, 1956; Van 
Remmen and Richardson, 2001). Low levels of ROS production has been 
implicated in initiating cell survival signalling, however excessive ROS 
production can cause lipid peroxidation damage to cell membranes and to 
DNA, this includes mitochondrial DNA (mtDNA) which has no associated 
histones and is therefore less protected against radical damage than nuclear 
DNA (Duchen, 2004; Burroughs and French, 2007). A consequence of the 
oxidative phosphorylation process is the generation of unpaired electrons that 
interact with O2 resulting in the generation of superoxide ions, highly reactive 
free radical species (Duchen, 2004; Burroughs and French, 2007). These are 
readily converted to other free radical species, such as hydrogen peroxide 
(H2O2) and hydroxyl ions (OH
-) where excessive levels are thought to damage 
the ETC of the mitochondria (Duchen, 2004; Burroughs and French, 2007).  
As age increases, the accumulated ROS and therefore free radical production 
is proposed to contribute to decreased mitochondrial function, leading to 
further increased of ROS production due to the electron transport chain (ETC) 
uncoupling, increased mtDNA mutations, and decreased ATP synthesis, all of 
which contribute to declining physiological function as a consequence of 
ageing (Huang and Manton, 2004). 
 
BDNF signal transduction pathways in the brain are important mediators of 
both genetic and environmental influences upon the ageing process (Mattson 
et al., 2004b). Decreased neuronal plasticity during the adult life span has 
been correlated with a reduction in the level of effectors i.e. BDNF, of 
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plasticity responses (Ruttiger et al., 2007). Croll et al. (1998) showed that 
BDNF mRNA is decreased in the pons and BDNF protein decreases in the 
midbrain of aged rats, and proposed that memory ability and impaired 
learning as measured with the Morris water maze resulted as a consequence 
of these reductions (Croll et al., 1998). Previous publications have suggested 
an involvement of BDNF in the pathogenesis of AD (Holsinger et al., 2000; 
Roka et al., 2000; Laske et al., 2006). Using western blotting and 
immunohistochemical techniques, Ferrer et al. (1999) demonstrated the 
selective decline of the BDNF and TRKB signaling pathway in the frontal 
cortex and hippocampus of individuals affected by long-lasting severe AD and 
age-matched controls. These data suggest that the decrease in BDNF and 
subsequent signalling may play a role in the cognitive decline that occurs 
during ageing (Ferrer et al., 1999). The reduction of BDNF as the ageing 
process occurs suggests that there would be a decrease in the ERK1/2 
signalling pathways and phosphorylation of RSK90, and therefore a reduction 
of CREB phosphorylation which activates the Bcl-2, anti-apoptotic 
mitochondrial protein, discussed earlier. 
 
The PI3-Kinase pathway is responsible for phosphorylating AKT to initiate cell 
survival actions following stimulation. Recent studies have shown a 
phosphorylation of AKT decreases as age increases. Nie et al. (2009) 
investigated the effects of ageing on AKT signalling in hippocampal tissue 
senescence-accelerated mice (SAMP10) and age-matched control mice. This 
study found whilst AKT mRNA remained constant during ageing, 
phosphorylated AKT was reduced in aged SAMP10 mice we, which was 
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accompanied by deterioration in performance of learning and memory tasks 
from 6 months of age (Nie et al., 2009). This suggests a potential decline in 
AKT may contribute to the learning and memory deficits seen during ageing. 
 
An increase in protein damage has been shown to occur during ageing 
whereby HSP induction is reduced, resulting in the disregulation of mis-folded 
proteins and reduction of anti-apoptotic effects (Calderwood et al., 2009). 
Induction of HSP in response to heat shock declines in ageing cells, where 
cells lose the capacity to activate the transcriptional pathways leading to HSP 
synthesis (Keller et al., 2008; Calderwood et al., 2009). This attenuation of 
HSP induction can lead insufficient levels of HSPs available to regulate 
abnormal polypeptides, resulting in toxic accumulation which can initiate the 
apoptotic pathway (Sherman and Goldberg, 2001; Calderwood et al., 2009). 
There is plenty of evidence showing age increased accumulation of abnormal 
proteins, damaged by processes such as oxidative damage, isomerised 
residues and inactivation due to conformational change, where the reduction 
in HSP limits the ability of cells to deal with abnormal or misfolded proteins 
(Sherman and Goldberg, 2001). In addition to ageing, this has been 
suggested to indirectly contribute towards the progression of 
neurodegenerative diseases e.g. AD (Sherman and Goldberg, 2001). 
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1.8 Major Aims  
The aim of this project was to determine whether IR1072 has neuroprotective 
effects, if any, in in vitro and behavioural or molecular beneficial effects in 
ageing CD-1 and TASTPM mice (in vivo). We used molecular i.e. 
immunoblotting, immunohistochemistry and behavioural techniques in order to 
address the following areas to achieve our overall aim: 
 
1) to confirm behavioural cognitive benefits of IR1072 in aged CD-1 mice 
2) to determine the effects of IR1072 in an Alzheimer disease mouse 
model (TASTPM)  
3) to delineate the mechanisms underpinning the photomodulatory effects 
of IR1072 in CD-1 and TASTPM mice 
4) to define the influence of age upon the photomodulatory effects of 
IR1072. 
 
1.8.1 Primary hypothesis 
IR1072 treatment elicits a beneficial effect in the ageing mammalian CNS via 
a multiple-step mechanism 
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Chapter 2: Materials and Methods 
 
2.1 Animals 
 
All mouse strains were maintained in the Life Sciences Support Unit (LSSU) 
located at the University of Durham. All animals had unlimited access to food 
and water until behavioural experiments commenced, and were maintained 
on a 12 hour light/dark cycle.  
 
CD-1 mice were the in-house, inbred mouse strain used in this study, and 
were maintained at the University of Durham. 
 
TASTPM mice (heterozygous double transgenic mice (TASTPM) with the 
Swedish (K670N; M671L) double familial mutation (Thy-1-APP695Sw, Line 10 
(TAS10)) and the PS1 (M146V) mutation (Thy-1-PS-1M146V)) were 
backcrossed onto a pure C57BL/6 background originally obtained from 
GlaxoSmithKline (Harlow, Essex, UK) where a breeding programme was set 
up at the University of Durham and has continued for 2 years. 
 
Pregnant (Embryonic day 17) Sprague-Dawley female rats were obtained 
from Harlem (UK). The rats were maintained in the LSSU at the University of 
Durham. 
 
All animal husbandry, breeding and experimental procedures was performed 
in accordance with the Animals (Scientific Procedures) Act 1986. 
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2.2 Pure Cortical neuronal Cultures 
 
All neuronal cultures were seeded and maintained in sterile Iwaki 24 well 
plates. The 24 well plates were coated using a poly-D-lysine solution 
(50μg/ml) and incubated for 1 hour at room temperature (RT). The poly-D-
lysine solution was removed from the wells and subsequently rinsed with 
sterile water to remove any excess poly-D-lysine. The plates were left to air-
dry for a further 1 hour at RT.  
 
Pregnant female Sprague-Dawley rats at embryonic stage 17 (E17) were 
stunned and killed by neck dislocation (schedule 1). The embryonic sack was 
dissected and rinsed in ice-cold Hank's buffered saline solution (HBSS (-)) 
buffer (5mM KCl, 0.4mM KH2PO4, 137mM NaCl, 4mM NaHCO3, 5mM 
Glucose, 5mM HEPES, 1mM Sodium Pyruvate, pH 7.4). The rat pups were 
decapitated and the heads rinsed in fresh HBSS (-) buffer, where the cortices 
were dissected and any visible blood vessels were removed.  
 
The cortices were triturated 20 times in ~2mls of HBSS (-) using a wide-
mouthed fire polished pipette, made up to a final volume of 10ml HBSS (+) 
(HBSS plus 1.25mM CaCl2, 0.5mM MgCl2, 0.85mM MgSO4, pH 7.4) and left 
for 90 seconds to settle and remove any non-dispersed tissue. 
 
The suspension was centrifuged at 500rpm for 1min, and the pellet was 
discarded. The supernatent was further triturated 10-20 times using a small-
mouthed fire polished pipette and made up to a final volume of ~5mls with 
HBSS (+) buffer.  
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Cell population was determined using a haemocytometer, and a final cell 
density of 3000cells/mm2 in Neurobasal culture medium containing, 2% B27 
supplement, 20 units/ml penicillin, 20μg/ml streptomycin, 2.5μM Glutamate, 
0.5mM Glutamax-1 was achieved.  
 
Cultures were fed on DIV3, using Neurobasal culture medium absent of 
glutamate. Experiments were carried out on DIV 7 (Figure 2-1).  
 
 
 
 
Figure 2-1: Pure cortical neuronal cultures produced in this study (DIV 7). 
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2.3 IR1072 Treatments 
 
2.3.1 IR1072 Treatment Apparatus 
The IR1072 treatment apparatus consists of 1072nm IR LED array which 
encloses the animals under investigation on all 6 sides facilitating irradiation 
of the target from every conceivable direction. The 1072nm LEDs are pulsed 
at 600 Hz with a duty cycle of 300 microseconds. The temperature of the 
LEDs are kept as close to room temperature as possible by a standard 
cooling fan, which reduces potential for thermal drift of the peak wavelength. 
The same specification and duty cycle for the 1072nm LEDs used in the panel 
for cell lines was the same. The treatment cycle for in vivo experiments is 6 
minutes and 3 minutes for in vitro experiments. The LEDs were supplied by 
Virulite Distribution Limited. 
 
2.3.1.1 In Vitro 
Pure neuronal cultures (DIV7) received 5 x 3 minute sham- or IR1072-
treatments and incubated in a 37ºC, 5%CO2, 95% O2 incubator. After 4 hours, 
the media was removed and the sham- or IR-treated cultures were subjected 
to a 10 minute incubation with exposure buffer solution (EBS) buffer (2.5mM 
CaCl2, 5mM KCl, 137mM NaCl, 0.3mM KH2PO4, 4mM NaHCO3, 0.3mM 
Na2HPO4, 5.6mM glucose, 0.01mM glycine, 10mM HEPES, pH7.4) alone 
(sham; n=6) or EBS containing 1mM glutamate (insult; n=6) for 10 minutes at 
RT, where the buffer was replaced with fresh media and incubated at 37ºC, 
5%CO2, 95% O2. Twenty-four hours following the sham or insult treatment, an 
MTT assay (Mosmann, 1983) was performed by adding 0.5 mM MTT (3-(4,5-
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Dimethylthiazol-2-YI)-2,5-diphenyltetrazolium bromide) to all treated cultures 
in order to determine cell viability. 
 
2.3.1.2 In Vivo 
2.3.1.2.1 Acute IR Treatments 
CD-1 male mice or TASTPM male mice were exposed to IR1072 treatment 
box for 6 minute daily sessions over a 10 day period. Brains were dissected 
immediately following the final IR1072 treatment and prepared for 
immunoblotting or mitochondrial studies. 
 
2.3.1.2.2 Chronic IR Treatments 
CD-1 male mice or TASTPM mice were exposed to sham or IR1072 
treatments for 6 minute sessions for two consecutive days, biweekly over 5-6 
months, during which time weights of the mice and internal box temperatures 
for sham and IR treatments were monitored. Sham treatments were carried 
out using a replica IR treatment box that did not emit infra-red light. Following 
IR treatments, mice were subjected to 12 day behavioural testing on the 3-D 
radial maze, as described in Chapter 4. Brains were dissected immediately 
following the final behavioural test and prepared for immunoblotting, 
immunohistochemistry, or ligand autoradiography purposes. 
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2.4 Behavioural Paradigm: 9-arm 3D Radial Maze 
 
2.4.1 Food Deprivation 
Chronically treated Sham or IR1072-treated CD-1 mice or TASTPM mice 
were food-deprived for 24hrs prior to behavioural testing, and subsequently 
given 5g of food daily. TASTPM mice required food pellets to be soaked in 
water beforehand in order to soften the food, otherwise mice were unable to 
feed properly. Water availability remained ad libitum for all mice. During 
behavioural testing, 1 small food pellet was available on the end of each arm. 
One sham and one IR-treated TASTPM female mouse died before 
behavioural testing (cause unknown). 
 
2.4.2 9-arm 3-D Radial maze 
The maze is made from grey PVC (5 mm thick). It consists of 9 arms radiating 
from a central platform. Each arm (51 x 11.2 cm) is made from two segments, 
extended from an octagonal shaped central hub (43 cm in diameter) and can 
be manipulated independently. The first segment of an arm (15.2 x 11.2 cm) 
directly attached to the central platform was tilted to form a 60º slope and 
constitutes a bridge that allows access to the second segment (35 x 11.2 cm) 
of the arm which is presented horizontally either at the same (flat arm 
configuration), below (lowered arm configuration) or above (raised arm 
configuration) the level of a central platform. In order to change the 
configurations of the maze, the central platform can be raised or lowered. 
Each entry to a bridge is narrowed with a short wire mesh wall (8 x 4 cm) 
either on the left or on the right side. The narrowing of the entries to and exits 
from the bridges are designed to prevent mice relying entirely on sequential 
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arm choices. The end of each arm is extended with panels of identical size 
(20.2 x 11.2 cm). These panels are used for holding intra-maze cues made of 
distinctive pattern drawings designed on plastic adhesive material and 
attached to a PVC board (18 x 11.2 cm). Sidewalls, about 1 cm high, 
extended the length of each arm. There are no enclosures surrounding the 
central platform, bridges or arms. The maze is totally surrounded with a heavy 
beige-light colored curtain. A camera is centered 180 cm above the central 
platform. The ambient light at the surface of the central platform is 180 Lux. 
 
Testing procedures: Naïve food deprived mice were introduced to the maze 
to acquire a spatial working memory task. They had no previous experience 
or habituation to the maze. They are placed in the central platform and let free 
to explore the maze until 9 arm choices are made or 10 minute elapsed. One 
food pellet is available at the end of each arm. A first visit to an arm is a 
recorded as unique visit (correct choice) and any subsequent visit is 
considered as a repeated choice or incorrect choice. A mouse can make up to 
8 repeated visits to the same arm. Animals are tested one session a day on 
12 consecutive days. 
 
Tools and recording measures: During the test, mice were observed on a 
screen monitor connected to a video camera suspended above the test arena. 
The video record of the experiment is run on a computer screen monitor 
through a capture card. The experiment is also video taped, the experimenter 
can review the VCR tape and check the accuracy of the recording at any time. 
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An in-house computer program is used to record the frequency of entries as 
well as the duration and latencies of entries of pre-defined areas of the maze. 
 
Measurements and statistical analysis: Several measurements were 
considered. A session last until 9 choices are made or 10 minute elapsed. An 
entry to an arm or a bridge is recorded whenever a mouse crosses with all 
four paws the line that delimits these areas. 
 
1) Number of repeated visits to arms: This measure refers to incorrect 
choices or errors. An arm that is visited only once during a session is 
considered as a unique entry to that arm (a correct choice). A session last 
until 9 choices are made or 10 minute elapsed. Each entry to an arm is 
considered as one choice. An animal can make up to 9 visits to the same 
arm. The first visit is considered a unique visit or a correct choice and 
subsequent visits are considered repeated choice or incorrect choices. In 
the first few sessions a mouse may visit a few arms or may not visit any 
arms. In this case, a mouse that did not visit any arm would receive a 
penalty of 9 repeated visits. For a mouse that made less than 9 choices, 
the number of the remaining arm choices is added to their actual number 
of repeated arm visits. For example, a mouse that has made 5 choices 
and 2 repeat visits to arms will be recorded having made 3 unique visits 
and 6 repeated visited (the actual 2 repeats + the remaining 4 arm 
choices). A mouse that has made 5 choices and 0 repeat visit to arms will 
be recorded having made 5 unique visits and 4 repeated visited. 
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2) Number of arm entries before first repeated arm visit: An arm that is 
visited only once during a session is considered as a unique entry to that 
arm (see number of repeated visits to arms below). A mouse that did not 
visit any arm will be recorded as having made 0 unique visits before first 
repeat. A mouse that made less than 9 choices with no repeat was 
recorded as having made the first repeated choice after the last arm visit. 
This measurement indicates whether an animal made an arm repeat 
earlier or later in a session. 
3) Number of bridge and arm entries: An entry to a bridge was recorded 
only once if a mouse entered a bridge and continued to an arm. A return 
from an arm to a bridge within the same visit was not recorded. 
4) Arm/Bridge ratio for number of entries: Number of arm entries divided 
by the number of bridges entries. A ratio close to 1 describes an animal 
that continued to an arm each time it visited a bridge. A ratio close to 0 
described an animal that made numerous visits to bridges before engaging 
onto an arm. In the former, the animal showed no hesitations or fewer 
hesitations to engage fully onto an arm whereas in the latter the animal 
demonstrated more hesitations before adventuring on an arm. 
5) Arm/Bridge ratio for duration of entries: Duration of arm entries divided 
by duration of bridge entries. A ratio close to 1 described an animal that 
spent an approximate equal amount of time on the arms and the bridges. 
A ratio close to 0 described an animal that spent less time on the arms 
than on the bridges while a ratio above 1 indicated the opposite. The 
former could have indicated that animals are reluctant to spent longer time 
in the arms (brief entries). 
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6) Number of bridge entries before first arm visit: Animals that did not 
visit any arm in a session received the highest recorded number of bridges 
visited before first entry from any mouse in that session. 
7) Latency of first entry to a bridge: The time spent by a mouse in the 
central platform before it entered one of the bridges for the first time with 
all four paws. A mouse that did not enter a bridge received the highest 
score which was 10 minute. 
8) Latency of first entry to an arm: The time spent by a mouse in the 
central platform and bridges before entering the arm for the first time. A 
mouse that did not enter any arm received the highest score which was 10 
minute. 
9) Total time spent in the central platform: The time was recorded from 
the entry of a mouse with all four paws in the central platform until it exited 
to a bridge. 
10) Total time spent on the bridges: The time recorded from the entry of a 
mouse with all four paws in a bridge until exiting the central platform or to 
an arm. If a mouse entered a bridge and continued to an arm, then the 
time on an arm was subtracted from the time spent on a bridge. 
11) Total time spent on the arms: The time recorded from the entry of a 
mouse with all four paws in an arm until it exiting to the bridge. 
12) Session duration: Animals were removed from the maze at the end of a 
session when 10 minute elapsed or when the animal returned to the 
central platform after 9 choices were made. A choice was considered any 
visit or repeated visit to an arm. 
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2.5 Immunoblotting 
 
2.5.1 Sample Preparation 
CD-1 or TASTPM mice were sacrificed by CO2 narcosis and brains were 
rapidly dissected, where the left hemisphere was separated and snap frozen 
to be stored at -20ºC in preparation for homogenisation. The brains were 
individually homogenised in 5ml of homogenisation buffer (50mM Tris-Base, 
5mM ethylenediaminetetraacetic acid (EDTA), 5mM ethyleneglycotetraacetic 
acid (EGTA) and 150μM protease inhibitor cocktail III (PICIII), pH7.4) per 
cortices, where protein concentration was determined spectrophotometrically 
by the Lowry Protein Assay (Lowry et al., 1951). Protein (10-50μg) was 
prepared for immunoblotting in 3X sample buffer (30mM NaH2PO4, 30% (v/v) 
glycerol, 0.05% (w/v) Bromophenol blue, 7.5% (w/v) sodium dodecyl sulphate 
(SDS), made up in dH2O) made up to a final volume of 15μl with dH2O and 
applied to an SDS-PAGE gel or stored at -20ºC.  
 
Dithiothreitol (DTT; 23.5mM final concentration, from a 200mM stock solution 
made with dH2O) was added to the samples and mixed thoroughly, pulsed at 
13000rpm, incubated for 5 minutes at 95°C, pulsed again at 13000rpm, and 
mixed thoroughly in preparation for electrophoresis. 
 
2.5.2 Immunoblotting 
Samples for immunoblotting were subjected to SDS-PAGE (Chazot et al., 
2002). For sample loading, wells were formed in a 6.5% SDS-PAGE stacking 
gel (56.9% (v/v) dH2O, 24.7% (v/v) stacking gel buffer (1M Tris, 1% (w/v) 
SDS), 16.1% (v/v) acrylamide (40%), 2% ammonium persulphate (APS; 1mM 
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stock made with dH2O) and 0.25% TEMED) using a 0.75mm 10 well comb, 
set above 10%-15% acrylamide resolving gels (47.6% (v/v) dH2O, 23.8% (v/v) 
acrylamide (40%), 23.8% running gel buffer (0.5M Tris, 8mM EDTA, pH6.8, 
0.4% SDS (w/v), pH 8.8), 4.8% APS (1mM stock made with dH2O), and 0.8% 
TEMED). Once set, Hoefer Mighty small II vertical slab gel electrophoresis 
tanks were filled with electrode buffer (5mM Tris, 0.38mM Glycine, 2mM 
EDTA, pH 8.8) and prepared samples or a pre-stained standard (10-250kDa) 
were loaded in to the wells using a 50μl syringe. 
 
Electrophoresis was conducted at 180V and 10mA, until the samples had 
entered the resolving gel, and subsequently increased to 15mA until 
electrophoresis has finished. 
 
The protein from the resolving gel was then transferred to a nitrocellulose 
membrane using a Hoefer TE series transfer unit, set at 50V, <200mA for 
2.5hrs in transfer buffer (25mM Tris, 192mM Glycine, 20% Methanol (v/v)). 
 
2.5.3 Antibody labelling of immunoblots 
The nitrocellulose was incubated in a block buffer consisting of 5% Marvel 
(dried skimmed milk (w/v)), 0.2% Tween 20 (v/v), and NaOH (4mM) made up 
with TBS (50mM Tris, 0.9% sodium chloride (w/v), pH7.4) for 1 hour at RT. 
Following blocking, the nitrocellulose was probed with a primary antibody in 
incubation buffer (2.5% Marvel (w/v) in TBS) at antibody-specific incubation 
times at 4°C (see Table 2-1). Following primary antibody incubation, the 
nitrocellulose was subjected to four 10 minute washes (5% Marvel (w/v), 0.2% 
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Tween 20 (v/v) made up with TBS) and incubated with HRP-linked anti-rabbit 
secondary antibody for 1hr, after which further four 10 minute washes 
followed, and finally rinsed in TBS buffer. 
 
Following antibody labelling, the nitrocellulose was incubated in a luminol 
solution (100mM Tris, pH8.5, 1.25M Luminol) containing 1mM p-coumaric 
acid, and 0.5% (v/v) hydrogen peroxide (30% stock) for 1 minute and exposed 
to ECL hyperfilm (Amersham) at varying exposure times depending on the 
primary antibody being used. The hyperfilm was developed manually using 
Kodak GBX fixer and developer solutions.  
 
The signal volumes from each lane were scanned and analysed using Image 
J to quantify the optical density of the labelled bands compared to the 
background. Protein levels were standardised using mouse β-actin primary 
antibody (1:5000 dilution, purchased from Sigma). 
 
2.6 Immunohistochemistry 
 
2.6.1 Tissue preparation 
CD-1 or TASTPM mice were sacrificed by CO2 narcosis and brains were 
rapidly dissected, where the right hemisphere was separated and placed in 
fixative solution (4% paraformaldehyde, 0.1M Na2PO4, 0.1M NaH2PO4, pH 
adjusted with NaOH). Samples were post-fixed for one week in fixative 
solution, and subsequently dehydrated using sucrose infiltration, where the 
tissue is placed in 10% sucrose, then 20% sucrose made up with Phosphate 
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Buffered Saline (PBS diluted from a 10X stock purchased from Sigma). Once 
dehydrated, the tissue was snap frozen in iso-pentane -70ºC for 1 minute and 
stored at -80ºC. Samples were sliced sagitally into 25μm thick sections at   -
25ºC using a Leica model CM 3050S Cryostat. Sections were transferred into 
a 24 well plate, with each well containing PBS 0.05% (w/v) sodium azide and 
stored at 4ºC.  
 
2.6.2 Immunohistochemistry 
In order to inhibit endogenous peroxidase activity, samples were incubated in 
a solution consisting of 10% (v/v) methanol, 3% (v/v) hydrogen peroxide (30% 
stock), made up in TBS, and incubated for 30 minutes at RT.  
 
The samples were subjected to three 5 minute washes in 0.2% (v/v) Triton-X-
100 in TBS (TBS-T), and incubated in 0.2% (w/v) glycine in TBS for 30 
minutes at room temperature in order to quench any excess 
paraformaldehyde. 
 
The samples were further incubated in a blocking solution consisting of 10% 
foetal calf serum (FCS) in TBS-T, after which a primary antibody was added 
at the respective concentration and incubation time (see Table 2-1) in 1% 
FCS in TBS at 4ºC. 
 
Following the primary antibody incubation, the samples were left to equilibrate 
to RT for 1 hour. Once the samples had reached RT, TBS-T washes followed 
as previous and samples were incubated with 50μl of anti-rabbit biotinylated 
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secondary antibody (from Vectastain ABC kit, purchased from Vector 
Laboratories) diluted in 10ml of 1% Fotal Calf Serum (FCS) in TBS for 2 hours 
at RT.  
 
Following another wash stage, the samples were incubated with ABC reagent 
(100μl reagent A and 100μl reagent B (from Vectastain ABC kit) diluted in 5ml 
TBS; made up 30 minutes prior to use) for one hour at RT. Samples were 
subjected to another wash stage as previous, with a further two 5 minute 
washes with TBS alone. 
 
Samples were allowed to develop in 3,3-Diaminobenzidine (DAB) solution 
(200μl TBS, 100μl DAB and 100μl H2O2 in 5ml dH2O; DAB peroxidase 
substrate kit obtained from Vector Laboratories) until the optimal signal had 
been achieved (see Table 2-1), where the DAB solution was removed and the 
reaction stopped with dH2O and further rinsed. Sections were dehydration 
mounted and set with DPX mountant. Stained sections were viewed on a 
Nikon Eclipse E400 microscope, where images were photographed using 
Progen Eyepeice 1.3 and 3M Pixel camera. 
 
2.7 AMPA Autoradiography 
 
2.7.1 Tissue Preparation 
CD-1 or TASTPM mice were sacrificed by CO2 narcosis and brains were 
rapidly dissected, where the brain underwent sucrose infiltration, as per 
immunohistochemical tissue preparation. Once the brains had been 
dehydrated, they were snap frozen in iso-pentane -40ºC for 3 minutes and 
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stored at -80ºC. Samples were sliced horizontally into 20μm thick sections at -
25ºC using a Leica Cryostat model CM 3050S. Sections were collected on to 
poly-D-lysine coated glass slides and stored at -20ºC. 
 
2.7.2 Ligand Autoradiography with [3H] AMPA 
Sections were left to reach RT for at least 1 hour before the protocol 
commenced. The sections were then pre-incubated for 20 minutes in pre-
incubation buffer (30mM Tris, pH 7.4) on ice. 
 
Following pre-incubation, sections were transferred to radioligand buffer 
(30mM Tris pH7.4, 20nM [3H] AMPA and 100mM KSCN) and incubated on ice 
for 1 hour. For non-specific binding, sections followed the same protocol as 
radiolabelled sections except with the addition of 1mM glutamate into the 
radioligand buffer. 
 
After incubation with the radioligand or non-specific buffer, sections were 
subjected to three 15 second washes with wash buffer (30mM Tris, pH7.4, 
100mM KSCN) and a final wash of dH2O; all conducted on ice. 
 
After the washes, sections were left overnight to dry before being placed in an 
autoradiography cassette exposed to [3H] Hyperfilm (Amersham), prepared in 
a darkroom and left for 5 weeks before manual developing using the Kodak 
GBX fixer solutions as per immunoblots. 
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2.8 Mitochondrial Respiratory Studies 
 
2.8.1 Mitochondrial isolation 
TASTPM or CD-1 mice were stunned and decapitated, where the forebrain 
and liver were dissected and immediately placed in ice-cold brain or liver 
isolation buffer (220mM Mannitol, 60mM Sucrose, 5mM Tris-HCl, 0.5mM 
(EGTA), and 1mg/ml Bovine Serum Albumin, pH 7.4 or 250mM sucrose, 
3.4mM Tris-HCl pH7.4, respectively). The tissue was rinsed several times in 
isolation buffer to remove any excess blood, and finely chopped in a small 
volume (~5ml) of isolation buffer. 
 
A glass dounce homogeniser, in a 7ml mortar with a loose pestle was used to 
homogenise the tissue gently 3-4 times, then 7-8 times with a tight pestle 
where a smooth suspension was achieved. The homogenate was transferred 
to a centrifuge tube and centrifuged at 500g (0-4°C) Beckman J20 rotor for 10 
minutes. Following centrifugation, the pellet was discarded and the 
supernatant centrifuged for a further 10 minutes at 12,000g (0-4°C). This 
remaining pellet is the crude mitochondrial pellet which contains mitochondrial 
synaptosomes and other membranous material.  
 
The supernatant from the liver preparation was discarded and the pellet 
resuspended in 0.5ml isolation buffer in preparation for oxidative 
phosphorylation studies.  
 
The supernatant from the brain preparation was discarded and the pellet was 
resuspended in 9ml of isolation buffer and aliquoted in layers on to 10ml ice 
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cold Percoll solution (250mM sucrose, 5mM Tris-HCl, 0.1mM EGTA, and 18% 
Percoll, pH7.4) and centrifuged at 12,000g for 45 minutes. 
 
A loose mitochondrial pellet, free from most contamination was formed at the 
bottom of the tube and a synaptosomal layer on the top. The mitochondrial 
layer was isolated and resuspended in chamber buffer (220mM Mannitol, 
60mM Sucrose, 5mM Tris-HCl, and 1mg/ml Bovine Serum Albumin, pH 7.4) 
and centrifuged twice at 12,000g for 10 minutes to remove the Percoll. The 
final pellet was resuspended in ~100μl chamber buffer for respiration studies. 
protein concentration was determined spectrophotometrically by the Lowry 
Protein Assay (Lowry et al., 1951).  
 
2.8.2 Oxidative Phosphorylation Protocol 
A Clark-type oxygen electrode was used to measure mitochondrial oxygen 
consumption polargraphically (Sweetman and Weetman, 1969) with a 
maximum bath volume of 1ml (Rank bros, Bottisham, UK). A Kipp and Zonen 
Flat bed recorder was calibrated to give a full scale deflection of 10mV and a 
chart speed of 0.5mm/sec, and used to record the changes in oxygen 
consumption.  
 
A reaction chamber with a final volume of 0.3ml containing incubation buffer 
plus 5mM KH2PO4 was produced, where the buffer was saturated with oxygen 
(139ng O atoms/ml), and the experiment began with the addition of brain (0.3-
0.5mg) or liver (0.9-1.2mg) mitochondrial protein was used to measure 
mitochondrial respiration. After the endogenous respiration of substrates was 
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recorded for 1 minute, substrate (5mM glutamate plus 5mM malate, or 5mM 
succinate) was added in order to record state 4 respiration, where the 
mitochondria would respire in the presence of excess amount of oxygen and 
substrate, and the absence of ADP. After 1min, ADP (167µM) was added 
creating a reaction where ADP, substrate and oxygen are present in excess 
and so measuring state 3 respiration. Once all ADP had been phosphorylated, 
the respiration returned to state 4 where substrate and oxygen were found in 
excess, absent of ADP (Chance and Williams, 1956). 
 
Respiratory rates were calculated as nanoatoms of oxygen consumed per 
minute per mg mitochondrial protein. RCI was calculated by dividing the state 
3 respiration rate by the return to state 4 respiration rate. This value gives an 
indication of the integrity of the mitochondria, and is a measure of the coupling 
of oxidation in the ETC to ATP synthesis. Values greater than 3 and 2, for 
glutamate plus malate and succinate respectively, indicate tightly coupled 
mitochondria (Chance and Williams, 1956). 
 
2.8.3 Electron Microscopy 
An electron micrograph (Figure 2-2) was obtained to prove the presence of 
intact mitochondria from the mitochondrial isolation protocol detailed. Electron 
Microscopy was conducted by Mrs. Christine Richardson in the Histology 
laboratory at the University of Durham. 
 
Following mitochondrial isolation, the pellet was resuspended in Karnovsky 
fixative (2% paraformaldehyde, 2.5% glutaraldehyde in 0.1M phosphate 
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buffer, pH7.4) for 2 hours, after which the suspension was divided into 1.5ml 
eppendorf tubes and centrifuged at 2,000g for 1 minute. The supernatant 
(fixative) was removed and the pellet received 3 x 5 minute washes in 0.1M 
phosphate buffer. The pellet was then resuspended and post-fixed in 1% 
Osmium Tetroxide in 0.1M phosphate buffer for 1 hr. The supernatant was 
removed and the pellet was again washed 3 x 5 minute washes in 0.1M 
phosphate buffer. The pellet was then dehydrated through a series of 
alcohols: 
 50%, 70%, 95% alcohol 3 x 5min 
 100% alcohol 3 x 10min 
 
The pellet was then resuspended in a 50:50 mixture of 100% 
alcohol:propylene oxide 3 x 5min incubations. The pellet then received 3 x 10 
minute incubations with propylene oxide, and a further 3 x 1hr incubations 
with the 50:50 mixture of propylene oxide:araldite. The pellet was then 
incubated overnight with araldite, where the following day the pellet was 
subjected to two changes of araldite and polymerised at 60ºC for 24hrs. 
 
The mitochondrial samples were received ultrathin sectioning at 60nm, where 
sections were picked up on to 200 mesh copper grids and stained with 1% 
uranyl acetate made in 70% alcohol for 10 minutes, and Reynold's lead citrate 
for 10 minutes. Sections were viewed using a Hitachi S7600 Transmission 
Electron Microscope. 
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Figure 2-2: A representative electron micrograph image of A) brain and B) liver mitochondria 
prepared from the isolation protocol. The scale bar represents 500nm, at a A) 50,000X 
magnification and a B) 30,000X magnification. 
 
 
 
 
 
B A 
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 Table 2-1: Table depicting the varying antibodies and concentrations for differing protocols used in this study. BDNF; Brain Derived Neurotrophic Factor; 
ERK1/2 or ERK1/2-P; unphosphorylated or phosphorylated extracellular-signal regulated kinase 1 or 2, respectively; AKT, Protein Kinase B; CREB, Cyclic 
Adenosine Monophosphate (AMP) Response Element Binding; HSP, Heat Shock Protein; Aβ, β-amyloid; APP, Amyloid Precursor Protein; SDS, Sodium 
Dodecyl Dulphate; Rb, rabbit; Ab, antibody. 
Sample 
Sets 
Commercial Antibody Information Immunoblotting Immunohistochemistry 
Antibody 2º Ab Company SDS Gel (%) 1º Ab Dilution Days Inc Exposure time (min) 1º Ab Conc. Days Inc. Dev Time 
C
D
-1
 &
 T
A
S
T
P
M
 
BDNF Rb AbCam 10 1:1000 1 1-3 1:2000 1 5 
ERK1/2 Rb Cell Signalling 10 1:1000 1 1-3 1:4000 1 5 
ERK1/2-P Rb Cell Signalling 10 1:125 2-3 10 1:250 2-3 10 
CREB Rb Cell Signalling 10 1:125 2-3 10 1:1000 1 5 
CREB-P Rb Cell Signalling - - - - 1:250 2-3 5 
AKT Rb Cell Signalling 10 1:2000 1 1-3 1:1000 1 5 
AKT-P Rb Cell Signalling 10 1:1000 2-3 1-3 1:1000 1 5 
HSP27 Rb Cell Signalling 15 1:125 2-3 10 1:200 2-3 10 
HSP40 Rb Cell Signalling 10 1:125 1-2 7-10 1:200 2-3 10 
HSP60 Rb Cell Signalling 10 1:125 1-2 5-10 1:200 2-3 10 
HSP70 Rb Cell Signalling 10 1:125 1-2 5-10 1:200 2-3 10 
HSP90 Rb Cell Signalling 10 1:125 1-2 5-10 1:200 2-3 10 
HSP105 Rb Cell Signalling 10 1:250 1-2 5-10 1:200 2-3 10 
T
A
S
T
P
M
 
βA1-42 Rb Chemicon - - - - 1:250 1 5 
βA1-40/42 Rb Chemicon 10 1:250 1-2 1-5 1:4000 1 5 
APP Rb Chemicon 10 1:1000 1-2 1-5 1:2000 1 5 
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Chapter 3: Acute IR1072 Treatment: Effects in rat 
neuronal cultures (in vitro) and CD-1 mice (in vivo) 
 
3.1 Introduction 
 
3.1.1 In vitro model system - neuronal cultures 
Neuronal cultures are a useful in vitro experimental model for studying all 
aspects of neuronal processes including therapies that may influence 
neuronal differentiation, excitability, and synapse formation and/or function in 
vivo (Sicaeros and O'Dowd, 2007; van Rensburg et al., 2009). Where n-
numbers in in vivo experimental protocols are counted as one n-number per 
single animal, in vitro models class one n-number as a population of cells in a 
growth vessel, as the process of de-differentiation commences immediately 
after the tissue has been extracted from the parent tissue therefore 
establishing a unique model system in a constant state of change (Hartung et 
al., 2002), ensuing the possibility of hundreds of n-numbers per single animal, 
and consequently a cheaper and more ethical, i.e. reduction in animals, 
approach to establishing data preceding more expensive in vivo 
investigations.  
 
For this investigation, a treatment regime for an in vitro neuronal culture 
system was devised based on a previous study by Bradford et al. (2005) who 
tested a range of IR treatment protocols on cell viability in human 
lymphocytes, and found that cells irradiated with IR1072 using a 5 x 3 minute 
treatment protocol was significantly higher than that of cells irradiated with 
other IR wavelengths using the same protocol. The preliminary aim was to 
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establish whether IR1072 preconditioning had any protective effect on cell 
viability in a neuronal in vitro model system of excitotoxicity before 
establishing any molecular changes of IR1072 preconditioning in an in vivo 
animal model of premature ageing. 
 
3.1.2 In vivo model system - CD-1 mice 
CD-1 mice have a high mortality rate at approximately 2 years of age, and 
have been shown to have learning deficits at a premature age, as young as 3 
months old, where circulating amyloidosis has been implicated as a major 
contributing factor (Ennaceur et al., 2008). Ennaceur et al. (2008) performed 
detailed behavioural analysis of male and female 4 month old and 13 month 
old CD-1 mice, and found that 4 month old male CD-1 mice make significantly 
more errors in the behavioural task compared to young female CD-1 mice. 
This correlates with previous reports that 3 month old male CD-1 mice were 
unable to acquire a working memory task in a continuous choice procedure 
(Mizumori et al., 1982). As CD-1 mice show learning deficits at as early an 
age as 3 month old (Mizumori et al., 1982), another preliminary aim was to 
investigate protein expression or mitochondrial respiratory changes in young 
CD-1 mice following acute exposure to IR1072, before instigating more costly 
and time consuming chronic IR1072 exposure protocols. 
 
Previously, 10 daily sessions of 6 minute IR1072 exposures has been shown 
to improve overall cognitive performance in middle-aged mice (12 monh old) 
compared to young 3 month old CD-1 mice. This study has undertaken the 
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same treatment protocol, 10 daily 6 minute sessions of IR1072, in CD-1 mice 
in order to obtain our objectives.  
 
The aim of this chapter was to establish preliminary data pertaining to the 
neuroprotective effect of IR1072 on in vitro (neuronal cultures) and in vivo 
(CD-1 mice) systems, and to investigate proposed primary (mitochondria) and 
secondary (signalling) mechanisms of IR1072 LILT. 
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3.2 Results 
 
3.2.1 IR1072-preconditioning of pure neuronal cultures: Cell viability 
Glutamate excitotoxicity, has been hypothesized to play a key role in neuronal 
dysfunction and neuronal death in several neurological disease states in the 
CNS (Akaike, 1994; Skaper et al., 2001; Canzoniero and Snider, 2005). 
Glutamate excitotoxicity is generally accepted to act through the glutamate 
NMDA subtype receptors in cortical neurons, since the excitotoxic event can 
be abolished by addition of NMDA receptor antagonists (Meldrum, 1990; 
Santos et al., 2001; Skaper et al., 2001; van Rensburg et al., 2009). 
Overstimulation of these receptors can result in calcium overload which may 
compromise mitochondrial integrity, accelerating free radical production and 
can ultimately lead to cell death (de Bock et al., 1998; Skaper et al., 2001). A 
reproducible and reliable in vitro model of excitotoxicity is critical to 
understanding the cellular and molecular mechanisms of neurodegenerative 
processes in vivo (van Rensburg et al., 2009).  
 
An in vitro excitotoxic model was used in this study, which was adapted for 
pure neuronal cultures in a study conducted by Van Rensburg et al. (2009) 
where pure neuronal cultures were treated with an insult of 1mM glutamate for 
10 minute, to achieve approximately 10-30% neuronal loss, determined 24 
hours following the insult using an MTT assay. Preceding the excitotoxic 
insult, neuronal cultures were preconditioned with 5 x 3 minute IR1072 
exposure and incubated for four hours at 37ºC. 
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Data was analysed using a one-way ANOVA followed by Bonferroni post-test. 
Data represent mean ± SEM. The experiments can be divided into three types 
in terms of severity of insult: Mild, moderate, and severe. 
 
Formulation used to calculate the increase in neuronal cell viability following 
IR1072 irradiation was as follows:  
  
Increase in % cell viability following IR x 100= % neuroprotection 
     Total % neuronal loss 
    
i.e  Sham % insult - IR % insult X 100 
    Sham % insult 
 
(100 - [-IR-G] ) - (100 - [+IR+G]) x 100 = % neuroprotection 
   (100 - [-IR-G]) 
 
 
e.g. Mild Insult: (100 - 85.99) - (100 - 98.61) = 14.01 - 1.39 x 100 = 90.08% 
        (100-85.99)     14.01 
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3.2.1.1 Mild insult 
In the presence of glutamate (n=6, 85.99 ± 8.18%), sham-preconditioned 
neuronal cultures displayed a significant decrease in cell viability (14.01%) 
compared to control insults absent of glutamate (n=6, 100.0 ± 7.56 p<0.01%). 
In the presence of glutamate (n=6, 96.32 ± 2.78%), IR1072-preconditioned 
neuronal cultures displayed no change in cell viability, compared to control 
insults absent of glutamate (n=6, 98.61 ± 4.26%, Figure 3-1) Cell viability in 
IR1072-treated neuronal cultures that received a glutamate insult (n=6, 96.32 
± 2.78%) was significantly increased (90.08%, p<0.01) compared to sham- 
preconditioned cultures (n=6, 85.99 ± 8.178) which had received the same 
insult. 
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Figure 3-1: Column graph showing the effects of IR1072 on cell viability in DIV7 mixed 
cortical cultures following a mild excitotoxic insult. Abbreviations: -IR-G, sham pre-treatment 
and sham insult (representing 100%); -IR+G, sham pre-treatment and glutamate insult; +IR-
G, IR pre-treatment and sham insult; +IR+G, IR pre-treatment and glutamate insult. Cell 
viability determined via an MTT assay. Mean values +/- SEM for n = 6 replicates from one 
culture, *p < 0.05, **p < 0.01. 
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3.2.1.2 Modest insult 
In the presence of glutamate (n=6, 75.29 ± 5.43%), sham-preconditioned 
neuronal cultures displayed a significant decrease in cell viability (24.7%, 
p<0.001) in sham-preconditioned cultures, compared to control insults absent 
of glutamate (n=6, 99.99 ± 4.26%). In the presence of glutamate (n=6, 86.33 ± 
5.14%), IR1072-preconditioned neuronal cultures displayed a significant 
decrease in cell viability (19.4%, p<0.001), compared to control insults absent 
of glutamate (n=6, 107.2 ± 7.03%, Figure 3-2). Cell viability in IR1072-
preconditioned neuronal cultures that received a glutamate insult (n=6, 75.29 
± 5.43%) was significantly increased (44.7%, p<0.01) compared to sham- 
preconditioned cultures (n=6, 86.33 ± 5.14%) which had received the same 
insult.  
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Figure 3-2: Column graph showing the effects of IR1072 on cell viability in DIV7 mixed 
cortical cultures following a moderate excitotoxic insult. Abbreviations: -IR-G, sham pre-
treatment and sham insult (also representing 100%); -IR+G, sham pre-treatment and 
glutamate insult; +IR-G, IR pre-treatment and sham insult; +IR+G, IR pre-treatment and 
glutamate insult. Cell viability determined via an MTT assay. Mean values +/- SEM for n = 6 
replicates from one culture, ** p < 0.01, ***p<0.001. 
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3.2.1.3 Severe insult 
In the presence of glutamate (n=6, 66.29 ± 5.55%), sham-preconditioned 
neuronal cultures displayed a significant decrease in cell viability (33.71%, 
p<0.001), compared to control insults absent of glutamate (n=6, 100.0± 
8.39%). In the presence of glutamate (n=6, 66.37 ± 8.54%), IR1072-
preconditioned neuronal cultures displayed a significant decrease in cell 
viability (27.1%, p<0.001), compared to control insults absent of glutamate 
(n=6, 91.27 ± 7.58%, Figure 3-3). No difference in cell viability in IR1072-
preconditioned neuronal cultures that received a glutamate insult (n=6, 66.37 
± 8.537%) was shown (0.002%) compared to sham-preconditioned cultures 
(n=6, 66.29 ± 5.55%) which had received the same insult.  
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Figure 3-3: Column graph showing the effects of IR1072 on cell viability in DIV7 mixed 
cortical cultures following a severe excitotoxic insult. Abbreviations: -IR-G, sham pre-
treatment and sham insult (also representing 100%); -IR+G, sham pre-treatment and 
glutamate insult; +IR-G, IR pre-treatment and sham insult; +IR+G, IR pre-treatment and 
glutamate insult. Cell viability determined via an MTT assay. Mean values +/- SEM for n = 6 
replicates from one culture, ***p< 0.001  
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3.2.2 IR1072-preconditioning in CD-1 mice: Mitochondrial respiratory 
studies.  
 
Chance and Williams (1956) developed the polarographic method using an 
oxygen electrode for measuring respiratory rates in cells and subcellular 
systems including isolated mitochondria (Ernster, 1993) which has been used 
in this study (Chance and Williams, 1956). The ratio between the respiratory 
rate during state 3 (active state of respiration) and the return to state 4 
(controlled respiratory rate after all ADP is phosphorylated) is called the 
respiratory control index (RCI); this gives a ratio which allows one to ascertain 
the integrity of coupling of oxidation and reduction within the ETC to 
phosphorylation of ADP to ATP (Campello et al., 1964). In order to assess the 
impact, if any, of IR1072 on Complex I and II of the ETC, respiration studies 
using the polarographic method were performed on isolated sham or IR1072-
preconditioned (in vivo) CD-1 mouse brain and liver mitochondria. 
 
All Data were statistically analysed using a two tailed student t-test. Data 
represent mean ± SEM. 
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In the presence of glutamate (5mM) plus malate (5mM), IR1072 treated 7 
month old CD-1 mice (n=2) brain showed no significant differences in 
endogenous (66.62 ± 1.783 ng O min-1 mg-1 protein) , state 4 (80.08 ± 5.425 
ng O min-1 mg-1 protein), state 3 (171.5 ± 16.63 ng O min-1 mg-1 protein) and 
return to state 4 (73.32 ± 4.917 ng O min-1 mg-1 protein) respiratory rates 
compared to age-matched sham controls (n=3) endogenous (48.91 ± 13.98 
ng O min-1 mg-1 protein), state 4 (66.38 ± 10.48 ng O min-1 mg-1 protein), state 
3 (136.3 ± 3.494 ng O min-1 mg-1 protein) and return to state 4 (52.41 ± 17.47 
ng O min-1 mg-1 protein) respiratory rates (Figure 3-4).  
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Figure 3-4: The effect of acute sham- or IR- treatment on glutamate plus malate respiratory 
rates in male 7m old CD-1 mouse (in vivo) brain mitochondria. Respiratory rates of glutamate 
plus malate at A) endogenous state B) state 4 C) state 3 and D) the return to state 4. Mean 
values ± SEM, n = 2 for each group. 
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In the presence of glutamate (5mM) plus malate (5mM), the RCI of IR1072 
treated 7 month old CD-1 mice brain (n=2, 2.775 ± 0.4124) shows no 
significant difference compared to RCI of age-matched sham controls (2.701 
± 0.0764) (Figure 3-5).  
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Figure 3-5: The effect of acute sham- or IR- treatment on glutamate plus malate RCI in male 
7m old CD-1 mouse (in vivo) brain mitochondria Mean values ± SEM, n = 2 for each group. 
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In the presence of succinate (5mM), IR1072 treated 7 month old CD-1 mice 
brain (n=3) displayed higher state 4 (193.2 ± 10.79 ng O min-1 mg-1 protein, 
p<0.05) , state 3 (684.6 ± 40.59 ng O min-1 mg-1 protein, p<0.05), and return 
to state 4 (208.8 ± 11.31 ng O min-1 mg-1 protein, p <0.05) respiratory rates 
compared age-matched sham controls (n=3) state 4 (125.6 ± 13.79 ng O min-
1 mg-1 protein), state 3 (492.6 ± 31.39 ng O min-1 mg-1 protein) and return to 
state 4 (140.7 ± 14.96 ng O min-1 mg-1 protein) respiratory rates. No 
significant differences were found between IR1072 treated CD-1 mice 
endogenous rate (60.59 ± 11.67 ng O min-1 mg-1 protein) and sham treated 
mice (60.08 ± 5.446 ng O min-1 mg-1 protein) (Figure 3-6).  
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Figure 3-6: The effect of acute sham- or IR- treatment on succinate RCI in male 7m old CD-1 
mouse (in vivo) brain mitochondria. Respiratory rates of succinate at A) endogenous state B) 
state 4 C) state 3 and D) the return to state 4. Mean values ± SEM, n = 3 for each group, 
*p<0.05. 
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In the presence of succinate (5mM), the RCI of IR1072 treated 7 month old 
CD-1 mice brain (n=3, 4.016 ± 0.6048) showed no significant differences 
compared to age-matched sham controls (n=3, 3.477 ± 0.233) (Figure 3-7).  
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Figure 3-7: The effect of acute sham- or IR- treatment on succinate RCI in male 7m old CD-1 
mouse (in vivo) brain mitochondria. Mean values ± SEM, n = 3 for each group. 
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In the presence of glutamate (5mM) plus malate (5mM), IR1072 treated 7 
month old CD-1 mice liver (n=3) showed no significant differences in 
endogenous (36.15 ± 1.347 ng O min-1 mg-1 protein) , state 4 (17.28 ± 0.802 
ng O min-1 mg-1 protein), state 3 (197.2 ± 11.24 ng O min-1 mg-1 protein) and 
return to state 4 (17.87 ± 2.524 ng O min-1 mg-1 protein) respiratory rates 
compared to age-matched sham controls (n=3) endogenous (37.39 ± 0.797 
ng O min-1 mg-1 protein), state 4 (15.36 ± 2.827 ng O min-1 mg-1 protein), state 
3 (217.2 ± 7.707 ng O min-1 mg-1 protein) and return to state 4 (16.33 ± 2.162 
ng O min-1 mg-1 protein) respiratory rates (Figure 3-8).  
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Figure 3-8: The effect of acute sham- or IR- treatment on glutamate plus malate RCI in male 
7m old CD-1 mouse (in vivo) liver mitochondria. Respiratory rates of glutamate plus malate at 
A) endogenous state B) state 4 C) state 3 and D) the return to state 4. Mean values ± SEM, n 
= 3 for each group. 
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In the presence of glutamate (5mM) plus malate (5mM), IR1072 treated 7 
month old CD-1 mice liver (n=3, 4.187 ± 0.0827) showed a trend toward a 
decrease in RCI (p= 0.0532) compared to age-matched sham controls (n=3, 
4.735 ± 0.1842) (Figure 3-9).  
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Figure 3-9: The effect of acute sham- or IR- treatment on glutamate plus malate RCI in male 
7m old CD-1 mouse (in vivo) liver mitochondria. Mean values ± SEM, n = 3 for each group. 
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In the presence of succinate (5mM), IR1072 treated 7 month old CD-1 mice 
liver (n=3) showed no significant differences in endogenous (39.86 ± 1.188 ng 
O min-1 mg-1 protein), state 4 (75.14 ± 5.578 ng O min-1 mg-1 protein), state 3 
(352.4 ± 9.790 ng O min-1 mg-1 protein) and return to state 4 (70.93 ± 3.951 
ng O min-1 mg-1 protein) respiratory rates compared to age-matched sham 
controls (n=3) endogenous (37.86 ± 2.526 ng O min-1 mg-1 protein) , state 4 
(62.20 ± 3.530 ng O min-1 mg-1 protein), state 3 (370.7 ± 19.89 ng O min-1 mg-
1 protein) and return to state 4 (56.88 ± 5.746 ng O min-1 mg-1 protein) 
respiratory rates (Figure 3-10). 
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Figure 3-10: The effect of acute sham- or IR- treatment on succinate RCI in male 7m old CD-
1 mouse (in vivo) liver mitochondria. Respiratory rates of succinate at A) endogenous state B) 
state 4 C) state 3 and D) the return to state 4. Mean values ± SEM, n = 3 for each group. 
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In the presence of succinate (5mM), IR1072 treated 7 month old CD-1 mice 
liver (n=3, 4.323 ± 0.1452) showed a trend toward a decrease in RCI (p<0.05) 
age-matched sham controls (n=3, 3.559 ± 0.1105) (Figure 3-11).  
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Figure 3-11: The effect of acute sham- or IR- treatment on succinate RCI in male 7m old CD-
1 mouse (in vivo) liver mitochondria. Mean values ± SEM, n = 3 for each group, *p<0.05. 
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Glutamate (5mM) plus Malate (5mM)       
 
Succinate (5mM) 
 
Figure 3-12: A typical trace showing Oxidative Phosphorylation for Complex I & II. Traces 
generated by measuring the respiratory rate of mitochondria alone (endogenous) for 1 
minute, after adding glutamate (5mM) plus malate (5mM; Complex I) or succinate (5mM; 
Complex II) for 1 minute (State 4), by adding ADP (167µM; State 3) and allowing all the ADP 
to be phosphorylated (Return to State 4).  
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3.2.3 IR1072-preconditioning in CD-1 mice: ERK1/2 and HSP expression 
It has been proposed that low-powered laser irradiation (red and near infra-
red spectrum) does not work via the stress signal pathway i.e. p38 and JNK 
pathways, but rather through the ERK1/2 signalling pathway heavily 
implicated in neuroprotection (Gao and Xing, 2009). A possible primary 
mechanism of low power laser irradiation is activation through dimerization of 
receptors, i.e. TRKB receptors, that are in the "right energetic state" to accept 
the laser energy, leading to their autophosphorylation and downstream effects 
(Karu, 1999; Gao and Xing, 2009). However, the mitochondrial ETC appears 
to be the primary photoacceptor, therefore through changes in respiration, 
MMP and/or mitochondrial retrograde signalling, ERK1/2 signalling is more 
likely to be the secondary mechanism associated with near IR irradiation (Gao 
and Xing, 2009). Although HSP are implicated in activation of the stress signal 
pathways rather than ERK1/2 signalling, they are also heavily implicated in 
neuroprotection, where induction of HSP expression is associated with aiding 
protein misfolding and improved healing of damaged tissues in animal models 
and in humans. HSP also act by inhibiting various pro-apoptotic factors 
associated with mitochondrial dysfunction. 
 
Age matched sham- or IR1072-preconditioned CD-1 mouse brain tissue was 
subjected to quantitative immunoblot analysis to assess the protein 
expression of phosphorylated and unphosphorylated ERK1/2, BDNF, another 
protein heavily implicated in neuroprotection mainly via the ERK1/2 pathway, 
CREB, a transcription factor subsequently upregulated by ERK1/2 activation, 
and selected HSP associated with neuroprotection. Although AKT acts via the 
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PI3 kinase pathway, it is associated with cell survival and, as a 
neuroprotective effect was shown previously in cell viability in neuronal 
cultures, it seemed apt to investigate any possible upregulation of this cell 
survival protein. 
 
Protein levels were standardised using mouse β-actin primary antibody. Data 
were statistically analysed using a two tailed student t-test. Data represent 
mean ± SEM. 
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Table 3-1: Protein expression profile of 4 month old CD-1 mice following acute IR1072 
treatment compared to age-matched sham-treated CD-1 mice. Arrows represent an increase 
(↑) or decrease (↓) in protein expression in IR-treated CD-1 compared to age-matched sham 
controls, and respective figure numbers. Abbreviations; BDNF, Brain Deived Neurotrophic 
Factor; ERK1/2, Extracellular Signal-regulated Kinase; CREB, Cyclic Adenosine 
Monophosphate (AMP) Response Element Binding; AKT, Protein Kinase B; HSP, Heat Shock 
Protein. Data were statistically analysed using a two tailed student t-test. Pink cells represent 
significant results and blue cells represent a trend. n=4 for each group, *p<0.05, **p<0.01.  
 
Effect of Acute IR1072 treatment on protein expression in 4 month 
old CD-1 mice 
1º Ab p value Result Figure 
BDNF **0.0096 ↓ 3-13 
ERK1 0.0511 ↓ 3-14 
 ERK2 0.1021 NS 
ERK1-P 0.8107 NS 
Data not shown 
ERK2-P 0.5372 NS 
CREB 0.4082 NS Data not shown 
AKT 0.1839 NS Data not shown 
HSP60 0.0816 ↑ 3-15 
HSP70 *0.011 ↑ 3-16 
HSP90 0.1069 NS Data not shown 
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IR1072-treated CD-1 mice (n=5) showed a significant decrease (0.6050 ± 
0.108, p<0.01) in BDNF expression compared to age-matched sham controls 
(n=5, 0.7786 ± 0.039; Figure 3-13). 
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Figure 3-13: Effects of BDNF expression in acutely sham or IR1072 treated 4 month old CD-
1 mouse brain (in vivo) where A) is an Immunoblot representation where each lane 
represents an individual mouse, therefore one n number and B) is a column graph showing 
the quantitative results of BDNF expression from the immunoblot. Abbreviations: BDNF, Brain 
Derived Neurotrophic Factor. Mean values ± SEM, n = 5 for each group, **p<0.01. 
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IR1072-treated CD-1 mice (n=4) showed a trend for decreased ERK1 and 2 
expression (0.377 ± 0.064, p=0.0511 and 0.888 ± 0.036, p=0.1021, 
respectively) compared to age-matched sham controls (n=4, 0.5725 ± 0.148 
and 1.005 ± 0.115, respectively) (Figure 3-14).  
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Figure 3-14: Effects of ERK1/2 expression in acutely sham or IR1072 treated 4 month old 
CD-1 mouse brain (in vivo) where A) is an Immunoblot representation, each lane represents 
an individual mouse therefore one n number and B) is a column graph showing the 
quantitative results of a) ERK1 and ii) ERK 2 expression. Abbreviations: BDNF, extracellular 
signal regulating kinase. Mean values ± SEM, n = 4 for each group. 
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IR1072-treated CD-1 mice (n=4) showed a trend for decreased HSP60 
expression (0.263 ± 0.042, p= 0.0816) compared to age-matched sham 
controls (n=4, 0.4730 ± 0.196) (Figure 3-15).  
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Figure 3-15: Effects of HSP60 expression in acutely sham or IR1072 treated 4 month old CD-
1 mouse brain (in vivo) where A) is an Immunoblot representation where each lane 
represents an individual mouse, therefore one n number and B) is a column graph showing 
the quantitative results of HSP60 expression. Abbreviations: HSP, Heat Shock Protein. Mean 
values ± SEM, n = 4 for each group. 
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IR1072-treated CD-1 mice (n=4) showed a significant increase (2.285 ± 
0.686, p<0.05) in HSP70 expression compared to age-matched sham controls 
(n=4, 0.9321 ± 0.293; Figure 3-16).  
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Figure 3-16: Effects of acute sham or IR1072 treatments on HSP70 expression in treated 4 
month old CD-1 mouse brain (in vivo) where A) is an Immunoblot representation where each 
lane represents an individual mouse, therefore one n number and B) is a column graph 
showing the quantitative results of HSP70 expression. Abbreviations: HSP, Heat Shock 
Protein. Mean values ± SEM, n = 4 for each group, *p<0.05. 
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3.3 Discussion 
 
The aim of this chapter was to establish the neuroprotective effects, if any, of 
acute IR1072-preconditioning using in vitro and in vivo methodologies, and if 
so, propose a mechanism relating to IR1072 in order to warrant further 
investigations.  
 
The pure neuronal cultures produced in this study are evenly dispersed with a 
minimal presence of glial cells (<5%). Variations in glutamate cell death is 
dependant on cultures prepared on various dates and therefore may be due 
to quality of culture preparation as well as total duration of the culture 
preparation. Despite this, the cultures were consistently seeded at a density of 
3000 cells/mm2. Due to these variations in cell death, the results were divided 
in to three classes of insult, mild, moderate and severe depending on the 
neuronal loss achieved. The level of protection following IR1072-
preconditioning in the pure neuronal cultures was dependent on the level of 
neuronal loss, where the more severe the insult the neuronal cultures 
received, the less, if any, the protection. However, in the minor insult of 
approximately 14% neuronal loss, a 90% protection was achieved with IR 
treatment.  In fact, the cell viability in the mild glutamate insult group of the 
IR1072-preconditioned cultures was higher than the control insult, possibly 
indicating a potentiated effect of IR1072-preconditioning. Lin et al. (2008) 
preconditioned, rather than insulted, rat cortical cultures with glutamate before 
subjecting the cultures to oxygen-glucose deprivation, in an in vitro model of 
ischemia. They showed that pre-treatment with N-methyl-D-aspartate (NMDA) 
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receptor antagonists prevented OGD-induced cell death, whereas alpha-
amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptor did not. 
However, protective efficacy of glutamate preconditioning was blocked by 
NMDA or AMPA receptor blockers, and if extracellular calcium was removed 
the neuroprotective effect was abolished. Also, glutamate preconditioning 
increased levels of phosphorylated CREB and Bcl-2. They demonstrated that 
low levels of glutamate, 120μM for 40 minutes, produced the maximal 
protective effect at a minimal cost to neuronal loss (10%). They proposed that 
glutamate preconditioning protected neurons via AMPA receptor and NMDA 
receptor activation, where an influx of intracellular calcium induced 
Ca2+/calmodulin-dependent kinase II (CAMKII) autophosphorylation which 
activated CREB and led to upregulation of Bcl-2 and ultimately preventing 
apoptosis (Lin et al., 2008). Although this study used a 10 minute 1mM 
glutamate insult (rather than preconditioning) only a 14% neuronal loss 
occurred in the mild insult group which, combined with IR1072 pre-treatment, 
could have lead to an upregulation of CREB therefore elicited neuroprotective 
effects rather than neurotoxic events seen in sham controls. The more severe 
insults of 25% and 33% neuronal loss may have resulted in high level of 
calcium toxicity that was unable to recover from just CREB activation alone, 
therefore resulting in little or no neuroprotective effect. LILT has also been 
shown to have an insult-dependant neuroprotective effect. Liang et al. (2006) 
pre-treated primary neuronal cultures from postnatal rat visual cortex with 
LED LILT (670nm) before being subjected to a potassium cyanide insult for 
28h, in order to induce cell death via the apoptotic pathway. Liang showed 
LILT pretreatment reduced apoptosis from 36% to 17.9% (100μM potassium 
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cyanide) and from 58.9% to 39.6% (300μM potassium cyanide), representing 
a 50.3% and 32.8% reduction, respectively. Liang also showed that LILT 
significantly decreased potassium cyanide-induced caspase-3 and Bax 
expression and increased Bcl-2 levels, indicating that LILT partially protects 
neurons from cyanide-induced apoptosis by down-regulating apoptosis and 
upregulation anti-apoptotic proteins (Liang et al., 2006). These results indicate 
that the level of insult achieved is influential on LILT-induced neuroprotection. 
Similar results have been obtained with anaesthetic precondition (results not 
shown) 
 
Naturally, mitochondrial studies were a focus of this primary investigation 
since mitochondria have been postulated to be the primary photo-targets 
during IR irradiation. Mitochondria are sensitive to irradiation with near-IR, 
50% of which is reportedly absorbed in the liver by mitochondrial 
chromophores, such as cytochrome c oxidase (Liang et al., 2006). As the 
IR1072-preconditioning in vivo apparatus irradiated the entire body of the CD-
1 mice, the brain and liver were the primary targets for mitochondrial 
respiratory studies. The electron micrograph (Figure 2-2) confirms isolation of 
in-tact liver and brain mitochondria from the protocol implicated. The RCI 
value has been shown to give an indication on whether a mitochondrial 
preparation is tightly or loosely coupled (Campello et al., 1964) 
 
Glutamate plus malate or succinate can be used to stimulate the complex 
activity in the oxidative phosphorylation assay in order to measure complex I 
or II activity, respectively (Figure 3-12) (Chance and Williams, 1956; Markham 
et al., 2004). Thus, not only is this a useful tool to measure the coupling and 
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therefore the reliability of a mitochondrial preparation at different complexes, it 
is also a procedure to evaluate where the physiological changes may take 
place in mitochondria when examining various parameters i.e. IR1072-
preconditoning in vivo. 
 
Table 3-2: Comparison of RCI values produced in this investigation and that performed by 
Chance & Williams (1956). Abbreviations: RCI, respiratory control index, G&M, gluatmate and 
malate.  
 Tissue G&M RCI Succinate RCI 
This investigation 
CD-1 brain 2.70 ± 0.08 3.48 ± 0.23 
CD-1 Liver 4.74 ± 0.18 3.56 ± 0.11 
Chance & Williams (1956)  
>3 >2 
 
Mitochondrial complex II of the ETC in complex II was affected in both brain 
and liver mitochondria following 10 day in vivo treatment IR1072. Reports 
show that low-level laser therapy (wavelength of 904 nm) significantly 
increases the activities of complexes II and IV of mitochondrial respiratory 
chain components, but does not affect succinate dehydrogenase activity and 
has been discussed as a possible photacceptor for near-IR light. Changes 
occur in complex II, albeit RCI or respiratory rates following LILT. IR1072-
preconditioning had no effect for both respiration and RCI for complex I in liver 
and brain mitochondria, probably because complex I has been shown to act 
as a photoacceptor for the blue spectral region, but not for the red or near 
infra-red light (Gao and Xing, 2009). Another possible reason is that the RCI 
of the glutamate plus malate for brain mitochondria was lower than 3, 
indicating loosely coupled mitochondria and therefore a less reliable 
mitochondrial preparation, although this is unlikely as the RCI was only 0.3 
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units lower than the recommended RCI.  These results confirm previous 
reports of increased complex II activity in laser LILT treated ulcerations 
created in wistar rats (Silveira et al., 2007) and may show that complex II in 
the mitochondrial respiratory chain may be acting as a photoacceptor for IR 
LILT, therefore increasing the respiratory activity. 
 
Due to time constraints and cost effectiveness i.e. one mitochondrial 
preparation of approximately 50-100μl requires at least 3 mouse brains, we 
have only investigated the effects of acute IR1072 treatment in 7 month old 
CD-1 mice. Further investigations to assess the effect of chronic exposure of 
IR1072 in younger and older CD-1 mice, on individual complex activity would 
be required to try to determine the mechanistic nature of IR1072 exposure on 
the mitochondrial respiratory chain.  
 
This increase in complex activity could be contributing to the rise in MMP, & 
ATP generation seen in previous studies. As discussed previously, these can 
lead to cell signalling pathways involved in neuroprotection. Surprisingly, we 
found that 10 day IR1072 treatment reduced BDNF and ERK1/2 levels in 4 
month old CD-1 mice, which does not correlate with previous findings of 
increased BDNF gene expression following IR LILT (Byrnes et al., 2005b), 
although ERK1/2 phosphorylated, therefore activated ERK1/2 and CREB, is 
unchanged. This could be due to differences in wavelength, as Byrnes et al. 
(2005b) used an 810nm wavelength which has been suggested to act through 
cytochrome c oxidase where 904nm, and now 1072nm, has been shown to 
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increase activity in complex II, which could possibly elicit differential effects. 
These differences may also simply be due to species or protocol differences.  
 
However, despite inducing a downregulation in ERK1/2 signalling pathways, 
IR1072 produced different effects in HSP expression. IR1072, appeared to 
reduce the expression of HSP60, which plays a role in inducing caspase-3, an 
enzyme involved in cleaving and therefore activating the caspases involved in 
the apoptotic caspase cascade, and increase HSP70 expression, a well-
studied HSP involved in several anti-apoptotic actions. In a study by 
Novoselova et al. (2006) irradiated macrophages and splenic lymphocytes 
with 632.8nm laser increased HSP70, but reduced HSP90 expression 
(Novoselova et al., 2006), suggesting upregulation of HSP70, at least, may be 
involved in the neuroprotective effects seen with LILT. 
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Chapter 4: Effect of chronic IR1072 (in vivo) treatment 
on behaviour: 3D radial maze 
 
4.1 Introduction 
 
The nine-arm 3D radial maze is a modification of an eight-arm radial maze, 
where an animal's response to the novelty of an open space environment are 
assessed in either a single session (emotional) or multiple sessions (learning, 
memory and emotional; Ennaceur et al., 2006b). It has been proposed that 
the first few exposures to the maze are likely to induce fear of novelty-induced 
anxiety, therefore these initial sessions were assessed for emotional 
responses as well as working memory, following which repeated exposures 
are thought to diminish anxiety as learning improves (Ennaceur et al., 2006b). 
In this study, the food-deprived mice were introduced to the maze without 
prior habituation, where food pellets were placed at the end of each arm and 
mice are subjected to daily sessions in order to test working memory 
(Michalikova et al., 2008). Therefore, this behavioural paradigm is able to 
assess the motor activity, emotional responses and working memory 
performance of an animal within the same experimental settings and testing 
conditions (Ennaceur et al., 2006b). The mice were placed in the central 
platform and required to cross a bridge to reach the end of the arm that 
contains the food pellet. This study used the raised arm configuration, as 
previous results find that rats and mice show a preference for this 
configuration as the visual cue may need to be above the horizontal plane of 
their snouts in order for them see which arm they need to access to retrieve a 
pellet (Ennaceur et al., 2006b).  
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Figure 4-1: 3D radial maze where a) central platform b) bridge c) arm and d) visual cue. 
 
A perfect working memory would consist of a mouse moving from one arm to 
the next, completing one visit to each arm without repeats or errors. Hesitation 
or reluctance to move to different areas of the maze is an emotional response, 
not memory impairment (Ennaceur et al., 2008), therefore various parameters 
are recorded in order to assess emotional responses and working memory.  
 
Previous studies have shown IR1072 to have a beneficial effect in learning 
and memory following a 10-minute treatment. Michalikova et al. (2008) 
subjected young (3 months old) and middle-aged (12 months old) mice to 10 
daily sessions of 6 minute IR1072 exposures, and found IR1072 to improve 
overall cognitive performance in middle-aged mice comparable to young 3 
month old CD-1 mice. We have altered this protocol to use a chronic form of 
IR1072 treatment, whereby mice received 10 minute IR1072 sessions, over 
two consecutive days, bi-weekly for 5-6 months. 
 
The aim of this chapter was to determine whether a chronic form of IR1072 
treatment in younger (7 month old) and older (13 month old) male CD-1 mice 
would confirm previous findings of improved cognitive performance following 
short term IR1072 irradiation. 
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4.2 Results 
4.2.1 Chronic IR1072-preconditioning in 7 month old CD-1 mice: 3D 
radial maze 
Group means were tested for significance with a two-way ANOVA repeated 
measures. This was followed up with Newman-Keuls post-hoc comparisons. 
Statistics were calculated using the statistical package Statistica for Windows 
(version 5.5). Results were considered significant when p≤ 0.05.  
 
There were no significant differences in the number of repeated visits to arms 
between sham or IR1072 treated 7 month old CD-1 mice (F1,14=0.07, 
p>0.10), significant differences between sessions (F9,140=4.93, p<0.0001) 
but no significant interactions between groups and sessions (F9,140=0.82, 
p>0.10; Figure 4-2). 
 
There were no significant differences in the number of arm entries before first 
repeated arm visit, between sham or IR1072 treated 7 month old CD-1 mice 
(F1,14=0.31, p>0.10), significant differences between sessions (F9,140=3.76, 
p<0.0001) but no significant interactions between groups and sessions 
(F9,140=1.38, p>0.10; Figure 4-2). 
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Figure 4-2: Graphs depicting the learning and memory in 7 month old IR1072-treated CD-1 
mice and age-matched sham controls. Behavioural parameters; number of repeated arm 
visits and the number of arm visits before first repeated arm visit. Sessions refer to daily 10 
minute 3D radial maze testing over 10 days, S1-10. Group means were tested for significance 
with a two-way ANOVA repeated measures. This was followed up with Newman-Keuls post-
hoc comparisons, n=8 for each group. 
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There were no significant differences in the number of arm entries, between 
sham or IR1072 treated 7 month old CD-1 mice (F1,14<0.64, p>0.10), 
significant differences between sessions (F9,140>6.40, p<0.0001) but no 
significant interactions between groups and sessions (F9,140<1.47, p>0.10; 
Figure 4-3). 
 
There were no significant differences in the arm/bridge ratio for number of 
entries between sham or IR1072 treated 7 month old CD-1 mice (F1,14=0.75, 
p>0.10), no significant differences between sessions (F9,140=0.54, p>0.10) 
and no significant interactions between groups and sessions (F9,140=0.84, 
p>0.10; Figure 4-3). 
 
There were no significant differences in the arm/bridge ratio for duration of 
entries between sham or IR1072 treated 7 month old CD-1 mice (F1,14=052, 
p>0.10), no significant differences between sessions (F9,140=0.98, p>0.10) 
and no significant interactions between groups and sessions (F9,140=0.95, 
p>0.10; Figure 4-3). 
 
There were no significant differences in the number of bridge entries before 
first arm visit between sham or IR1072 treated 7 month old CD-1 mice 
(F1,14=0.58, p>0.10), significant differences between sessions 
(F9,140=11.27, p<0.0001) but no significant interactions between groups and 
sessions (F9,140=0.80, p>0.10; Figure 4-3). 
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There were no significant differences in the latency of first entry to an arm 
between sham or IR1072 treated 7 month old CD-1 mice (F1,14=1.20, 
p>0.10), no significant differences between sessions (F9,140=1.33, p>0.10) 
and no significant interactions between groups and sessions (F10,140=1.17, 
p>0.10; Figure 4-3). 
 
There were no significant differences in the total time spent on the bridges 
between sham or IR1072 treated 7 month old CD-1 mice (F1,14=0.26, 
p>0.10), no significant differences between sessions (F9,140=1.41, p>0.10) 
and no significant interactions between groups and sessions (F9,140=0.28, 
p>0.10; Figure 4-3). 
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Figure 4-3: Graphs depicting emotional responses in 7 month old IR1072-treated CD-1 mice 
and age-matched sham controls. Behavioural parameters; arm/bridge ratio of number of 
entries or duration of entries, number of arm or bridge entries, latency to first entry onto an 
arm and time spent on an arm. Sessions refer to daily 10 minute 3D radial maze testing over 
10 days, S1-10. Group means were tested for significance with a two-way ANOVA repeated 
measures. This was followed up with Newman-Keuls post-hoc comparisons, n=8 for each 
group. 
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There were no significant differences in the total time spent on the arms 
between sham or IR1072 treated 7 month old CD-1 mice (F1,14=0.001, 
p>0.10), significant differences between sessions (F9,140=3.58, p<0.0001) 
but no significant interactions between groups and sessions (F9,140=0.37, 
p>0.10; Figure 4-4). 
 
There were no significant differences in the total time spent in the central 
platform between sham or IR1072 treated 7 month old CD-1 mice 
(F1,14=3.47, p<0.09), significant differences between sessions (F9,140=6.77, 
p<0.0001), but no significant interactions between groups and sessions 
(F9,140=1.32, p>0.10; Figure 4-4). 
 
There were no significant differences in the session duration between sham or 
IR1072 treated 7 month old CD-1 mice (F1,14=4.17, p<0.06), significant 
differences between sessions (F9,140=7.88, p<0.0001), but no significant 
interactions between groups and sessions (F9,140=1.54, p>0.10; Figure 4-4). 
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Figure 4-4: Graphs depicting general mobility responses in 7 month old IR1072-treated CD-1 
mice and age-matched sham controls. Behavioural parameters; Time spent on the bridges, 
time spent on the central platform and sessions' duration. Sessions refer to daily 10 minute 
3D radial maze testing over 10 days, S1-10. Group means were tested for significance with a 
two-way ANOVA repeated measures. This was followed up with Newman-Keuls post-hoc 
comparisons, n=8 for each group. 
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4.2.2 Chronic IR1072-preconditioning in 13 month old CD-1 mice: 3D 
radial maze 
Group means were tested for significance with a two-way ANOVA repeated 
measures. This was followed up with Newman-Keuls post-hoc comparisons. 
Statistics were calculated using the statistical package Statistica for Windows 
(version 5.5). Results were considered significant when p≤ 0.05.  
 
There were no significant differences in the number of repeated visits to arms 
between sham or IR1072 treated 13 month old CD-1 mice (F1,14=1.06, 
p>0.10), there were significant differences between sessions (F10,140=2.64, 
p<0.009) but no significant interactions between groups and sessions 
(F10,140=0.49, p>0.10; Figure 4-5). 
 
There were no significant differences in the number of arm entries before first 
repeated arm visit, between sham or IR1072 treated 13 month old CD-1 mice 
(F1,14=0.98, p>0.10), significant differences between sessions 
(F10,140=3.63, p<0.0001) but no significant interactions between groups and 
sessions (F10,140=0.83, p>0.10; Figure 4-5). 
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Figure 4-5: Graphs depicting the learning and memory in 13 month old IR1072-treated CD-1 
mice and age-matched sham controls. Behavioural parameters; number of repeated arm 
visits and the number of arm visits before first repeated arm visit. Sessions refer to daily 10 
minute 3D radial maze testing over 11 days, S1-11. Group means were tested for significance 
with a two-way ANOVA repeated measures. This was followed up with Newman-Keuls post-
hoc comparisons, n=8 for each group. 
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There were no significant differences in the number of arm entries, between 
sham or IR1072 treated 13 month old CD-1 mice (F1,14<0.71, p>0.10), 
significant differences between sessions (F10,140>2.65, p<0.005) but no 
significant interactions between groups and sessions (F10,140<0.47, p>0. 10; 
Figure 4-6). 
 
There were no significant differences in the arm/Bridge ratio for number of 
entries between sham or IR1072 treated 13 month old CD-1 mice 
(F1,14=1.05, p>0.10), significant differences between sessions 
(F10,140=8.19, p<0.0001) but no significant interactions between groups and 
sessions (F10,140=0.54, p>0.10; Figure 4-6). 
 
There were no significant differences in the arm/Bridge ratio for duration of 
entries between sham or IR1072 treated 13 month old CD-1 mice 
(F1,14=0.06, p>0.10), significant differences between sessions 
(F10,140=4.41, p<0.0001) but no significant interactions between groups and 
sessions (F10,140=0.84, p>0.10; Figure 4-6). 
 
There were no significant differences in the number of bridge entries before 
first arm visit between sham or IR1072 treated 13 month old CD-1 mice 
(F1,14=0.49, p>0.10), significant differences between sessions 
(F10,140=17.44, p<0.0001) but no significant interactions between groups 
and sessions (F10,140=1.36, p>0.10; Figure 4-6). 
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There were no significant differences in the latency of first entry to an arm 
between sham or IR1072 treated 13 month old CD-1 mice (F1,14=0.66, 
p>0.10), significant differences between sessions (F10,140=3.36, p<0.0006) 
but no significant interactions between groups and sessions (F10,140=0.43, 
p>0.10; Figure 4-6). 
 
There were no significant differences in the total time spent on the bridges 
between sham or IR1072 treated 13 month old CD-1 mice (F1,14=1.89, 
p>0.10), significant differences between sessions (F10,140=5.23, p<0.0001) 
but no significant interactions between groups and sessions (F10,140=0.80, 
p>0.10; Figure 4-6). 
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Figure 4-6: Graphs depicting emotional responses in 13 month old IR1072-treated CD-1 mice 
and age-matched sham controls. Behavioural parameters; arm/bridge ratio of number of 
entries or duration of entries, number of arm or bridge entries, latency to first entry onto an 
arm and time spent on an arm. Sessions refer to daily 10 minute 3D radial maze testing over 
11 days, S1-11. Group means were tested for significance with a two-way ANOVA repeated 
measures. This was followed up with Newman-Keuls post-hoc comparisons, n=8 for each 
group. 
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There were no significant differences in the total time spent on the arms 
between sham or IR1072 treated 13 month old CD-1 mice (F1,14=0.39, 
p>0.10), significant differences between sessions (F10,140=3.18, p<0.001) 
but no significant interactions between groups and sessions (F10,140=1.03, 
p>0.10; Figure 4-7). 
 
There were no significant differences in the total time spent in the central 
platform between sham or IR1072 treated 13 month old CD-1 mice 
(F1,14=2.75, p>0.10), no significant differences between sessions 
(F10,140=1.04, p>0.10), and no significant interactions between groups and 
sessions (F10,140=0.64, p>0.10; Figure 4-7). 
 
There were no significant differences in the session duration between sham or 
IR1072 treated 13 month old CD-1 mice (F1,14=0.31, p>0.10), no significant 
differences between sessions (F10,140=1.80, p>0.10), and no significant 
interactions between groups and sessions (F10,140=0.69, p>0.10; Figure 4-
7). 
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Figure 4-7: Graphs depicting general mobility responses in 13 month old IR1072-treated CD-
1 mice and age-matched sham controls. Behavioural parameters; Time spent on the bridges, 
time spent on the central platform and sessions' duration. Sessions refer to daily 10 minute 
3D radial maze testing over 11 days, S1-11. Group means were tested for significance with a 
two-way ANOVA repeated measures. This was followed up with Newman-Keuls post-hoc 
comparisons, n=8 for each group. 
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4.3 Discussion 
 
In the present study, 3 or 7 month old CD-1 mice received chronic IR1072 
irradiation which consisted of 10 minutes exposures over two consecutive 
days, bi-weekly for 5 months where behaviour was tested using the 3D radial 
maze. This behavioural paradigm examined emotional responses to novelty 
and open spaces in initial exposures to the test, in addition to learning and 
memory performance which continued throughout the successive testing 
sessions. Although these results are insignificant statistically, there appears to 
be a trend in the older 13 month old mice as the IR and sham mean values 
are consistently separated apart in each data set. There was significance 
between sessions but this was to be expected, as once the mouse appears to 
overcome the anxiety of the novelty and open space environment, learning 
should commence therefore test parameters would differ between sessions. 
 
Number of repeated arm visits and number of arm visits before arm repeats 
are a measure of learning and memory on the 3D maze. Repeated arm visits 
are classed as an error made by the animal, where the decision to visit a 
unique arm in order to receive a pellet is the correct choice. The animals 
should learn a repeat arm visit is an error as the arm would be without a pellet 
as they have already visited the arm to retrieve the pellet. In younger mice, 
the sham and IR-treated mice appeared to make a similar amount of errors 
throughout the sessions. The amount of correct choices before an error or 
repeated arm visit was made was variable throughout the sessions in the 
younger sham or IR treated mice, where no real pattern emerged. IR-treated 
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CD-1 mice appeared to commit less errors on the 3D behavioural maze 
throughout all 10 sessions compared to sham treated CD-1 mice. Number of 
arm visits before an arm repeat measures how many correct or unique 
choices the mouse makes before an error is committed. Again, the amount of 
correct choices the IR-treated CD-1 mice made before an error was 
committed was greater than the sham-treated mice, throughout the sessions, 
particularly in sessions 9-11. However, it is important to note that the errors 
made by the sham and IR-treated younger mice was between 2 and 6 
throughout the sessions, averaging at around 4, whereas in the older mice the 
amount of errors committed by the sham treated mice was between 6 and 7 
(demonstrating a severe learning impairment) and the IR-treated mice was 
between 4 and 6, which is lower than the sham-treated mice however towards 
the end of the session the errors committed by the IR-treated older mice had 
lowered to around 4-5 errors, similar to the average errors made in the 
younger mice. The correct or unique arm visits made by younger mice before 
an error was committed was between 1 and 5 for both sham and IR -treated 
mice, whereas older sham treated mice was between 1 and 3 and IR-treated 
older mice was between 2 and 4 on average, which is also higher than the 
sham-treated mice and more similar to the younger mice, where more correct 
choices were made before an error occurred. Not only does this show a age-
dependant memory impairment in the older sham-treated mice compared to 
the younger mice, but this also implies that IR1072 may have an effect on the 
acquisition of working memory and possibly reverses the memory impairment 
shown during ageing. The severity of learning deficits (due to excessive 
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anxiety) at both ages is perhaps to extreme to reverse robustly by IR1072 
treatments. 
 
The emotional response or anxiety measures for an animal on the 3D radial 
maze consisted of the number of arms entered, the number of bridges 
entered before the first arm visit, the time spent on the arm, arm/bridge ratio 
for the number of entries or duration of entries, and the latency of first entry on 
to an arm.  
 
The index arm/bridge ratio is used to assess the difference in anxiety between 
sham and IR-treated groups, where the lower the ratio the higher the anxiety 
and vice versa. For the younger sham or IR-treated mice the ratio was low in 
the first session of the test for both number of entries and duration of entries, 
but sharply increased as sessions commenced where this increase levelled 
off at session 3-4 for both entry numbers and duration. The arm/bridge ratio 
for number of entries in older sham and IR-treated CD-1 mice began low but 
increased much slower than the younger CD-1 mice. This suggests that the 
younger mice recover from anxiety induced by the novel, open-spaced 
environment faster than the older mice. Sham and IR groups in the younger 
mice appeared to be the same almost, and the same can be said about the 
arm/bridge ratio for duration of entries in older sham and IR-treated, however 
the IR-treated mice displayed higher arm/bridge ratio for the number of entries 
compared to sham-treated mice, suggesting IR1072 treatment may have a 
beneficial effect on the anxiety state in older CD-1 mice (although again this 
did not reach significance). 
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CD-1 mice for both young and old groups did not make all eight arm choices 
on the first sessions, but this steadily improved as sessions commenced. 
Younger CD-1 mice appeared to make similar arm entries in sham or IR-
treated groups, however IR-treated older CD-1 mice made more entries in to 
the arms in the initial sessions and throughout, suggesting the IR-treated 
group displayed lower anxiety response than sham-treated groups. The 
younger mice made more arm entries in general compared to older mice, 
which may suggest that aged CD-1 mice express a higher anxiety response 
compared to younger mice, where IR1072 could potentially reverse this 
response. Again this was only a trend rather than a robust significant effect.  
 
A high number of entries to bridges before first arm visit is thought reflect the 
hesitations or reluctance of mice to engage onto an arm. The younger CD-1 
mice showed a high number of bridge sessions in the initial "anxiety phase" of 
the test, where by session 3 the number of bridge entries before the first arm 
entry had stabilised to around for 4 or 5 entries per session, and there was no 
real difference between sham and IR groups. Older mice made more bridge 
entries before first arm visit, and appeared to have a longer anxiety phase 
where numbers stabilised at session 5 to around 7 or 8 bridge entries before 
first arm visit, however improvement was shown in every session. Apart for 
the initial session, IR-treated mice appeared to make less bridge entries 
before the first arm visit than sham, suggesting less hesitation to enter a 
bridge. These results show an age-dependant difference in CD-1 mice, where 
older mice appear to be more hesitant than the younger mice, and that IR 
appears to improve this somewhat (trend yet not significant). 
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Measures of latencies, and duration are not specific indices of memory 
function (Ennaceur et al., 2008). Making a fast decision or choice does not 
guarantee an accurate or a correct response, and taking longer time to make 
a decision or a choice can be equivalent to increasing a memory retention 
interval leading to confusion between choices (Ennaceur et al., 2008). They 
are likely to reflect a physical or physiological state of animals as well as the 
exploratory strategy or pattern of responses adopted by animals (Ennaceur et 
al., 2008). The latency of young CD-1 mice to make the first arm entry 
seemed to be lower than the older CD-1 mice in general, suggesting again 
that younger mice are less hesitant to engage in initial arm entry, however the 
latency times gradually improved or reduced in the older CD-1 mice as 
sessions commenced, whereas the younger mice appeared to stabilise at 
around 150-200msec. There was no apparent difference between sham and 
IR groups in the younger CD-1 mice, but the IR-treated mice in the older 
group took less time to engage in the first arm visit compared to sham-treated 
mice, suggesting IR1072 treated mice to be less hesitant than sham-treated.  
 
The time spent in the arms is another indicator of emotional response. The 
younger and older mice appeared to spend longer in the arms as the sessions 
commenced, where there was no real differences shown between sham and 
IR groups in the younger or older mice.  
 
The central platform and the bridges are the two places were a decision can 
be made about the choice of an arm (Ennaceur et al., 2008). The amount of 
time the younger mice spent on the central platform began high where a 
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steady decrease in time spent on the platform occurred, where the time 
increased slightly then levelled off. In the older mice the time spent in the 
central platform was pretty much constant throughout all sessions. The IR-
treated group showed a trend to spend less time in the central platform in both 
younger and older mice compared to sham-treated groups. The younger mice 
appeared to spend a similar amount of time in the bridges throughout the 
sessions, and regardless of if they were sham- or IR-treated. The older IR-
treated mice appeared to spend more time on the bridges compared to sham-
treated mice. Lengthy duration on the central platform may reflect the 
hesitation and reluctance of mice to engage onto the bridges (Ennaceur et al., 
2008). The older IR-treated mice spend less time on the central platform and 
more time on the bridges and arms compared to sham-treated mice, 
suggesting that sham treated groups may be more hesitant than the IR-
treated groups. 
 
The sessions duration is an indication of how long the animal takes to 
complete the maze. The younger mice showed a slight fall in session time 
from sessions 1-5, but slightly increased in sessions 5-10. The IR-treated 
younger mice appeared to have longer session times compared to the sham-
treated group. In contrast, session time in the older sham and IR-treated 
group did not vary between sessions or groups.  
 
Previous experiments have shown that all mice of different strains and ages 
are able to climb the bridges to reach the raised arms (Ennaceur et al., 2008). 
In fact, mice seem to prefer climbing, and the raised arm configuration 
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appears more attractive to mice than the flat or lowered arm configurations 
(Ennaceur et al., 2008). In addition, the bridge floors are covered with wire 
mesh to provide mice with further grip on the floor though our experiments 
demonstrate that mice can climb the bridges tilted by 60º without wire mesh, 
therefore mobility or inability of the mouse to complete the maze due maze 
design is not an issue (Ennaceur et al., 2006a). 
 
Notably, the level of anxiety (arm/bridge ratio of < 0.4) displayed by both mice 
age groups was excessively high compared to other mice strains and simpler 
tests, which may account for the poor learning performance seen in both age 
groups. The limited performance is distinct from the previous findings and 
may reflect distinct animal husbandry or inexperienced animal handling 
(Michalikova et al., 2009) 
 
As the time spent on bridges and arms are higher in younger mice and the 
sessions duration is lower than older mice, this suggests that most of the time 
younger mice enter the bridges and continue to arms while the older mice 
remain in the central platform for longer without venturing to bridges, 
suggesting that general mobility and decision making may be affected with 
age in CD-1 mice.  
 
In conclusion, older subjects were found to require more time to solve a 3D 
spatial navigation task and to acquire spatial information in a novel 
environment compared to younger adults. The IR1072 treatment in older mice 
appeared to trend to an improvement in the anxious state and cognitive 
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performance of the CD-1 mice, although not significantly compared to sham-
treated CD-1 mice. These findings display modest effects less robust than 
previous data showing overall cognitive improvement following 10 daily 
sessions of IR1072 in 12 month old CD-1 mice, performed by highly 
experienced behaviourists. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  128 
Chapter 5: Age-dependant molecular changes in CD-1 
mice: Effect of chronic IR1072 (in vivo) treatment 
 
5.1 Introduction 
 
5.1.1 Animal model of premature ageing: CD-1-mice 
Mizumori et al. (1982) tested S-1 rats versus CD-1 mice on the radial maze 
behavioural test and found that rats were able to readily solve this behavioural 
paradigm but CD-1 mice were not, and suggested that mice in general may 
have limited learning capacity, but stressed that testing the performance of 
other strains is of great importance in order to determine if it is in fact a strain 
difference rather than a species difference. Since then, CD-1 mice have been 
shown to develop early behavioural and learning deficits (Parmigiani et al., 
1999; Ennaceur et al., 2008) and amyloidosis with age, where the latter is 
thought to be the cause of premature death repeatedly reported in this strain 
of mouse (Conner et al., 1983; Frith and Chandra, 1991; Engelhardt et al., 
1993; Gruys et al., 1996). Chen et al. (2006) compared brain volumes of C57 
mice compared to the age-matched CD-1 mice in order to relate the improved 
performance of the C57 strain over the other mouse strains as seen in 
previous studies (Rogers et al., 1999). They found that C57 mice had 
consistently larger total brain volumes, despite their substantially smaller 
gross body weight compared to CD-1 mice, where the cerebral cortex and 
ventricular compartments (lateral and 3rd and 4th ventricles) had increases of 
10% and 13%, respectively, in C57 mice compared to CD-1 (Chen et al., 
2006). Sunyer et al. (2009) showed that C57 had decreased GABAB receptor 
subunit 2 compared to age-matched CD-1 mice, whereby activation of 
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presynaptic GABAB receptors inhibits neurotransmitter release of several 
neurotransmitters and postsynaptic GABAB receptors induce a slow inhibitory 
current through activation of inwardly rectifying K+ channels (Sunyer et al., 
2009). These results may contribute toward a better understanding of the 
early learning deficits shown in the CD-1 mouse strain. 
 
There is little evidence showing changes in protein changes involved in the 
CD-1 mice as they age, so one aim of this chapter was to establish any 
changes in protein expression involved in learning and memory processes 
that may be contributing to the severe age-dependent learning deficits and 
premature ageing seen in this mouse strain.  Another aim was to establish 
any protein changes, age-dependant or otherwise, that may occur following 
chronic IR1072 treatment in younger (7 month old) and older (13 month old) 
CD-1 mice using immunoblotting, immunohistochemical and 
autoradiographical techniques. 
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5.2 Results 
 
5.2.1 CD-1 Age Timeline: Immunoblot analysis 
Protein levels were standardised using mouse β-actin primary antibody. Data 
were statistically analysed using a two tailed student t-test. Data represent 
mean ± SEM. 
 
Table 5-1: Protein expression profile in 3, 10 or 12 month old CD-1 mice. Arrows represent 
an increase (↑) or decrease (↓) in protein expression in IR-treated CD-1 mice compared to 
age-matched sham controls. Abbreviations; BDNF, Brain Deived Neurotrophic Factor; 
ERK1/2, Extracellular Signal-regulated Kinase; CREB, Cyclic Adenosine Monophosphate 
(AMP) Response Element Binding; AKT, Protein Kinase B; HSP, Heat Shock Protein. Data 
were statistically analysed using a two tailed student t-test. Pink cells represent significant 
results and blue cells represent a trend. n=3 for each group, *p<0.05.  
 
  CD-1 TL 
  3mv10m 3mv12m 10mv12m 
  p value result p value result p value result 
BDNF 0.0768 10m↓ *0.0227 12m↓ 0.0165 12m↓ 
ERK1 0.5864 NS 0.9919 NS 0.6573 NS 
ERK2 0.3524 NS 0.3203 NS 0.8201 NS 
ERK1-P       
ERK2-P       
CREB 0.0652 10m↑ 0.3317 NS 0.103 NS 
CREB-P       
AKT 0.6451 NS 0.8324 NS 0.8605 NS 
AKT-P       
HSP27 0.5561 NS 0.0831 12m↓ *0.0325 12m↓ 
HSP40 0.3146 NS 0.5798 NS 0.2531 NS 
HSP60 0.5345 NS 0.2807 NS 0.5012 NS 
HSP70 0.8596 NS 0.6737 NS 0.325 NS 
HSP90 0.3666 NS 0.05 12m↓ 0.4053 NS 
HSP105 0.112 NS 0.1206 NS 0.8299 NS 
 
 
 
 
  131 
CD-1 mice at 12 months of age (n=3, 0.341 ± 0.181) showed significantly 
decreased BDNF expression compared to mice at 3 months (n=3, 2.578 ± 
0.5938, p<0.05) and 10 months of age (n=3, 1.153 ± 0.096, p<0.05). CD-1 
mice at 10 months of age showed a trend for decreased BDNF expression 
compared to 3 month old mice (n=3, p<0.1) (Figure 5-1).  
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Figure 5-1: Age-dependent changes in BDNF expression in 3, 10 and 12m old CD-1 mouse 
brain where A) is an Immunoblot representation where each lane represents an individual 
mouse and B) is a column graph showing the quantitative results of BDNF expression from 
the immunoblot. Abbreviations: BDNF, Brain Derived Neurotrophic Factor. Mean values ± 
SEM, n = 3 for each group, *p<0.05. 
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CD-1 mice at 10 months of age (n=3, 0.5913 ± 0.1145) showed a trend for 
increased CREB expression compared to mice at 3 months (n=3, 0.244 ± 
0.076, p<0.1). CD-1 mice at 3 or 10 months showed no difference in CREB 
expression compared to 12 month old mice (n=3, 0.338 ± 0.037) (Figure 5-2).  
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Figure 5-2: Age-dependent changes in CREB expression in 3, 10, and 12m old CD-1 mouse 
brain where A) is an Immunoblot representation where each lane represents an individual 
mouse and B) is a column graph showing the quantitative results of CREB expression from 
the immunoblot. Abbreviations: CREB, cAMP (cyclic adenosine monophosphate) response 
element binding. Mean values ± SEM, n = 3 for each group. 
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CD-1 mice at 12 months of age (n=3, 0.175 ± 0.088) showed significant 
decreased HSP27 (band 2) expression compared to mice at 10 months of age 
(0.6103 ± 0.1034, p<0.05) and a trend for decreased expression compared to 
3 months (n=3, 0.784 ± 0.250, p<0.1). CD-1 mice at 10 months showed no 
difference in HSP27 expression compared to 3 month old mice (Figure 5-3).  
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Figure 5-3: Age-dependent changes in HSP27 expression in 3, 10 and 12m old CD-1 mouse 
brain where A) is an Immunoblot representation where each lane represents an individual 
mouse, and B) is a column graph showing the quantitative results of i) band 1 and ii) band 2 
of HSP27 expression. Abbreviations: HSP27, Heat Shock Protein 27. Mean values ± SEM, n 
= 3 for each group *p<0.05. 
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CD-1 mice at 12 months of age (n=3, 0.360 ± 0.090) showed a trend for 
decreased HSP90 expression compared to mice at 3 months of age (0.624 ± 
0.032, p<0.1). CD-1 mice at 10 months of age (n=3, 0.498 ± 0.119) showed 
no difference in HSP90 expression compared to 3 month or 12 month old 
mice (Figure 5-4).  
A 
 
3m 10m 12m
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Age (months)
H
S
P
9
0
 E
x
p
re
s
s
io
n
 
Figure 5-4: Age-dependent changes in HSP90 expression in 3, 10 and 12m old CD-1 mouse 
brain where A) is an Immunoblot representation where each lane represents an individual 
mouse, and B) is a column graph showing the quantitative results of HSP90 expression. 
Abbreviations: HSP90, Heat Shock Protein 90. Mean values ± SEM, n = 3 for each group. 
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5.2.2 CD-1 Age Timeline: Immunohistochemical analysis 
Table 5-2: Summary table depicting immunohistochemical analysis of various protein 
expression in 3, 10, or 12 month old CD-1 mice. Arrows represent an increase (↑) or decrease 
(↓) in protein expression in older mice. Abbreviations; BDNF, Brain Deived Neurotrophic 
Factor; ERK1/2, Extracellular Signal-regulated Kinase; CREB, Cyclic Adenosine 
Monophosphate (AMP) Response Element Binding; AKT, Protein Kinase B; HSP, Heat Shock 
Protein. n=3 for each group.  
 
Effect of Chronic IR1072 treatment on protein expression in CD-1 TL 
1º Ab Result 
BDNF - 
ERK1 - 
ERK2 - 
ERK1-P - 
ERK2-P - 
CREB - 
AKT - 
AKT-P - 
HSP27 ↓ 
HSP40 - 
HSP60 - 
HSP70 - 
HSP90 - 
HSP105 - 
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A decrease in HSP27 expression in the cortex, CA2/3 and CA1 was observed 
in 3, 10, and 12 month old CD-1 mice (Figure 5-5). 
 
 
Figure 5-5: Immunohistochemical representation of HSP27 expression in 3, 10, or 12 month 
old CD-1 mice in various brain regions. Abbreviations: BDNF; Ctx, cerebral cortex; CA (1/2/3), 
Cornu ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 for each 
group, X100 magnification. 
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5.2.3 Chronic IR1072 Treatment: CD-1 mice 
 
5.2.3.1 Chronic IR1072-preconditioning in 7 month old CD-1 mice: 
Immunoblot analysis 
 
Protein levels were standardised using mouse β-actin primary antibody. Data 
were statistically analysed using a two tailed student t-test. Data represent 
mean ± SEM. 
 
Table 5-3: Protein expression profile following chronic IR1072 treatment in 7 month old CD-1 
mice compared to age-matched sham-treated CD-1 mice. Arrows represent an increase (↑) or 
decrease (↓) in protein expression in IR-treated CD-1 mice compared to age-matched sham 
controls, and respective figure numbers. Abbreviations; BDNF, Brain Deived Neurotrophic 
Factor; ERK1/2, Extracellular Signal-regulated Kinase; CREB, Cyclic Adenosine 
Monophosphate (AMP) Response Element Binding; AKT, Protein Kinase B; HSP, Heat Shock 
Protein. Data was statistically analysed using a two tailed student t-test. Pink cells represent 
significant results and blue cells represent a trend. n=4 for each group, *p<0.05, **p<0.01.  
 
 
Effect of Chronic IR1072 treatment on protein expression in 
7 month old CD-1 mice 
1º Ab p value Result Figure 
BDNF **0.0026 ↑ Figure 5-6 
ERK1 **0.0069 ↓ Figure 5-7 
ERK2 ***0.0006 ↓ Figure 5-7 
ERK1-P 0.0799 ↓ Figure 5-8 
ERK2-P 0.1373 NS Data not shown 
CREB 0.6651 NS Data not shown 
AKT *0.0498 ↓ Figure 5-9 
AKT-P 0.1073 NS Data not shown 
HSP27 0.0843 ↑ Figure 5-10 
HSP40 0.4575 NS Data not shown 
HSP60 0.4271 NS Data not shown 
HSP70 *0.0108 ↓ Figure 5-11 
HSP90 0.8165 NS Data not shown 
HSP105 0.7176 NS Data not shown 
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IR1072-preconditioned 7 month old CD-1 mice (n=4, 1.302 ± 0.095) showed a 
significant increase in BDNF expression compared to age-matched sham 
controls (n=4, 0.798 ± 0.038, p<0.01) (Figure 5-6).  
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Figure 5-6: BDNF expression in chronically IR1072 treated (in vivo) 7 month old CD-1 mouse 
brain and age-matched sham controls where A) is an Immunoblot representation where each 
lane represents an individual mouse and B) is a column graph showing the quantitative 
results of BDNF expression. Protein expression were standardised to total β-actin levels. 
Abbreviations: BDNF, Brain Derived Neurotrophic Factor. Mean values ± SEM, n = 4 for each 
group, **p<0.01. 
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IR1072-preconditioned 7 month old CD-1 mice (n=4, 0.635 ± 0.164) showed a 
significant decrease in ERK1 expression compared to age-matched sham 
controls (n=4, 1.372 ± 0.081, p<0.01). IR1072-preconditioned 7 month old 
CD-1 mice (n=4, 1.459 ± 0.123) showed a significant decrease in ERK2 
expression compared to age-matched sham controls (n=4, 2.778 ± 0.158, 
p<0.001) (Figure 5-7).  
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Figure 5-7: ERK1/2 expression in chronically IR1072 treated (in vivo) 7 month old CD-1 
mouse brain and age-matched sham controls where A) is an Immunoblot representation 
where each lane represents an individual mouse, and B) is a column graph showing the 
quantitative results of i) ERK1 and ii) ERK2 expression. Protein expression were standardised 
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to total β-actin levels. Abbreviations: ERK1/2, Extracellular Signal-regulated Kinase 1 or 2. 
Mean values ± SEM, n = 4 for each group, **p<0.01, ***p<0.001. 
IR1072-preconditioned 7 month old CD-1 mice (n=4, 0.359 ± 0.124) showed a 
trend for decreased ERK1-P expression compared to age-matched sham 
controls (n=4, 0.659 ± 0.071, p<0.1). IR1072-preconditioned 7 month old CD-
1 mice (n=4, 0.613 ± 0.181) showed no significant difference in ERK2-P 
expression compared to age-matched sham controls (n=4, 0.979 ± 0.113) 
(Figure 5-8).  
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Figure 5-8: ERK1/2-P expression in chronically IR1072 treated (in vivo) 7 month old CD-1 
mouse brain and age-matched sham controls where A) is an Immunoblot representation 
where each lane represents an individual mouse, and B) is a column graph showing the 
quantitative results of i) ERK1-P and ii) ERK2-P expression. Protein expression were 
standardised to total β-actin levels. Abbreviations: ERK1/2-P, Phosphorylated Extracellular 
Signal-regulated Kinase 1 or 2. Mean values ± SEM, n = 4 for each group. 
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IR1072-preconditioned 7 month old CD-1 mice (n=4, 0.788 ± 0.034) showed a 
significant decrease in AKT expression compared to age-matched sham 
controls (n=4, 1.049 ± 0.099, p<0.05) (Figure 5-9).  
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Figure 5-9: AKT expression in chronically IR1072 treated (in vivo) 7 month old CD-1 mouse 
brain and age-matched sham controls where A) is an Immunoblot representation where each 
lane represents an individual mouse, and B) is a column graph showing the quantitative 
results of AKT expression. Protein expression were standardised to total β-actin levels. 
Abbreviations: AKT, Protein Kinase B. Mean values ± SEM, n = 4 for each group, *p<0.05. 
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IR1072-preconditioned 7 month old CD-1 mice (n=4, 0.227 ± 0.080) showed a 
trend for increased HSP27 expression compared to age-matched sham 
controls (n=4, 0.041 ± 0.041, p<0.1) (Figure 5-10).  
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Figure 5-10: HSP27 expression in chronically IR1072 treated (in vivo) 7 month old CD-1 
mouse brain and age-matched sham controls where A) is an Immunoblot representation 
where each lane represents an individual mouse, and B) is a column graph showing the 
quantitative results of i) band 1 and ii) band 2 HSP27 expression. Protein expression were 
standardised to total β-actin levels. Abbreviations: HSP27, Heat Shock Protein 27. Mean 
values ± SEM, n = 4 for each group. 
 
 
 
Sham IR 
1 
2 
  143 
IR1072-preconditioned 7 month old CD-1 mice (n=4, 0.719 ± 0.060) showed a 
trend for increased HSP70 expression compared to age-matched sham 
controls (n=4, 1.038 ± 0.063, p<0.05) (Figure 5-11).  
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Figure 5-11: HSP70 expression in chronically IR1072 treated (in vivo) 7 month old CD-1 
mouse brain and age-matched sham controls where A) is an Immunoblot representation 
where each lane represents an individual mouse, and B) is a column graph showing the 
quantitative results of HSP70 expression. Protein expression were standardised to total β-
actin levels. Abbreviations: HSP70, Heat Shock Protein 70. Mean values ± SEM, n = 4 for 
each group, *p<0.05. 
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5.2.3.2 Chronic IR1072-preconditioning in 7 month old CD-1 mice: 
Immunohistochemical analysis 
 
Immunohistochemical analysis did not reveal differences between groups 
IR1072-treated 7 month old CD-1 mice and age matched sham controls. 
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5.2.3.3 Chronic IR1072-preconditioning in 13 month old CD-1 mice: 
Immunoblot analysis 
 
Protein levels were standardised using mouse β-actin primary antibody. Data 
was statistically analysed using a two tailed student t-test. Data represent 
mean ± SEM for n numbers. 
 
Table 5-5: Protein expression profile in 13 month old CD-1 mouse brain following chronic 
IR1072 treatment compared to age-matched sham-treated controls. Arrows represent an 
increase (↑) or decrease (↓) in protein expression in IR-treated CD-1 mice compared to age-
matched sham controls, and respective figure numbers. Abbreviations; BDNF, Brain Deived 
Neurotrophic Factor; ERK1/2, Extracellular Signal-regulated Kinase; CREB, Cyclic Adenosine 
Monophosphate (AMP) Response Element Binding; AKT, Protein Kinase B; HSP, Heat Shock 
Protein. Data were statistically analysed using a two tailed student t-test. Pink cells represent 
significant results (p<0.05) and blue cells represent a trend (p<0.1). n=4 for each group, 
*p<0.05, **p<0.01.  
 
Effect of Chronic IR1072 treatment on protein expression in 13 month 
old CD-1 mice 
1º 
CD-1_O 
p value Result Figure 
BDNF 0.1009 NS Data not shown 
ERK1 *0.0198 ↓ Figure 5-12 
 ERK2 **0.0041 ↓ 
ERK1-P 0.2467 NS Data not shown 
ERK2-P 0.083 ↓ Figure 5-13 
CREB **0.0011 ↑ Figure 5-14 
AKT *0.0335 ↑ Figure 5-15 
AKT-P 0.5873 NS Data not Shown 
HSP27 *0.015 ↑ Figure 5-16 
HSP40 *0.0117 ↑ Figure 5-17 
HSP60 **0.0072 ↑ Figure 5-18 
HSP70 0.1392 NS Data not shown 
HSP90 0.9898 NS Data not shown 
HSP105   Incomplete 
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IR1072-preconditioned 13 month old CD-1 mice (n=4, 0.240 ± 0.079) showed 
a significant decrease in ERK1 expression compared to age-matched sham 
controls (n=4, 0.801 ± 0.160, p<0.05). IR1072-preconditioned 13 month old 
CD-1 mice (n=4, 1.157 ± 0.160) showed a significant decrease in ERK2 
expression compared to age-matched sham controls (n=4, 1.896 ± 0.038, 
p<0.01) (Figure 5-12).  
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Figure 5-12: ERK1/2 expression in chronically IR1072 treated (in vivo) 13 month old CD-1 
mouse brain and age-matched sham controls where A) is an Immunoblot representation 
where each lane represents an individual mouse, and B) is a column graph showing the 
quantitative results of ERK1/2 expression. Protein expression were standardised to total β-
actin levels. Abbreviations: ERK1/2, Extracellular Signal-regulated Kinase 1 or 2. Mean 
values ± SEM, n = 4 for each group, *p<0.05, **p<0.01. 
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IR1072-preconditioned 13 month old CD-1 mice (n=4, 0.406 ± 0.060) showed 
a trend for decreased ERK2-P expression compared to age-matched sham 
controls (n=4, 0.843 ± 0.202, p<0.1). IR1072-preconditioned 13 month old 
CD-1 mice (n=4, 0.330 ± 0.066) showed no significant difference in ERK1-P 
expression compared to age-matched sham controls (n=4, 0.517 ± 0.130) 
(Figure 5-13).  
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Figure 5-13: ERK1/2-P expression in chronically IR1072 treated (in vivo) 13 month old CD-1 
mouse brain and age-matched sham controls where A) is an Immunoblot representation 
where each lane represents an individual mouse, and B) is a column graph showing the 
quantitative results i) ERK1-P and ii) ERK2-P expression. Protein expression were 
standardised to total β-actin levels. Abbreviations: ERK1/2-P, phosphorylated Extracellular 
Signal-regulated Kinase 1 or 2. Mean values ± SEM, n = 4 for each group. 
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IR1072-preconditioned 13 month old CD-1 mice (n=4, 0.700 ± 0.0198) 
showed a significant increase in CREB expression compared to age-matched 
sham controls (n=4, 0.199 ± 0.083, p<0.01) (Figure 5-14).  
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Figure 5-14: CREB expression in chronically IR1072 treated (in vivo) 13 month old CD-1 
mouse brain and age-matched sham controls where A) is an Immunoblot representation 
where each lane represents an individual mouse, and B) is a column graph showing the 
quantitative results CREB expression. Protein expression were standardised to total β-actin 
levels. Abbreviations: CREB, cAMP (cyclic adenosine monophosphate) response element 
binding. Mean values ± SEM, n = 4 for each group, **p<0.01. 
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IR1072-preconditioned 13 month old CD-1 mice (n=4, 0.791 ± 0.045) showed 
a significant increase in AKT expression compared to age-matched sham 
controls (n=4, 0.630 ± 0.038, p<0.05) (Figure 5-15).  
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Figure 5-15: Effects of BDNF expression in chronically sham or IR1072 treated 4 month old 
CD-1 mouse brain (in vivo) where A) is an Immunoblot representation where each lane 
represents an individual mouse, and B) is a column graph showing the quantitative results of 
BDNF expression from the immunoblot. Protein expression were standardised to total β-actin 
levels. Abbreviations: AKT, Protein Kinase B. Mean values ± SEM, n = 5 for each group, 
*p<0.05. 
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IR1072-preconditioned 13 month old CD-1 mice (n=4, 0.318 ± 0.060) showed 
a significant increase in HSP27 expression compared to age-matched sham 
controls (n=4, 0.054 ± 0.050, p<0.05) (Figure 5-16).  
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Figure 5-16: HSP27 expression in chronically IR1072 treated (in vivo) 13 month old CD-1 
mouse brain and age-matched sham controls where A) is an immunoblot representation 
where each lane represents an individual mouse, and B) is a column graph showing the 
quantitative results HSP27 expression. Protein expression were standardised to total β-actin 
levels. Abbreviations: HSP27, Heat Shock Protein 27. Mean values ± SEM, n = 4 for each 
group, *p<0.05. 
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IR1072-preconditioned 13 month old CD-1 mice (n=4, 0.526 ± 0.057) showed 
a significant increase in HSP40 expression compared to age-matched sham 
controls (n=4, 0.169 ± 0.082, p<0.05) (Figure 5-17).  
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Figure 5-17: HSP40 expression in chronically IR1072 treated (in vivo) 13 month old CD-1 
mouse brain and age-matched sham controls where A) is an immunoblot representation 
where each lane represents an individual mouse, and B) is a column graph showing the 
quantitative results HSP40 expression. Protein expression were standardised to total β-actin 
levels. Abbreviations: HSP40, Heat Shock Protein 40. Mean values ± SEM, n = 4 for each 
group, *p<0.05. 
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IR1072-preconditioned 13 month old CD-1 mice (n=4, 1.063 ± 0.180) showed 
a significant increase in HSP60 expression compared to age-matched sham 
controls (n=4, 0.3101 ± 0.056, p<0.01) (Figure 5-18).  
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Figure 5-18: HSP60 expression in chronically IR1072 treated (in vivo) 13 month old CD-1 
mouse brain and age-matched sham controls where A) is an immunoblot representation 
where each lane represents an individual mouse, and B) is a column graph showing the 
quantitative results HSP60 expression. Protein expression were standardised to total β-actin 
levels. Abbreviations: HSP60, Heat Shock Protein 60. Mean values ± SEM, n = 4 for each 
group, **p<0.01. 
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5.2.3.4 Chronic IR1072-preconditioning in 13 month old CD-1 mice: 
Immunohistochemical analysis 
 
Table5-6: Protein expression profile in the brain regions of 13 month old CD-1 mice following 
chronic IR1072 treatment. Arrows represent an increase (↑) or decrease (↓) in protein 
expression in IR-treated CD-1 mice compared to age-matched sham controls. n=4 for each 
group. 
 
Effect of Chronic IR1072 treatment on protein expression in 13 month 
old CD-1 mice 
1º Ab Result 
BDNF - 
ERK1/2 - 
ERK1/2-P ↓ Ctx, CA2/3, CA1 
CREB - 
AKT - 
AKT-P - 
HSP27 ↑ Ctx, DG 
HSP27-P ↑ CA1, CA2/3 
HSP40 ↑ DG 
HSP60 - 
HSP70 - 
HSP90 - 
HSP105 ↓ CA1 
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A decrease in ERK1/2-P expression in the cortex, CA2/3 and CA1 was 
observed in IR1072 treated 13 month old CD-1 mice compared to age 
matched sham controls (Figure 5-19). 
 
Figure 5-19: Immunohistochemical representation of ERK1/2-P expression in IR1072-treated 
13m old CD-1 mice and age-matched sham controls in various brain regions. Abbreviations: 
ERK1/2-P, Extracellular Signal-regulated Kinase; Ctx, cerebral cortex; CA (1/2/3), Cornu 
ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=4 for each group, 
X100 magnification. 
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An increase in HSP27 expression in the cortex and dentate gyrus was 
observed in IR1072 treated 13 month old CD-1 mice compared to age 
matched sham controls (Figure 5-20). 
 
Figure 5-20: Immunohistochemical representation of HSP27 expression in IR1072-treated 
13m old CD-1 mice and age-matched controls in various brain regions. Abbreviations: 
HSP27, Heat Shock Protein 27; Ctx, cerebral cortex; CA (1/2/3), Cornu ammonis; DG, 
Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=4 for each group, X100 
magnification. 
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An increase in HSP27-P expression in the CA2/3 and CA1 was observed in 
IR1072 treated 13 month old CD-1 mice compared to age matched sham 
controls (Figure 5-21). 
 
Figure 5-21: Immunohistochemical representation of HSP27-P expression in IR1072-treated 
13m old CD-1 mice and age-matched sham controls in various brain regions. Abbreviations: 
HSP27-P, phosphorylated Heat Shock Protein 27; Ctx, cerebral cortex; CA (1/2/3), Cornu 
ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=4 for each group, 
X100 magnification. 
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An increase in HSP40 expression in the dentate gyrus was observed in 
IR1072 treated 13 month old CD-1 mice compared to age matched sham 
controls (Figure 5-22). 
 
Figure 5-22: Immunohistochemical representation of HSP40 expression in IR1072-treated 
13m old CD-1 mice and age-matched sham controls in various brain regions. Abbreviations: 
HSP40, Heat Shock Protein 40; Ctx, cerebral cortex; CA (1/2/3), Cornu ammonis; DG, 
Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=4 for each group, X100 
magnification. 
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An increase in HSP105 expression in the dentate gyrus was observed in 
IR1072 treated 13 month old CD-1 mice compared to age matched sham 
controls (Figure 5-23). 
 
Figure 5-23: Immunohistochemical representation of HSP105 expression in IR1072-treated 
13m old CD-1 mice age-matched sham controls in various brain regions. Abbreviations: 
HSP105, Heat Shock Protein 105; Ctx, cerebral cortex; CA (1/2/3), Cornu ammonis; DG, 
Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=4 for each group, X100 
magnification. 
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5.2.3.5 Ageing and chronic IR1072-preconditioning in CD-1 mice: AMPA 
receptor expression 
 
There are three families of ionotropic glutamate receptors, NMDA, AMPA and 
kainate receptors (Kent et al., 2002; Bergink et al., 2004; Burroughs and 
French, 2007) which are mainly postsynaptic and regulate fast excitations and 
synaptic plasticity associated with the opening of cation-permeable ligand-
gated ion channels (Meldrum, 2000; Kent et al., 2002; Burroughs and French, 
2007). Depolarisation of the postsynaptic membrane by activation of other 
receptor subtypes, such as AMPA or kainate receptors, will remove the Mg2+ 
block from resting NMDA receptors, where activation of the NMDA receptor 
occurs subsequently resulting in the flow of Ca2+ and other ions through the 
NMDA receptor channel, a signal that has a role in synaptic plasticity (Bergink 
et al., 2004; Burroughs and French, 2007). AMPA and kainate receptors (non-
NMDA receptors) are associated with voltage-independent channels that gate 
a depolarising current mainly carried by Na+ ions, which in turn promote the 
activation of voltage-dependent NMDA receptor (Bergink et al., 2004; 
Burroughs and French, 2007). 
 
AMPA receptors are composed of four subunits, each of which has a binding 
pocket for glutamate, and are postsynaptic mediators for fast excitatory 
neurotransmission are involved in learning and memory (Franciosi, 2001; 
Lynch, 2004; Mathew et al., 2008). Once glutamate binds to AMPA receptors, 
a conformational change occurs between the extracellular domain and 
transmembrane pore of the receptor, which opens the channel and allows 
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current to pass through the postsynaptic membrane (Lynch, 2004). When the 
transmitter is released from the binding pocket the current is terminated and 
the channel is in the deactivated state, or the extracellular domains produces 
a conformational change on the transmembrane channel, thus disrupting 
interaction between AMPA receptor subunits where the channel is prevented 
from reopening despite the bound transmitter still being present, resulting in a 
desensitized state of the receptor (Lynch, 2004). The size and shape of 
excitatory postsynaptic currents are regulated by these rapid desensitization 
and deactivation states of the receptor, where synthetic positive modulators of 
the AMPA receptors, such as ampakines, do not act on AMPA receptors 
directly but delay the receptor from deactivating or desensitizating in the 
presence of an agonist, thus prolonging the current flow (Lynch, 2004; 
Mathew et al., 2008). Ampakines act as positive modulators of the AMPA 
receptor, where they have been shown to facilitate synaptic transmission and 
formation of LTP in the hippocampus, thus aiding learning and memory 
(Lynch, 2004). Ampakines and other AMPA receptor positive modulators have 
been shown to increase BDNF production and the ERK1/2 signalling cascade, 
which is also heavily implicated in learning and memory. This study has 
performed AMPA receptor autoradiographical studies in CD-1 timeline at 3 
months, 10 months and 12 months of age, and chronically treated IR1072 7 
month or 13 month old CD-1 mice to determine whether IR1072 has any 
effect on modulation of AMPA receptor expression. 
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Figure 5-24: A) [
3
H]-AMPA autoradiographical images of CD-1 timeline showing anatomical 
AMPA receptor expression in brain structures as CD-1 mice age B) Quantification of AMPA 
receptor expression from autoradiographical images in various brain regions. Abbreviations: 
cb, cerebellum; stri, striatum. Mean values ± SEM, n = 3 per group, plus 3 replicates per n 
number.  
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Figure 5-25: A) [
3
H]-AMPA autoradiographical image and B) the respective quantification of 
AMPA receptor expression in various brain regions in chronically IR1072-treated 7 month old 
CD-1 mice and age-matched sham controls. Abbreviations: IR, IR1072; Hpc, Hippocampus; 
cb, cerebellum; stri, striatum. Mean values ± SEM, n = 4 per group, plus 3 replicates per n 
number.  
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Figure 5-26: A) [
3
H]-AMPA autoradiographical image and B) the respective quantification of 
AMPA receptor expression in various brain regions in chronically IR1072-treated 13 month 
old CD-1 mice and age-matched sham controls. Abbreviations: IR, IR1072; Hpc, 
Hippocampus; cb, cerebellum; stri, striatum. Mean values ± SEM, n = 2 for sham, and n=3 for 
IR1072 group, plus 3 replicates per n number.  
 
  164 
5.3 Discussion 
 
The aim of this chapter was to establish the protein changes of ERK1/2 
signalling, HSP or AMPA receptor expression that occur during ageing in CD-
1 mice, and also to establish any long-term protein changes following chronic 
IR1072 treatment in 7 month old or 13 month old male CD-1 mice. 
 
Table 5-7: Summary of the effects of ageing and IR1072 treatment on CD-1 mice. 
Abbreviations: CD-1TL, CD-1 age timeline; CD-1Y, sham vs IR1072 CD-1 7month old mice; 
CD-1O, sham vs IR1072 CD-1 13 month old mice; IR, IR 1072nm; BDNF; Brain Derived 
Neurotrophic Factor; ERK1/2 or ERK1/2-P, unphosphorylated or phosphorylated extracellular-
signal regulated kinase 1 or 2, respectively; CREB, Cyclic Adenosine Monophosphate (AMP) 
Response Element Binding; HSP, Heat Shock Protein; PI3, Phosphatidylinositol 3-Kinase. 
 
    
CD-1TL (months) 
Effects of Chronic IR 
on protein expression 
Pathways Protein 3 vs 10 3vs12 10vs12 CD-1Y CD-1O 
E
R
K
1
/2
 
BDNF ↓ *↓ *↓ **↑ - 
ERK1/2 - - - ***↓ **↓ 
ERK1/2-P    ↓ ↓ 
CREB ↑ - - - **↑ 
P
I3
 AKT - - - *↓ *↑ 
AKT-P - - - - - 
C
h
a
p
e
ro
n
e
s
 
HSP27  ↓ *↓ ↑ *↑ 
HSP40 - - - - *↑ 
HSP60 - - - - **↑ 
HSP70 - - - *↓ - 
HSP90 - ↓ - - - 
HSP105 - - - -  
 
As discussed earlier, amyloidosis has been shown to be present in ageing 
CD-1 mice, however this study investigated circulating serum amyloid using 
an SAA assay (purchased from Life Diagnostics Inc.) but found no significant 
differences in serum amyloid in ageing CD-1 mice or chronically IR1072-
treated CD-1 mice (data not shown). This could be due to the fact that studies 
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reporting these amyloid changes purchased the CD-1 mice from Charles 
Rivers, whereas the mice used in this study are the current in-house strain 
(housed for over two years), and also, more significantly, our CD-1 timeline 
was only up to 12 months of age. However premature death occurs at 
approximately 18 months of age in these CD-1 mice, and acute IR1072 
induced effects were shown in 4 month old CD-1 mice, therefore chronic 
IR1072 investigations were warranted. 
 
Many reports showing LILT eliciting a protective effect require an insult of 
some sort on a given in vitro or in vivo model, in order to generate sub-lethal 
effects, so any positive measures of LILT, as a preconditioning (preceding the 
insult) or neuroprotective (during the insult) therapy, to protect the model 
system can be determined. Most insults utilising in vitro or in vivo models are 
designed to induce stress on an experimental system to produce a sub-lethal 
decrease in tissue or cell viability and toxic signalling events. LILT has been 
shown to protect tissue or cells from sub-lethal insults, some of which include 
in vivo and in vitro models of ischemic damage (Ad and Oron, 2001; Whelan 
et al., 2001; Kolpakova et al., 2003), nutrition deprivation (Carnevalli et al., 
2003; Ricci et al., 2009), diabetes (Lim et al., 2009), Parkinson's disease 
(Ying et al., 2008) and proactive physical load (swimming; Zubkova et al., 
1995). In this present study, IR1072 was used during development where age 
was viewed as the "insult", and proteins involved in neuroprotection, and 
suggested to be decreased with age, were investigated.  
 
 
BDNF plays an important role in neuroplasticity and promotes axonal growth, 
but its secretion declines with age (Kennedy et al., 2009). An age-dependant 
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reduction in BDNF occurred in CD-1 mouse brain whereby protein expression 
decreased as mice grew older. Gooney et al. (2004) infused young (2-4 
months) and aged (20-24 months) Wistar rats with exogenous BDNF in order 
to induce LTP, which increases activation of TRKB and ERK signalling which 
in turn enhances evoked release of glutamate in synaptosomes. They found 
that in aged rats both BDNF induced LTP and the associated ERK signalling 
is reduced, suggesting the neuroprotective role of BDNF may be weakened 
with increasing age (Gooney et al., 2004; Sohrabji and Lewis, 2006). CD-1 
mice, treated with IR1072 from 3 months to 7 months of age or 7 months to 
13 months of age, show an increase or no change in BDNF expression, 
respectively. The increase in BDNF expression in the younger mice might 
lead to the assumption that ERK1/2 expression would increase, and similarly 
the unaltered BDNF expression shown in the older mice might lead to 
unaltered ERK1/2 expression, however an unexpected decrease in 
phosporylated and unphosphorylated ERK1/2 expression was found in both 
younger and older mice. Gooney also determined from the same set of 
experiments that aged rats appeared to have higher BDNF expression than 
younger rats, however the ERK1/2 signalling pathway was impaired despite 
the increase in BDNF, and concluded that TRKB and ERK is impaired with 
age, and this impairment must derive from age-related changes in TRKB 
receptor function (Gooney et al., 2004). Although BDNF expression is in 
disagreement with the ageing findings in this study, the increased BDNF 
expression and decreased ERK1/2 signalling seems to show a similar pattern 
in the IR1072 treated mice. These results suggest that IR1072 may be 
affecting the function of the TRKB receptor. There is a "dark side" as it were, 
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to ERK1/2 signalling, as well as a neuroprotective aspect. Sustained levels of 
ERK1/2 have been reported to promote cell death or promote cell survival in 
neurons depending upon the nature of the acute insult and the affected cell 
types (Chu et al., 2004). Some studies have shown that blocking ERK1/2 
activation in vivo, led to decreased brain injury in mice and gerbils (Wang et 
al., 2004). These changes in ERK1/2 expression despite BDNF expression 
should be further investigated with phosphorylated TRKB receptor expression 
to conclude if IR1072 may be effecting the receptor numbers either directly or 
indirectly. Gooney (2004) also found that although the biochemical responses 
to BDNF infusion are impaired with age, the phosphorylation of CREB was 
not, indicating intact retrograde signalling, which may explain the trend for 
increased expression of CREB in 10 month old mice compared to 3 month 
old. However the present study looked at total CREB as the signal for CREB-
P was never established, despite numerous attempts using various sample 
preparations and antibody concentrations/incubations to try to achieve a 
signal. Further investigations into the IR1072 ERK-independent increase in 
CREB expression are warranted. 
 
An age-dependant decrease in HSP27 has been shown in 12month old CD-1 
mice compared to 3 month old and 10 month old CD-1 mice. This correlates 
with previous data which has shown age-related changes in the heart and 
peripheral blood mono nuclear cell HSP27, where Colotti et al. (2005) 
demonstrated that age-related decreases occur in mRNA and protein 
expression of HSP27 HSP60, HSP72 in right atrium and left ventricle of the 
rat heart, and Njemini found basal levels of HSP27 expression decreased 
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during ageing (Colotti et al., 2005; Njemini et al., 2006). Decreased HSP27 
expression as ageing increases may result in increased protein misfolding, 
inactivation of AKT signalling and hence cell survival pathways, and pro-
apoptotic pathways activation with lessened inhibition from HSP27, resulting 
in an overall increase in apoptosis. This decrease in HSP27 at 10 and 12 
months, and also a trend for decreased expression of HSP90 at 12 months, 
compared to 3 months of age, may contribute towards the learning deficits 
previously reported in CD-1 mice (Ennaceur et al., 2008). 
 
A consistent and robust increase of HSP27 was shown in 7 month and 13 
month old CD-1 mice irradiated with IR1072. HSPs have been shown to be 
upregulated in mouse models of stress following LILT. Novoselova et al. 
(2007) irradiated the thymus zone projection of male NMRI mice of stress, 
modelled by lipopolysaccharide injection. Stress alone induced a significant 
increase in several macrophage cytokines, IL-1alpha, IL-1beta, IL-6, IL-10 
and TNF-alpha, where a single exposure of laser LILT (632.8nm) enhanced 
HSP25, HSP70, and HSP90 compared to sham controls and normalized the 
stress-induced cytokine production and suggested HSP normalised this stress 
response. This increase in HSP25 and 90 could have increased AKT 
signalling to promote cell survival, where HSP70 could be inhibiting the JNK 
signalling pathway in order to reduce pro-apoptotic proteins to be activated. 
Havasi et al. (2008) manipulated HSP27 expression in renal epithelial cells 
before transient metabolic stress, where it was demonstrated that enhanced 
HSP27 expression inhibited BAX activation, oligomerization, and translocation 
into mitochondria, reduced the leakage of both cytochrome c and AIF, and 
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significantly improved cell survival by more than 50% after stress, where 
decreased HSP27 expression activated BAX expression, induced 
mitochondrial injury and decreased cell survival. Interaction of BAX and 
HSP27 was not established before, during or after the insult, indicating that 
HSP27 acts on inhibiting BAX through an indirect pathway (Havasi et al., 
2008). They concluded that HSP27 antagonizes BAX-mediated mitochondrial 
injury and apoptosis by promoting AKT activation via a PI3-kinase pathway 
(Havasi et al., 2008). This could explain the significant increase in HSP27 and 
AKT shown in 13 month old CD-1 mice treated with IR1072, however a 
decrease in AKT expression was shown in 7 month old CD-1 mice irradiated 
with IR1072 although there was a trend for increased HSP27 expression. This 
suggests there may be an age-dependent effect of IR1072 on AKT expression 
in CD-1 mice.  
 
IR1072 appeared to induce HSP40 expression in 13 month old CD-1 mouse 
brains. Surprisingly, HSP70 was not induced which might be expected as 
HSP40 was induced and these proteins act in partnership, phosphorylating 
pro-apoptotic proteins and anti-apoptotic proteins to deactivate or activate, 
respectively, therefore preventing apoptosis. It has been proposed that 
HSP40 function as dimers and may bind and prime the non-native polypeptide 
into an extended conformation in preparation for the subsequent recognition 
and transference to HSP70 (Li et al., 2009). Perhaps an increase in HSP40 
expression indicates an increase in the amount of mis-folded proteins bound 
in preparation for normal protein refolding or UPC disposal. Another possibility 
is HSP40 could be inhibiting the JNK MAPK "stress" pathway indirectly 
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preventing activation of pro-proapoptotic proteins, and/or by preventing pro-
apoptotic protein translocation to the mitochondrial membrane directly 
whereby, in both instances, mitochondrial membrane permeabilisation and 
subsequent cytochrome c release is prevented, thus inhibiting apoptosis.  
 
HSP60 activation was established in 13 month old CD-1 mice, where this 
HSP is thought to play an important role in protein mis-folding and 
transportation of mitochondrial proteins, and also activation of caspase-3, a 
protein involved in the initiation of apoptosis. HSP60 is not thought of initiating 
apoptosis itself, but acts as a feed-forward mechanism during the late-stages 
of apoptosis to ensure optimal caspase activation. 
 
A significant decrease in AMPA receptor numbers were shown in both 7 
month old and 13 month old IR1072 irradiated CD-1 mice. This correlates with 
a previous in vitro study investigation using microwaves on neuronal cultures. 
Wang et al. (2005) studied the effect of non-thermal low-intensity microwaves 
on AMPA GluR2 and the amount of intracellular calcium in rat cerebral cortical 
neurons, and showed that GluR2 receptor numbers were down-regulated in 
irradiated neurons, resulting in a raised calcium concentration (Wang et al., 
2005). This effect of low intensity may indicate a photosensitive pathway that 
has yet to be explored. Several studies have suggested previously that 
calcium levels are increased following LILT (Alexandratou et al., 2002; Gao 
and Xing, 2009), however very little is known about LILT effects on AMPA 
receptor modulation, therefore further work to determine the effect of IR1072 
on AMPA receptor down-regulation should becarried out. 
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Overall, these results indicate that IR1072 may participate in neuroprotective 
pathways involved in apoptosis, however age may influence the proteins in 
which IR1072 may directly or indirectly up-regulates or down-regulates.  
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Chapter 6: Age-dependant molecular changes in 
TASTPM mice: Effect of chronic IR1072 (in vivo) 
treatment 
 
6.1 Introduction 
 
6.1.1 Alzheimer's Disease 
Alzheimer‟s disease (AD) is the most common cause of dementia in the 
Western world and the most prevelent neurodegenerative diseases (Gouras 
et al., 2005; Vardy et al., 2006). AD is characterized by progressive cognitive 
and behavioral decline, impacting on both sufferers and their carers (Vardy et 
al., 2006). Over a century ago, Alois Alzheimer described the pathological 
characteristics of Alzheimer‟s disease (AD) by the presence of extracellular 
Aβ plaques and intracellular neurofibrillary tangles in the brain (Richardson et 
al., 2003; Vardy et al., 2006; Howlett et al., 2008). Aβ is cleaved from the 
amyloid precursor protein (APP) by the „amyloidogenic pathway‟, involving the 
enzymes β-secretase and γ-secretase (Vardy et al., 2006). 
 
6.1.2 APP processing 
APP receives two cleavages, one in the extracellular domain (β-secretase 
cleavage) and the other in the β transmembrane region (γ-secretase 
cleavage), are necessary to release varying isoforms of Aβ from the APP 
molecule (Figure 6-1) (Chiang et al., 2008; Thinakaran and Koo, 2008). APP 
processing by α-secretase (non-amyloidogenic pathway) results in the 
production of a single soluble secreted fragment (P3) and one non-
amyloidogenic carboxy-terminal segment (Suzuki and Nakaya, 2008). The 
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processing of APP by β-secretase (amyloidogenic pathway) leads to the 
accumulation of Aβ fragments that make up amyloid plaques (Suzuki and 
Nakaya, 2008). The main components of Aβ plaques are Aβ1-40 and Aβ1-42 
(Chiang et al., 2008) where Aβ1-40 is the most prevalent species, whilst Aβ1-42 
is the most toxic (Melquiond et al., 2008). 
 
 
 
Figure 6-1: APP processing. Abbreviations: Aβ, β-amyloid; APP, Amyloid Precursor Protein. 
 
6.1.3 Alzheimer's Disease animal model: TASTPM mice 
Animal models of AD are a useful tool for exploring the pathological outcomes 
of the disease as well as preventative measures for disease acceleration, and 
therefore protection from irreversible neuronal loss, proposed to be caused by 
Aβ42 plaques and neurofibrillary tangles. Transgenic (Tg) mice that 
overexpress high levels of human APP containing familial AD mutations 
(PDAPP, Tg2576 and APP23) have been previously shown to develop 
astrocytosis and microgliosis, and to produce high levels of total Aβ in the 
cortex and hippocampus from the age of 6 months, but little evidence of the 
development of neurofibrillary tangles (NFT) or neuronal loss (Games et al., 
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1995; Hsiao et al., 1996; Sturchler-Pierrat et al., 1997; Moechars et al., 1999; 
Richardson et al., 2003).  
 
The TASTPM mouse line has been shown to have increased Aβ levels at 3 
months of age, Aβ plaques from 4 months of age and cognitive deficits from 6 
months of age (Howlett et al., 2004; Howlett, 2006; Choudhry et al., 2008). 
The major criticisms of animal models of AD is the lack of NFT and neuronal 
loss, and, like other animal models of AD, TASTPM mice do not display signs 
of NFT but does, however, show significant neuronal loss with age (Howlett, 
2006; Choudhry et al., 2008; Howlett et al., 2008). Howlett et al. (2006) 
immunolabelled and quantified neurons in TASTPM mouse brain of varying 
ages, and found a significant inverse correlation between Aβ load and 
neuronal counts and also between neuronal counts and animal age, where 
neuronal loss increased with age and Aβ deposition. Neuronal number in age-
matched wild type (WT) controls did not change with age. In addition to this, 
immunohistochemical analysis revealed an incidence of astrocytes, 
phosphorylated tau, and cathepsin D, a protease enzyme implicated in the 
processing of APP and phosphorylation of tau (Benes et al., 2008), increased 
in parallel with the age of TASTPM mice and Aβ deposition (Howlett et al., 
2008). Howlett et al. (2008) also showed that Aβ plaques in TASTPM mice 
consist of multiple forms of the peptide, including full length and N-terminally 
truncated, resembling those found in the human AD brain. Despite the lack of 
NFT formation, TASTPM mice would appear to model Alzheimer‟s disease 
reasonably well, as Aβ deposition, astrocytosis, phosphorylated tau and 
neuronal cell loss increase with age in this mouse model and therefore 
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provides a means of studying Aβ-associated neurodegeneration (Howlett, 
2006). We have used this animal model of AD for our chronic studies using 
IR1072 irradiation as the pathological signs of AD in this mouse model have 
been validated and confirmed, and are apparent at a younger age than other 
mouse models, lending itself to a cost-effective chronic treatment protocol. 
 
The aim of this chapter was to establish any protein changes in ERK1/2, AKT, 
or HSP signalling during ageing and/or following chronic IR1072 treatment in 
7 month old TASTPM male and female mice. This study also investigated 
both Aβ1-40 and Aβ1-42 plaques together or Aβ1-42 plaques alone.  
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6.2 Results 
 
6.2.1 TASTPM Age Timeline: Immunoblot analysis 
As this investigation is examining the effects of IR1072 on an animal model of 
AD, age and subsequent Aβ factors have a potential influence on protein 
expression, so naturally studying the effects of age on ERK1/2 and HSP 
protein expression is of interest in this study. Immunohistochemical analysis 
showed increase Aβ40/42 and Aβ42 deposits increased as the mice aged 
(Figure 6-9 and 6-10). 
 
Protein levels were standardised using mouse β-actin primary antibody. Data 
were statistically analysed using a two tailed student t-test. Data represent 
mean ± SEM. 
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Table 6-1: Protein expression profile in 3, 7, or 12 month old TASTPM mice. Arrows 
represent an increase (↑) or decrease (↓) in protein expression. Data were statistically 
analysed using a two tailed student t-test. Pink cells represent significant results (p<0.05) and 
blue cells represent a trend (p<0.1). n=3 for each group, *p<0.05, **p<0.01. Abbreviations: 
ADTL, TASTPM age timeline; BDNF; Brain Derived Neurotrophic Factor; ERK1/2 or ERK1/2-
P, unphosphorylated or phosphorylated extracellular-signal regulated kinase 1 or 2, 
respectively; CREB, Cyclic Adenosine Monophosphate (AMP) Response Element Binding; 
HSP, Heat Shock Protein; PI3, Phosphatidylinositol 3-Kinase.  
 
 AD TL (months) 
 3mv7m 3mv12m 7mv12m 
 p value result p value result p value result 
BDNF 0.0897 NS *0.0341 12m↓ 0.4509 NS 
ERK1 0.698 NS *0.0129 12m↓ *0.0441 12m↓ 
ERK2 0.1158 NS *0.0117 12m↓ 0.3416 NS 
ERK1-P 0.0943 NS 0.2337 NS 0.3535 NS 
ERK2-P 0.8478 NS 0.2983 NS 0.111 NS 
CREB 0.4274 NS 0.3797 NS 0.8401 NS 
CREB-P       
AKT **0.0019 7m↑ *0.0212 12m↑ *0.0488 12m↓ 
AKT-P 0.6021 NS 0.2396 NS 0.1245 NS 
HSP27       
HSP40 0.0793 NS **0.0095 12m↓ *0.0338 12m↓ 
HSP60 0.1568 NS 0.5474 NS 0.2765 NS 
HSP70 0.5401 NS 0.5654 NS 0.3277 NS 
HSP90 0.199 NS 0.0715 NS 0.128 NS 
HSP105 0.0949 NS *0.0121 12m↓ 0.2839 NS 
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TASTPM mice at 12 months of age (n=3, 0.435 ± 0.0486, p<0.05) showed 
significantly decreased BDNF expression compared to mice at 3 months of 
age (n=3, 0.6152 ± 0.030,) but no differences in BDNF expression when 
compared to mice at 7 months of age (n=3, 0.4916 ± 0.04691). TASTPM mice 
at 7 months of age showed a trend for decreased BDNF expression 
compared to 3 month old mice (Figure 6-2).  
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Figure 6-2: Age-dependant changes in BDNF expression in 3, 7, or 12 month old male 
TASTPM mice where A) is an Immunoblot representation where each lane represents an 
individual mouse and B) is a column graph showing the quantitative results of BDNF 
expression from the immunoblot. Protein expression were standardised to total β-actin levels. 
Abbreviations: BDNF, Brain Derived Neurotrophic Factor. Mean values ± SEM, n = 3 for each 
group, *p<0.05. 
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TASTPM mice at 12 months (n=3, 0.066 ± 0.0523) showed significantly 
decreased levels of ERK1 expression compared to mice aged 3 months (n=3, 
0.585 ± 0.110, p<0.05) and 7 months (n=3, 0.510 ± 0.144, p<0.05). TASTPM 
mice at 3 months showed no differences in ERK1 expression compared to 7 
months of age. TASTPM mice at 12 months (n=3, 0.635 ± 0.166) showed 
significantly decreased levels of ERK2 expression compared to mice aged 3 
months (n=3, 1.393 ± 0.047, p<0.05) and 7 months (n=3, 0.935 ± 0.224, 
p<0.05). TASTPM mice at 3 months showed no differences in ERK1 
expression compared to 7months of age (Figure 6-3).  
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Figure 6-3: Age-dependant changes in ERK1/2 expression in 3, 7, or 12 month old male 
TASTPM mice where A) is an Immunoblot representation where each lane represents an 
individual mouse and B) is a column graph showing the quantitative results of ERK1/2 
expression from the immunoblot. Abbreviations: ERK1/2, Extracellular Signal-regulated 
Kinase 1 or 2. Mean values ± SEM, n = 3 for each group, *p<0.05. 
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TASTPM mice at 7 months (n=3, 0.153 ± 0.0572) showed a trend for 
increased ERK1-P expression compared to 3 months (n=3, 0.020 ± 0.020, 
p<0.1) of age. TASTPM mice at 12 months (0.081 ± 0.038) showed no 
differences in ERK1-P expression compared to TASTPM mice at 3 or 7 
months of age. No differences in ERK2-P expression was shown between 
TASTPM mice aged 3 months (n=3, 0.553 ± 0.131), 7 months (n=3, 0.582 ± 
0.064) and 12 months (n=3, 0.367 ± 0.084) (Figure 6-4).  
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Figure 6-4: Age-dependant changes in phosphorylated ERK1/2 expression in 3, 7, or 12 
month old male TASTPM mice where A) is an Immunoblot representation where each lane 
represents an individual mouse and B) is a column graph showing the quantitative results of 
ERK1/2 expression from the immunoblot. Protein expression were standardised to total β-
actin levels. Abbreviations: ERK1/2, Extracellular Signal-regulated Kinase 1 or 2. Mean 
values ± SEM, n = 3 for each group. 
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TASTPM mice at 12 months (n=3, 0.5294 ± 0.021) showed significantly higher 
expression when compared to 3months (n=3, 0.410 ± 0.024, p<0.05) but 
significantly lower AKT expression compared to 7 months (n=3, 0.593 ± 
0.007, p<0.05) of age. TASTPM mice at 7 months showed significantly higher 
AKT expression compared to mice at 3 months of age (p<0.01) (Figure 6-5).  
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Figure 6-5: Age-dependant changes in AKT expression in 3,7, or 12 month old male 
TASTPM mice where A) is an Immunoblot representation where each lane represents an 
individual mouse and B) is a column graph showing the quantitative results of AKT expression 
from the immunoblot. Protein expression were standardised to total β-actin levels. 
Abbreviations: AKT, Protein Kinase B. Mean values ± SEM, n = 3 for each group, *p<0.05, 
**P<0.01. 
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TASTPM mice at 12 months old (n=3, 1.024 ± 0.103) displayed significantly 
lower HSP40 expression compared to 3 months (n=3, 4.014 ± 0.631, p<0.01) 
and 7 months (n=3, 2.29 ± 0.384, p<0.05) old mice. TASTPM mice at 7 
months show a trend for decreased expression compared to 3 months old 
mice (p<0.1) (Figure 6-6).  
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Figure 6-6: Age-dependant changes in HSP40 expression in 3,7, or 12 month old male 
TASTPM mice where A) is an Immunoblot representation where each lane represents an 
individual mouse and B) is a column graph showing the quantitative results of HSP40 
expression from the immunoblot. Protein expression were standardised to total β-actin levels. 
Abbreviations: HSP40, Heat Shock Protein 40. Mean values ± SEM, n = 3 for each group, 
*p<0.05, **P<0.01. 
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TASTPM mice at 12 months old (n=3, 0.510 ± 0.0577) showed a trend for 
decreased HSP90 expression compared to 3 months (n=3, 0.734 ± 0.072, 
p<0.1), but no differences were seen when compared to 7 month old mice 
(n=3, 0.622 ± 0.011) old mice. TASTPM mice at 7 months displayed no 
differences when compared to 3 months old mice (Figure 6-7).  
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Figure 6-7: Age-dependant changes in HSP90 expression in 3,7, or 12 month old male 
TASTPM mice where A) is an Immunoblot representation where each lane represents an 
individual mouse, therefore one n number and B) is a column graph showing the quantitative 
results of HSP90 expression from the immunoblot. Protein expression were standardised to 
total β-actin levels. Abbreviations: HSP90, Heat Shock Protein 90. Mean values ± SEM, n = 3 
for each group. 
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TASTPM mice at 12 months old (n=3, 1.496 ± 0.099) showed a significantly 
decreased HSP105 expression compared to mice at 3 months old (n=3, 2.497 
± 0.207, p<0.05), but no differences were seen when compared to 7 month 
old mice (n=3, 1.812 ± 0.236) old mice. TASTPM mice at 7 months showed a 
trend for decreased expression when compared to 3 months old mice (p<0.1) 
(Figure 6-8).  
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Figure 6-8: Age-dependant changes in HSP105 expression in 3,7, or 12 month old male 
TASTPM mice where A) is an Immunoblot representation where each lane represents an 
individual mouse and B) is a column graph showing the quantitative results of HSP105 
expression from the immunoblot. Protein expression were standardised to total β-actin levels. 
Abbreviations: HSP105, Heat Shock Protein 105. Mean values ± SEM, n = 3 for each group, 
*p<0.05. 
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6.2.2 TASTPM Age Timeline: Immunohistochemical analysis 
 
Table 6-2: Summary table depicting immunohistochemical analysis of various protein 
expression in 3, 7, or 12 month old TASTPM mice (n=3 for 3m old, 7m old and 12m old 
groups). Arrows represent an increase (↑) or decrease (↓) in protein expression in older mice 
and respective figure numbers. Abbreviations; BDNF, Brain Deived Neurotrophic Factor; 
ERK1/2, Extracellular Signal-regulated Kinase; CREB, Cyclic Adenosine Monophosphate 
(AMP) Response Element Binding; AKT, Protein Kinase B; HSP, Heat Shock Protein. n=3 for 
each group.  
 
Cell signalling protein expression in ageing TASTPM mice 
1º Ab Result 
BDNF - 
ERK1/2 - 
ERK1/2-P - 
CREB - 
AKT - 
AKT-P - 
HSP27  
HSP40 - 
HSP60 - 
HSP70 - 
HSP90 ↓ 
HSP105 - 
Aβ40/42 ↑ 
Aβ42 ↑ 
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The TASTPM timeline immunohistochemistry showed a reduction in HSP90 
as mice aged (Figure 6-9). 
 
Figure 6-9: Immunohistochemical representation of HSP90 expression in 3, 7, or 12 month 
old TASTPM mice in various brain regions. Abbreviations: HSP90, Heat Shock Protein 90; 
Ctx, cerebral cortex; CA (1/2/3), Cornu ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, 
Caudate Putamen. n=3 for each group, X100 magnification. 
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The TASTPM timeline showed an increase in Aβ1-40/42 deposits as mice aged 
(Figure 6-10). 
 
Figure 6-10: Immunohistochemical representation of Aβ1-40/42 expression in 3, 7, or 12 month 
old TASTPM mice in various brain regions. Abbreviations: Aβ, β-amyloid; Ctx, cerebral cortex; 
CA (1/2/3), Cornu ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. 
n=3 for each group, X100 magnification. 
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The TASTPM timeline showed an increase in Aβ1-42 deposits as mice aged 
(Figure 6-11). 
 
Figure 6-11: Immunohistochemical representation of Aβ1-42 expression in 3, 7, or 12 month 
old TASTPM mice in various brain regions. Abbreviations: Aβ, β-amyloid, Ctx, cerebral cortex; 
CA (1/2/3), Cornu ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. 
n=3 for each group, X100 magnification. 
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6.2.3 TASTPM Age Timeline: Serum Amyloid A Assay 
A Serum Amyloid A (SAA) assay was performed in ageing TASTPM mice in 
order to establish any differences in serum amyloid as mice age. SAA assay 
kit purchased from Life diagnostics Inc., kit protocol was followed. 
 
TASTPM mice at 7 months of aged (400.0 ± 9.200, n=3, p<0.05) showed a 
significant reduction in serum amyloid compared to 3 month old mice(487.6 ± 
25.24, n=3) and 12 month old mice (451.3 ± 6.76, n=3, p<0.05). There were 
no significant differences found between 3 months and 12 months old 
TASTPM mice (Figure 6-11). 
 
IR1072 and sham treated TASTPM mice revealed no significant differences in 
serum amyloid between groups (data not shown). 
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Figure 6-12: Graph showing decreased expression in serum amyloid during ageing in 
TASTPM mice. Abbreviations: SAA, Serum Amyloid A. Mean values ± SEM, n = 3 for each 
group, *p<0.05. 
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6.2.3 Chronic IR1072 Treatment: TASTPM mice 
Difficulties maintaining TASTPM mice in the LSSU arose initially, where 
female mice were having difficulties giving birth to live pups, and life-span for 
all mice were reduced to 6 or 7 months of age, due to unknown causes. 
Therefore limited numbers and lifespan of TASTPM mice dictated the 
following experiments. TASTPM mice, age-matched female and male, were 
pooled together in order to make the required n number per group for 
behavioural studies (n=8), where both female and male mice were 
preconditioned with 6 minute sham or IR1072 treatments, biweekly from 2 
months of age to 7 months of age. The following results show molecular 
changes in ERK1/2 signalling and HSP expression using quantitative 
immunoblotting and immunohistochemical analysis, where each sex was 
investigated separately.  
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6.2.3.1 Chronic IR1072 treatment in male TASTPM mice: Immunoblot 
analysis 
 
Protein levels were standardised using mouse β-actin primary antibody. Data 
were statistically analysed using a two tailed student t-test. Data represent 
mean ± SEM. 
 
Table 6-3: Protein expression profile in 7 month old male TASTPM mouse brain following 
chronic IR1072 treatment compared to age-matched sham-treated controls. Arrows represent 
an increase (↑) or decrease (↓) in protein expression in IR-treated TASTPM mice compared to 
age-matched sham controls, and respective figure numbers. Data were statistically analysed 
using a two tailed student t-test. Pink cells represent significant results (p<0.05) and blue cells 
represent a trend (p<0.1). n=4 for each group, **p<0.01. Abbreviations: BDNF; Brain Derived 
Neurotrophic Factor; ERK1/2 or ERK1/2-P, unphosphorylated or phosphorylated extracellular-
signal regulated kinase 1 or 2, respectively; CREB, Cyclic Adenosine Monophosphate (AMP) 
Response Element Binding; HSP, Heat Shock Protein; PI3, Phosphatidylinositol 3-Kinase. 
Effect of Chronic IR1072 treatment on protein expression in male 
7 month old TASTPM mice 
1º pvalue Result Figure 
BDNF **0.0003 ↓ Figure 6-12 
ERK1 0.4139 NS Data not shown 
ERK2 0.3472 NS Data not shown 
ERK1-P 0.6549 NS Data not shown 
ERK2-P 0.0532 NS Figure 6-13 
CREB **0.0034 ↑ Figure6-14 
AKT 0.4682 NS Data not shown 
AKT-P 0.49 NS Data not shown 
HSP27   Incomplete 
HSP40 0.2347 NS Data not shown 
HSP60 **0.0051 ↓ Figure 6-15 
HSP70 0.7877 NS Data not shown 
HSP90 0.0818 NS Figure 6-16 
HSP105 0.6592 NS Data not shown 
Aβ1-40/42-1 0.0038 **↓ 
Figure 6-17 Aβ1-40/42-2 0.0186 *↓ 
Aβ1-40/42-3 0.0077 **↓ 
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IR1072-preconditioned male TASTPM mice (n=4, 0.328 ± 0.044) showed a 
significant decrease in BDNF expression compared to age-matched sham 
controls (n=4, 0.743 ± 0.032, p<0.001) (Figure 6-13).  
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Figure 6-13: BDNF expression in chronically sham or IR1072 treated 7 month old TASTPM 
mouse brain (in vivo) where A) is an immunoblot representation where each lane represents 
an individual mouse and B) is a column graph showing the quantitative results of BDNF 
expression. Protein expression were standardised to total β-actin levels. Abbreviations: 
BDNF, Brain Derived Neurotrophic Factor. Mean values ± SEM, n = 4 for each group, 
***p<0.001. 
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IR1072-preconditioned male TASTPM mice (n=4, 0.3689 ± 0.1786) showed 
no differences in ERK1-P expression compared to age-matched sham 
controls (n=4, 0.483 ± 0.163). However, IR1072-preconditioned male 
TASTPM mice (n=4, 0.358 ± 0.069) showed displayed a trend for increased 
ERK2-P expression compared to age-matched sham controls (n=4, 0.613 ± 
0.081, p<0.1) (Figure 6-14).  
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Figure 6-14: ERK1/2-P expression in chronically sham or IR1072 treated 7 month old 
TASTPM mouse brain (in vivo) where A) is an immunoblot representation where each lane 
represents an individual mouse and B) is a column graph showing the quantitative results of 
phosphorylated ERK1/2-P expression. Protein expression were standardised to total β-actin 
levels. Abbreviations: ERK1/2-P, phosphorylated extracellular signal regulated kinase. Mean 
values ± SEM, n = 4 for each group. 
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IR1072-preconditioned male TASTPM mice (n=4, 1.432 ± 0.221) showed a 
significant increase in CREB expression compared to age-matched sham 
controls (n=4, 0.367 ± 0.057, p<0.01) (Figure 6-15).  
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Figure 6-15: CREB expression in chronically sham or IR1072 treated 7 month old TASTPM 
mouse brain (in vivo) where A) is an immunoblot representation where each lane represents 
an individual mouse and B) is a column graph showing the quantitative results of 
phosphorylated CREB expression. Protein expression were standardised to total β-actin 
levels. Abbreviations: CREB, cAMP (cyclic adenosine monophosphate) response element 
binding. Mean values ± SEM, n = 4 for each group, **p<0.01. 
Sham IR1072 
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IR1072-preconditioned male TASTPM mice (n=4, 0.606 ± 0.103) showed a 
significant decrease in HSP60 expression compared to age-matched sham 
controls (n=4, 1.590 ± 0.204, p<0.01) (Figure 6-16). 
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Figure 6-16: HSP60 expression in chronically sham or IR1072 treated 7 month old TASTPM 
mouse brain (in vivo) where A) is an immunoblot representation where each lane represents 
an individual mouse and B) is a column graph showing the quantitative results of 
phosphorylated HSP60 expression. Protein expression were standardised to total β-actin 
levels. Abbreviations: HSP, Heat Shock Protein 60. Mean values ± SEM, n = 4 for each 
group, **p<0.01. 
Sham IR1072 
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IR1072-preconditioned male TASTPM mice (n=4, 0.915 ± 0.030) showed a 
trend toward increased in HSP90 expression compared to age-matched sham 
controls (n=4, 0.726 ± 0.085, p<0.1) (Figure 6-17).  
A 
 
B 
Sham IR
0.00
0.25
0.50
0.75
1.00
IR Treatment
H
S
P
9
0
 E
x
p
re
s
s
io
n
 
Figure 6-17: HSP90 expression in chronically sham or IR1072 treated 7 month old TASTPM 
mouse brain (in vivo) where A) is an immunoblot representation where each lane represents 
an individual mouse and B) is a column graph showing the quantitative results of 
phosphorylated HSP90 expression. Protein expression were standardised to total β-actin 
levels. Abbreviations: HSP90, Heat Shock Protein 90. Mean values ± SEM, n = 4 for each 
group. 
 
Sham IR1072 
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IR1072-preconditioned male TASTPM mice (n=4, band 1: 0.128 ± 0.0289; 
band 2: 0.037 ± 0.0254; band 3: 0.448 ± 0.067) showed significant decreased 
Aβ1-40/42 expression compared to age-matched sham controls (n=4, band 1: 
0.743 ± 0.131; band 2: 0.510 ± 0.146; band 3: 1.015 ± 0.128) (Figure 6-18).  
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Figure 6-18: Aβ1-40/42 expression in chronically sham or IR1072 treated 7 month old TASTPM 
mouse brain (in vivo) where A) is an immunoblot representation where each lane represents 
an individual mouse and B) is a column graph showing the quantitative results of i) band 1, ii) 
band 2 and iii) band 3 of β-amyloid expression. Protein expression were standardised to total 
β-actin levels. Mean values ± SEM, n = 4 for each group. *p<0.05, **p<0.01. 
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6.2.3.2 Chronic IR1072 treatment in male TASTPM mice: 
Immunohistochemical analysis 
 
Table 6-4: Summary table depicting immunohistochemical analysis of various protein 
expression in IR1072-treated male TASTPM mice and sham-treated controls. Arrows 
represent an increase (↑) or decrease (↓) in protein expression in older mice. Abbreviations; 
BDNF, Brain Deived Neurotrophic Factor; ERK1/2, Extracellular Signal-regulated Kinase; 
CREB, Cyclic Adenosine Monophosphate (AMP) Response Element Binding; AKT, Protein 
Kinase B; HSP, Heat Shock Protein. n=3 for each group.  
 
Cell signalling protein expression in sham or IR1072-treated 
male TASTPM mice 
1º Ab Result 
BDNF ↓ Ctx, CA1 
ERK1/2 - 
ERK1/2-P ↓ Ctx, CA1, CA2/3, Cb 
CREB - 
AKT - 
AKT-P - 
HSP27  
HSP40 - 
HSP60 - 
HSP70 - 
HSP90  
HSP105 - 
Aβ40/42 ↓ Ctx 
Aβ42 - 
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IR1072-treated male TASTPM mice (n=4) showed a decrease in BDNF 
expression in the cortex and CA1 region of the hippocampus compared to 
age-matched sham controls (n=3) (Figure 6-19). 
 
Figure 6-19: Immunohistochemical representation of BDNF expression in IR1072-treated 
male TASTPM mice compared to age-matched sham controls in various brain regions. 
Abbreviations: BDNF, Brain Deived Neurotrophic Factor; Ctx, cerebral cortex; CA (1/2/3), 
Cornu ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 for sham 
and n=4 for IR groups, X100 magnification. 
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IR1072-treated male TASTPM mice (n=4) showed a decrease in ERK1/2 
expression in the cortex, the CA1/2/3 regions of the hippocampus and the 
cerebellum compared to age-matched sham controls (n=3) (Figure 6-20). 
 
Figure 6-20: Immunohistochemical representation of ERK1/2-P expression in IR1072-treated 
male TASTPM mice compared to age-matched sham controls in various brain regions. 
Abbreviations: Extracellular Signal-regulated Kinase 1 or 2; Ctx, cerebral cortex; CA (1/2/3), 
Cornu ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 for sham 
and n=4 for IR groups, X100 magnification. 
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Quantification of Immunohistochemical staining of Aβ1-40/42 and Aβ1-42 
expression showed that total Aβ1-40/42 (27.75 ± 5.22, n=4, p<0.05) and small 
Aβ1-40/42 plaque formation (17.00 ± 2.86, n=4, p<0.001) in IR1072 treated male 
TASTPM mice was significantly decreased in the cortex compared to age-
matched sham controls age-matched sham controls (41.67 ± 3.52, n=4 and 
32.000 ± 2.08, n=4, respectively) (Figure 6-21 - 6-23). All other parameters 
measured were statistically insignificant. IR1072 treated male TASTPM mice 
showed that Aβ1-42 plaque formation was not statistically different from sham-
treated TASTPM mice (Figure 6-24 - 6-26). 
 
  202 
 
 
Figure 6-21: Immunohistochemical representation of Aβ1-40/42 expression in IR1072-treated 
male TASTPM mice compared to age-matched sham controls in various brain regions. 
Abbreviations: Aβ, β-amyloid ; Ctx, cerebral cortex; CA (1/2/3), Cornu ammonis; DG, Dentate 
Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 for sham and n=4 for IR groups, 
magnification. 
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Figure 6-22: Quantification of immunohistochemical Aβ1-40/42 expression data in IR1072-
treated male TASTPM mice compared to age-matched sham controls in various brain 
regions. Abbreviations: Aβ, β-amyloid ; Ctx, cerebral cortex; CA (1/2/3), Cornu ammonis; DG, 
Dentate Gyrus; Cb, Cerebellum. n=3 for sham and n=4 for IR groups. 
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Figure 6-23: Quantification of immunohistochemical total Aβ1-40/42 expression data in IR1072-
treated male TASTPM mice compared to age-matched sham controls for A) various brain 
regions, B) plaque size C) total count. Abbreviations: Aβ, β-amyloid; Ctx, cerebral cortex; CA 
(1/2/3), Cornu ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 
for sham and n=4 for IR groups. 
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Figure 6-24: Immunohistochemical representation of Aβ1-42 expression in IR1072-treated 
male TASTPM mice compared to age-matched sham controls in various brain regions. 
Abbreviations: Aβ, β-amyloid ; Ctx, cerebral cortex; CA (1/2/3), Cornu ammonis; DG, Dentate 
Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 for sham and n=4 for IR groups, X100 
magnification. 
  206 
Ctx
Small Medium Large
0
10
20
30
40
Sham
IR
Plaque Size
N
u
m
b
e
r 
o
f 
A

1
-4
2
p
la
q
u
e
s
DG
Small Medium Large
0.0
2.5
5.0
7.5
10.0
12.5
15.0
17.5
Sham
IR
Plaque Size
N
u
m
b
e
r 
o
f 
A

1
-4
2
p
la
q
u
e
s
CA1
Small Medium Large
0
5
10
15
Sham
IR
Plaque Size
N
u
m
b
e
r 
o
f 
A

1
-4
2
p
la
q
u
e
s
CA2/3
Small Medium Large
0
1
2
3
4
5
6
7
8
9
10
11
12
Sham
IR
Plaque Size
N
u
m
b
e
r 
o
f 
A

1
-4
2
p
la
q
u
e
s
CPu
Small Medium Large
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
Sham
IR
Plaque Size
N
u
m
b
e
r 
o
f 
A

1
-4
2
p
la
q
u
e
s
Figure 6-25: Quantification of immunohistochemical Aβ1-42 expression data in IR1072-treated 
male TASTPM mice compared to age-matched sham controls in various brain regions. 
Abbreviations: Aβ, β-amyloid; Ctx, cerebral cortex; CA (1/2/3), Cornu ammonis; DG, Dentate 
Gyrus; CPu, Caudate Putamen. n=3 for sham and n=4 for IR groups. 
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Figure 6-26: Quantification of immunohistochemical total Aβ1-42 expression data in IR1072-
treated male TASTPM mice compared to age-matched sham controls for A) various brain 
regions, B) plaque size C) total count. Abbreviations: Aβ, β-amyloid; Ctx, cerebral cortex; CA 
(1/2/3), Cornu ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 
for sham and n=4 for IR groups. 
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6.2.3.3 Chronic IR1072 treatment in female TASTPM mice: Immunoblot 
analysis 
 
Protein levels were standardised using mouse β-actin primary antibody. Data 
were statistically analysed using a two tailed student t-test. Data represent 
mean ± SEM. 
 
Table 6-5: Protein expression profile in 7 month old female TASTPM mouse brain following 
chronic IR1072 treatment compared to age-matched sham-treated controls. Arrows represent 
an increase (↑) or decrease (↓) in protein expression in IR-treated TASTPM mice compared to 
age-matched sham controls, and respective figure numbers. Data were statistically analysed 
using a two tailed student t-test. Pink cells represent significant results (p<0.05) and blue cells 
represent a trend (p<0.1). n=4 for each group, *p<0.05, **p<0.01. Abbreviations: BDNF; Brain 
Derived Neurotrophic Factor; ERK1/2 or ERK1/2-P, unphosphorylated or phosphorylated 
extracellular-signal regulated kinase 1 or 2, respectively; CREB, Cyclic Adenosine 
Monophosphate (AMP) Response Element Binding; HSP, Heat Shock Protein; PI3, 
Phosphatidylinositol 3-Kinase. 
Effect of Chronic IR1072 treatment on protein expression in female 7 month 
old TASTPM mice 
1º p value Results Figure 
BDNF *0.0171 ↓ Figure 6-26 
ERK1 0.5005 NS Data not shown 
ERK2 0.0234 ↑ Figure 6-27 
ERK1-P 0.3395 NS Data not shown 
ERK2-P 0.864 NS Data not Shown 
CREB 0.0948 NS Figure 6-28 
AKT 0.1485 NS Data not shown 
AKT-P   Data not shown 
HSP27 0.1712 NS Incomplete 
HSP40 0.1925 NS Data not shown 
HSP60 **0.0057 ↑ Figure 6-29 
HSP70 0.2124 NS Data not shown 
HSP90 0.43 NS Data not shown 
HSP105 **0.0016 ↑ Figure 6-30 
Aβ1-40/42   Incomplete 
 
  209 
IR1072-preconditioned female TASTPM mice (n=3, 0.482 ± 0.0422) showed a 
significant decrease in BDNF expression compared to age-matched sham 
controls (n=3, 0.820 ± 0.075, p<0.05) (Figure 6-27).  
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Figure 6-27: BDNF expression in chronically sham or IR1072 treated 7 month old TASTPM 
mouse brain (in vivo) where A) is an immunoblot representation where each lane represents 
an individual mouse and B) is a column graph showing the quantitative results of BDNF 
expression. Protein expression were standardised to total β-actin levels. Abbreviations: 
BDNF, Brain Derived Neurotrophic Factor. Mean values ± SEM, n = 3 for each group, 
*p<0.05. 
 
Sham IR1072 
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IR1072-preconditioned female TASTPM mice (n=3, 0.372 ± 0.086) showed no 
differences in ERK1 expression compared to age-matched sham controls 
(n=3, 0.629 ± 0.095, p<0.05). However, IR1072-preconditioned female 
TASTPM mice (n=3, 1.412 ± 0.0367) showed significant increase in ERK2 
expression compared to age-matched sham controls (n=3, 0.601 ± 0.225, 
p<0.05) (Figure 6-28).  
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Figure 6-28: ERK1/2 expression in chronically sham or IR1072 treated 7 month old TASTPM 
mouse brain (in vivo) where A) is an immunoblot representation where each lane represents 
an individual mouse and B) is a column graph showing the quantitative results of ERK1/2 
expression. Protein expression were standardised to total β-actin levels. Abbreviations: 
ERK1/2, Extracellular Signal-regulated Kinase 1 or 2. Abbreviations: Mean values ± SEM, n = 
3 for each group, *p<0.05. 
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IR1072-preconditioned female TASTPM mice (n=3, 1.465 ± 0.027) showed a 
trend towards increased CREB expression compared to age-matched sham 
controls (n=3, 0.764 ± 0.320, p<1) (Figure 6-29).  
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Figure 6-29: CREB expression in chronically sham or IR1072 treated 7 month old TASTPM 
mouse brain (in vivo) where A) is an immunoblot representation where each lane represents 
an individual mouse and B) is a column graph showing the quantitative results of CREB 
expression. Protein expression were standardised to total β-actin levels. Abbreviations: 
CREB, cAMP (cyclic adenosine monophosphate) response element binding. Mean values ± 
SEM, n = 3 for each group. 
Sham IR1072 
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IR1072-preconditioned female TASTPM mice (n=3, 1.750 ± 0.078) showed 
significant increased HSP60 expression compared to age-matched sham 
controls (n=3, 0.7314 ± 0.1720, p<0.01) (Figure 6-30).  
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Figure 6-30: HSP60 expression in chronically sham or IR1072 treated 7 month old TASTPM 
mouse brain (in vivo) where A) is an immunoblot representation where each lane represents 
an individual mouse and B) is a column graph showing the quantitative results of HSP60 
expression. Protein expression were standardised to total β-actin levels. Abbreviations: 
HSP60, Heat Shock Protein 60. Mean values ± SEM, n = 3 for each group. p<0.01. 
Sham IR1072 
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IR1072-preconditioned female TASTPM mice (n=3, 1.256 ± 0.077) showed 
significant increased HSP105 expression compared to age-matched sham 
controls (n=3, 0.5259 ± 0.058, p<0.01) (Figure 6-31). 
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Figure 6-31: HSP105 expression in chronically sham or IR1072 treated 7 month old TASTPM 
mouse brain (in vivo) where A) is an immunoblot representation where each lane represents 
an individual mouse and B) is a column graph showing the quantitative results of HSP105 
expression. Protein expression were standardised to total β-actin levels. Abbreviations: 
HSP105, Heat Shock Protein 105. Mean values ± SEM, n = 3 for each group. **p<0.01. 
 
Sham IR1072 
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6.2.3.4 Chronic IR1072 treatment in female TASTPM mice: 
Immunohistochemical analysis 
 
Table 6-6: Summary table depicting immunohistochemical analysis of various protein 
expression in IR1072-treated female TASTPM mice and sham-treated controls. Arrows 
represent an increase (↑) or decrease (↓) in protein expression. Abbreviations; BDNF, Brain 
Deived Neurotrophic Factor; ERK1/2, Extracellular Signal-regulated Kinase; CREB, Cyclic 
Adenosine Monophosphate (AMP) Response Element Binding; AKT, Protein Kinase B; HSP, 
Heat Shock Protein. n=3 for each group.  
 
Cell signalling protein expression in sham or IR1072-treated 
female TASTPM mice 
1º Ab Result 
BDNF ↓ Ctx, CA1, CA2/3, DG 
ERK1/2 - 
ERK1/2-P - 
CREB - 
AKT - 
AKT-P - 
HSP27 - 
HSP40 - 
HSP60 - 
HSP70 - 
HSP90  
HSP105 ↑CA1, CA2/3 
Aβ40/42 ↓ DG, ↑ CPu 
Aβ42 ↓Ctx 
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IR1072-treated female TASTPM mice (n=3) displayed a decrease in BDNF 
expression in the cortex, CA1/2/3 and dentate gyrus region of the 
hippocampus compared to age-matched sham controls (n=3) ) (Figure 6-32). 
 
Figure 6-32: Immunohistochemical representation of BDNF expression in IR1072-treated 
female TASTPM mice compared to age-matched sham controls in various brain regions. 
Abbreviations: BDNF, Brain Derived Neurotrophic Factor; Ctx, cerebral cortex; CA (1/2/3), 
Cornu ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 for each 
group, X100 magnification. 
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IR1072-treated female TASTPM (n=3) mice showed an increased HSP105 
expression in CA1/2/3 regions of the hippocampus compared to age-matched 
sham controls (n=3) (6-33). 
 
Figure 6-33: Immunohistochemical representation of HSP105 expression in IR1072-treated 
female TASTPM mice compared to age-matched sham controls in various brain regions. 
Abbreviations: HSP105, Heat Shock Protein 105; Ctx, cerebral cortex; CA (1/2/3), Cornu 
ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 for each group, 
X100 magnification. 
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Results of immunohistochemical staining of Aβ1-40/42 and Aβ1-42 expression 
were quantified and revealed for IR1072 treated female TASTPM mice that 
total Aβ1-40/42 (116.33 ± 5.93, n=3, p<0.001) and small plaque formation (35.67 
± 5.21, n=3, p<0.01) was significantly increased in the caudate putamen 
compared to age-matched sham controls (97.00 ± 8.62, n=3 and 12.00 ± 
6.25, n=4, respectively). Small Aβ1-40/42 plaque counts were significantly 
reduced in the dentate gyrus of IR1072-treated female mice (14.67 ± 4.33, 
n=3, p<0.05) compared to age-matched sham controls (22.33 ± 0.67) (Figure 
6-33 - 6-35). Small Aβ1-42 plaque counts were significantly reduced in the 
cortex of IR1072-treated mice (33.33 ± 1.86, n=3, p<0.05) compared to age 
matched sham controls (45.67 ± 2.96, n=3). Total small Aβ1-42 plaque 
formation was significantly reduced in IR1072-treated female mice (83.00 ± 
8.08, n=3, p<0.05) compared to age matched sham controls (107.67 ± 9.67, 
n=3) (Figure 6-36 - 6-38). All other parameters measured were statistically 
insignificant. 
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Figure 6-34: Immunohistochemical representation of Aβ1-40/42 expression in IR1072-treated 
female TASTPM mice compared to age-matched sham controls in various brain regions. 
Abbreviations: Aβ, β-amyloid; Ctx, cerebral cortex; CA (1/2/3), Cornu ammonis; DG, Dentate 
Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 for each group, X100 magnification. 
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Figure 6-35: Quantification of immunohistochemical Aβ1-40/42 expression data in IR1072-
treated female TASTPM mice compared to age-matched sham controls in various brain 
regions. Abbreviations: Aβ, β-amyloid ; Ctx, cerebral cortex; CA (1/2/3), Cornu ammonis; DG, 
Dentate Gyrus; CPu, Caudate Putamen. n=3 for each groups. 
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Figure 6-36: Quantification of immunohistochemical total Aβ1-40/42 expression data in IR1072-
treated female TASTPM mice compared to age-matched sham controls for A) various brain 
regions, B) plaque size C) total count. Abbreviations: Aβ, β-amyloid ; Ctx, cerebral cortex; CA 
(1/2/3), Cornu ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 
for each group. 
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Figure 6-37: Immunohistochemical representation of Aβ1-42 expression in IR1072-treated 
female TASTPM mice compared to age-matched sham controls in various brain regions. 
Abbreviations: Aβ, β-amyloid; Ctx, cerebral cortex; CA (1/2/3), Cornu ammonis; DG, Dentate 
Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 for each group, X100 magnification. 
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Figure 6-38: Quantification of immunohistochemical Aβ1-42 expression data in IR1072-treated 
female TASTPM mice compared to age-matched sham controls in various brain regions. 
Abbreviations: Aβ, β-amyloid ; Ctx, cerebral cortex; CA (1/2/3), Cornu ammonis; DG, Dentate 
Gyrus; CPu, Caudate Putamen. n=3 for each groups. 
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Figure 6-39: Quantification of immunohistochemical total Aβ1-42 expression data in IR1072-
treated female TASTPM mice compared to age-matched sham controls for A) various brain 
regions, B) plaque size C) total count. Abbreviations: Aβ, β-amyloid ; Ctx, cerebral cortex; CA 
(1/2/3), Cornu ammonis; DG, Dentate Gyrus; Cb, Cerebellum; CPu, Caudate Putamen. n=3 
for each group. 
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6.4 Discussion 
 
The aim of this chapter was to establish the protein changes of ERK1/2 
signalling or HSP expression that occur during ageing in TASTPM animal 
model of AD, and also to establish any long-term protein changes following 
chronic IR1072 treatment in 7 month old TASTPM male and female mice. 
 
Table 6-6: Summary of the effects of ageing and IR1072 treatment on TASTPM mice. 
Abbreviations: AD1TL, TASTPM age timeline; ADF, sham vs IR1072 female TASTPM 
7month old mice; ADM, sham vs IR1072 male TASTPM 7 month old mice; IR, IR 1072nm; 
BDNF; Brain Derived Neurotrophic Factor; ERK1/2 or ERK1/2-P, unphosphorylated or 
phosphorylated extracellular-signal regulated kinase 1 or 2, respectively; CREB, Cyclic 
Adenosine Monophosphate (AMP) Response Element Binding; HSP, Heat Shock Protein; 
PI3, Phosphatidylinositol 3-Kinase. 
 
    
ADTL 
Effects of chronic IR on 
protein expression 
Pathways Protein 3 vs 7 3 vs 12 7 vs 12 ADF ADM 
E
R
K
1
/2
 
BDNF ↓ *↓ - *↓ *↓ 
ERK1/2 - *↓ *↓ *↑ - 
ERK1/2-P ↑ *↓ - - - 
CREB - - - ↑ **↑ 
P
I3
 AKT *↑ *↑ *↓ - - 
AKT-P - - - - - 
C
h
a
p
e
ro
n
e
s
 
HSP27    - - 
HSP40 ↓ **↓ *↓ - - 
HSP60 - - - *↑ **↓ 
HSP70 - - - - - 
HSP90 - ↓ - - ↑ 
HSP105 ↓ *↓ - *↑ - 
 
 
Increased Aβ deposition, astrocytosis, phosphorylated tau and neuronal cell 
loss are the pathological hallmarks of AD, and appear to increase in TASTPM 
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mice as they age. Immunolabelling of Aβ deposition in ageing TASTPM mice 
bred and maintained at the University of Durham confirmed previously 
published reports of Aβ plaque formation in 3 month old TASTPM mice, albeit 
few, and subsequent increases in plaque population as the mice aged. High 
density of varying sized plaques was formed in the cortex, hippocampus 
(CA1-3) and the dentate gyrus of 7 month and 12 month old TASTPM mice.  
 
An age-dependant decrease in BDNF and ERK1/2 protein expression 
occurred in TASTPM mouse brain whereby protein expression decreased as 
mice grew older. This decreased expression is likely to be caused by the high 
levels of Aβ plaques present in the older mice, as several studies show that 
even at low levels, Aβ interferes with downstream events that occur during 
various signalling cascades (Cotman, 2005; Chen et al., 2009). A reduction in 
neurotrophin levels has been shown to occur in some areas of the CNS of AD 
patients, and neurotrophic factors have begun to be used in clinical trials as 
therapeutic agents to prevent or reduce neuronal cell loss (Matrone et al., 
2008). Chen et al. (2009), showed that non-lethal application of Aβ in rat 
cortical cultures partially blocked BDNF-induced upregulation of activity-
regulated cytoskeleton-associated (Arc) protein, a protein involved in 
modulating synaptic plasticity. The Aβ blocking effect was proposed to act 
through the AKT or ERK1/2 signalling pathway, as Aβ prevented BDNF-
induced phosphorylation of eukaryotic initiation factor 4E binding protein 
(4EBP) and activation markers downstream in these pathways (Chen et al., 
2009). Tong et al. (2004) showed that low levels of Aβ in neuronal cultures 
interfered with BDNF signalling by suppressing ERK1/2 and PI3-K pathways 
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and BDNF activation of critical transcription factors, such as CREB, were 
significantly reduced, Aβ did not, however, effect basal levels of CREB or 
ERK1/2 expression in neuronal cultures. They showed that Aβ did not effect 
BDNF-induced PLCγ pathway activation or autophosphorylation of the TRKB 
receptor, indicating Aβ interferes at steps downstream of BDNF-induced 
signalling, possibly via the docking proteins that mediate signalling to ERK1/2 
and AKT pathways (Tong et al., 2004). Mok et al. (2006) showed Aβ 
treatment on vascular smooth muscle cells reduced ERK1/2-P, and Poon et 
al. (2009) showed that Aβ reduced BDNF signalling by impairing axonal 
transport. However, in contrast to these studies enhanced and prolonged 
ERK1/2-P in sporadic and familial AD fibroblasts in response to bradykinin, 
but not in age-matched controls, was shown in a study conducted by Zhao et 
al. (2002). They also report that bradykinin-induced CREB activation was no 
different between AD and age-matched controls (Zhao et al., 2002). As a 
reduction in BDNF occured, it is natural to assume that ERK1/2 expression 
may occur as BDNF stimulates the ERK signalling pathway. However this 
reduction in ERK expression did not occur in the aged CD-1 mice even 
though BDNF was reduced, so this may suggest that Aβ may be influencing 
the regulation of ERK1/2 protein expression with age in TASTPM mice. 
 
This study showed an age-dependent effect of AKT expression, whereby AKT 
expression increased from 3 months to 7 months, where levels were 
significantly reduced by the time mice reached 12 months of age. A similar 
expression pattern, however insignificant, was seen in activated AKT-P (data 
not shown). Chen et al. (2009), found that Aβ slightly increased AKT activity, 
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that was similar to the effect of the on PC12 and SH-SY5Y neuroblastoma 
cells from previous studies proposed to be caused by oxygen derived free 
radicals (Martin et al., 2001; Wei et al., 2002). Shay and Hagen (2009) found 
basal phospho-Ser473 AKT is 30% lower in aged rat hepatocytes when 
compared to young rat hepatocytes (Shay and Hagen, 2009). Activated 
caspases and accumulation of caspase cleavage products has been detected 
in postmortem AD brains, it has been suggested that once Aβ toxicity goes 
beyond a critical threshold, an apoptotic pathological cascade is initiated 
(Tong et al., 2004) Perhaps at 7 months old, the cell survival AKT pathway is 
increased in order to attempt to rescue and repair neurons from Aβ toxicity, 
but once Aβ accumulation tips the balance in favour of cell death at 12 
months old, the apoptotic caspase cascade is initiated and BDNF, ERK1/2 
and PI3K/AKT pathways are affected. 
An age-dependant decrease of HSP40 was seen in male TASTPM mice. 
Previous studies found an inverse correlation between tau and levels of HSP 
27, 40, 90 and alpha-crystallin in human AD brain samples, where it was 
proposed that HSP regulate the levels of soluble tau levels, but once the 
chaperone system has been saturated, granular tau oligomers form unabated 
and HSP levels are decreased (Sahara et al., 2007). Evans et al. (2006) 
showed the addition of HSP70/40 and HSP90 to pre-formed oligomers and 
fibrils caused structural changes in oligomers but had little effect on fibrils, 
suggesting that chaperones present in the same cellular compartment in 
which Aβ is produced, may suppress the early stages of self-assembly, but 
are not as effective once fibrils are formed, suggesting again that once the 
chaperone system is overloaded their functionality is limited. Kovacs et al. 
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(2006) demonstrated that heat shock alone was sufficient to induce PS1 
aggresome formation and HSP70 expression, where the presence of the 
heat-shock proteins HSP70 in aggresomes suggested chaperone-mediated 
transport of PS1 into the ER (Kovacs et al., 2006). They suggested 
malfunctioning of the proteasome or heat-shock stress response in the AD 
brain may lead to the accumulation of stable aggresomes of PS1, perhaps 
contributing to neurodegeneration. Although there was no significant changes 
in HSP70 expression in ageing TASTPM mice, it is well known that HSP40 
proteins have been shown to facilitate the folding of polypeptides through their 
interaction and regulation of partner HSP70 proteins (Nicoll et al., 2006), 
therefore a reduction in HSP40 seen in aging TASTPM mice may contribute 
towards malfunctioning of the HSP70 stress response. 
This study showed a significant decease in expression of HSP105 as 
TASPTM mice aged. As HSP105 has been shown to inhibit the JNK pathway, 
a decrease in HSP105 may reflect a higher amount of pro-apoptotic proteins 
being phosphorylated and therefore activated, where translocation to the 
mitochondrial membrane would result in the initiation of apoptosis and 
neuronal in these AD mouse models. 
 
IR1072 treatment appeared to show differences between male and female 
TASTPM mice. Howlett et al. (2004) investigated the differences between 
age, Aβ load and cognitive impairment in male and female TASTPM mice, 
and found that at all ages investigated, the Aβ load, in female TASTPM mice 
was greater than that in males, however there was no sex difference in the 
cognitive impairment demonstrated by TASTPM mice in the object recognition 
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task. They proposed that the Aβ deposition must reach a certain threshold 
before cognitive impairment is apparent, where the behavioural test used may 
not be sensitive enough to reveal graded impairments (Howlett et al., 2004). 
Another possibility is that the cognitive impairment may be more due to 
location of the Aβ deposits, their composition or the response of respective 
brain structures, rather than total Aβ load (Howlett et al., 2004). So differences 
in sex between male and female mice in response to IR1072 treatment may 
be due to the Aβ deposition reported previously. 
 
A reduction in BDNF expression in both female and male TASTPM mice 
following chronic IR1072 treatments was found, where ERK1/2 levels were 
increased in females however no difference in ERK levels occurred in males 
which underwent the same treatment. Previous studies have reported that 
estrogen may play a role in ERK1/2 signalling, particularly ERK1/2 protein 
expression. Svegliati-Baroni (2006) showed that biliary-digestive diversion 
determined a marked reduction of ERK1/2 phosphorylation in cholangiocytes, 
which was reversed by the administration of 17β-estradiol (Svegliati-Baroni et 
al., 2006). Thordarson et al. (2004) found that enhanced expression of 
ERK1/2 and ERK1/2-P were associated with an increase in mammary 
tumorigenesis, where expression of the estrogen receptor-α (ERα) was also 
significantly elevated (Thordarson et al., 2004). However, this study did not 
show an increase in ERK1/2-P. Although the results differ from the IR1072 
CD-1 data, BDNF expression, in both mouse stains, does not reflect the 
ERK1/2 protein expression in each respective experimental model. This could 
again suggest that IR1072 influences the function of the TRKB receptor, 
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where the differences may be dependant on the presence or absence of Aβ 
deposition. 
 
Increased CREB was shown in both female and male TASTPM mice. This 
implies that CREB activation may be increasing cell survival via the 
upregulation of Bcl-2. As with the aged CD-1 mice, the male and female 
TASTPM mice showed no alterations in phophorylated ERK1/2 signalling 
following LILT, however CREB was increased in both sexes therefore CREB 
expression may be through a mitochondria-related pathway. But again, the 
present study probed for total CREB therefore further work is needed to show 
whether active CREB is altered following LILT. 
 
An interesting clear differential response to IR was seen with HSP60. Female 
TASTPM mice showed an increase in HSP60, whereas male TASTPM mice 
showed a decrease in HSP60 expression. Previous studies have shown 
HSP60 expression were similar in skeletal muscle and liver in males and 
females except in the kidney, where HSP60 expression was twice as much in 
females compared to males (Voss et al., 2003). The brain was not 
investigated, however this difference in HSP60 expression could again be due 
to estrogen influences.  
 
Female mice treated with IR1072 showed an increase in HSP105. This 
increase in HSP105 may be inhibiting the JNK pathway and therefore 
decreasing the amount of pro-apoptotic proteins being phosphorylated and 
activated, therefore indirectly inhibiting the initiation of apoptosis. Male 
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TASTPM mice irradiated with IR1072, however, did not show any detectable 
differences in HSP105 expression. Male mice showed an increase in HSP90 
following IR1072 treatment however female mice showed no detectable 
difference in expression following irradiation. Previous studies showed that 
HSP90 was in fact present in lower levels in female hearts than in male hearts 
(Voss et al., 2003). This shows that at basal levels, there are sex differences 
in HSP90 expression, therefore IR1072 behaviour in mice may be dictated by 
hormonal differences between the sexes. Or another possibility may be that, if 
Aβ load is higher in female mice than male mice, this may be influencing the 
behaviour of IR1072 in TASTPM mice. 
 
TASTPM mice showed a decrease in Aβ1-40/42 expression following IR1072 
irradiation. Immunohistochemical analysis confirmed Aβ1-42 and Aβ1-40/42 are 
present in both female and male 7 month old mice (Figure 6-33 and 6-36, 
respectively). The plaques were divided in to classes dependent on size: 
small (<5μm), medium (5-20μm) and large (>20μm), and quantified by an 
individual impartial to this investigation. Data showed that the total number of 
Aβ1-40/42 plaques present in the cortex of AD male mice was decreased 
following chronic IR1072 irradiation, where it was shown that the number of 
small plaques present was particularly decreased. The dentate gyrus also 
showed a trend for decreased expression following IR1072 irradiation. A trend 
for decreased formation of medium sized Aβ1-40/42 and Aβ1-42 plaques in the 
CA1 region of the hippocampus has been shown in male mice following 
irradiation. A significant decrease of small sized Aβ1-40/42 plaques was shown 
in the dentate gyrus of female TASTPM mice chronically treated with IR1072 
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irradiation. However an increase in Aβ1-40/42 plaques, particularly small 
plaques, was shown following IR1072 irradiation. IR1072 irradiation appeared 
to reduce small Aβ1-42 plaques located in the cortex of female TASTPM mice. 
The total number of small Aβ1-42 plaques in all brain regions was significantly 
reduced following in female TASTPM mice chronically treated with IR1072. 
This significant decrease in Aβ plaques in both male and female TASTPM 
mice, confirmed by both immunoblotting and immunohistochemistry, could be 
an extremely important and significant finding in relation to IR1072 irradiation, 
suggesting a potential non-invasive and non-pharmacological therapy for AD. 
Very little or no plaques are presented in the cerebellum or caudate putamen. 
Total Aβ1-42 and Aβ1-40/42 load appeared to remain the same for both male and 
female IR1072-treated mice and age-matched sham controls.  
 
A signal was never accomplished with HSP27 for male TASTPM mice or Aβ 
for female TASTPM IR1072 treated mice, despite attempts using varying 
protocols, but due to time constraints and limited antibody availability this was 
never achieved, therefore further investigations in to whether this is a sex-
dependant effect are warranted. 
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Chapter 7: Overall Discussion and Future Work 
 
 
The aim of this project was to determine whether LED IR1072 LILT has any 
neuroprotective effects in pure neuronal cultures (in vitro) and behavioural or 
molecular beneficial effects in ageing CD-1 and TASTPM mice (in vivo). 
Some of the approaches to address these objectives are detailed in figure 7-
1. 
 
Figure 7-1: Primary aims to establish the effect of IR1072 on in vitro and in vivo systems. 
Blue boxes represents in vitro treatment and yellow boxes represent in vivo treatment. 
Abbreviations: ERK1/2, Extracellular Signal-regulated Kinase 1 or 2; HSP, Heat Shock 
Protein; AMPA, α-amino-3-hydro-5-methyl-4-isoxazole Proprionate. 
 
Previous results showed IR1072 treated human lymphocytes had the highest 
cell viability compared to viability following irradiation with other wavelengths, 
where IR1072 was also shown to partially protect human lymphocytes from 
UVA toxicity (Bradford et al., 2005), which led to the question "does IR1072 
have beneficial effects in other cell types"? Investigations into cell viability 
following excitotoxicity in sham or IR1072-treated pure neuronal cultures 
proved a insult-dependant protection of IR1072. As described earlier, the 
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proposed mechanism of LILT is primary acceptance of light in the red to near-
IR region is through photoacceptors located in the mitochondrion, namely 
cytochrome c oxidase. Through respiratory assays conducted in this study, it 
was shown that acute in vivo irradiation of IR1072 in CD-1 mice appears to 
increase respiration of the ETC via the complex II enzyme in the brain and 
liver, as well as having beneficial effects via signalling molecules in young 
CD-1 brain. This confirmed previous findings of increased mitochondrial 
respiration following LILT (Alexandratou et al., 2002; Zhang et al., 2009) 
which guided the project to determine the protective effects of IR1072 on 
signalling pathways related to mitochondrial retrograde signalling on naturally 
occurring toxic events that takes place during the ageing process. Some key 
proteins involved in LILT-related signalling processes, detailed in figure 7-2, 
were investigated in this study.  
 
The key findings in ageing CD-1 and TASTPM mice in the presence or 
absence of IR1072 are detailed in figures 7-3 and 7-4, respectively.  
 
Ageing CD-1 mice showed a reduction in BDNF, HSP27 and HSP90. This 
correlates with previous studies showing decreases in these key signalling 
molecules and has been assumed to be due to cells losing the capacity to 
activate transcriptional pathways leading to HSP and/or growth factor 
synthesis. In the presence of IR1072, ageing CD-1 mice showed an increase 
in BDNF, several HSP i.e. 27, 40 and 60, cell survival proteins AKT and 
CREB, despite a decrease in ERK1/2 signalling, where a reduction in AMPA 
receptors was also shown. Ageing TASTPM mice showed a decrease in 
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BDNF, ERK1/2, AKT, and several HSP i.e. 40, 90, and 105. In the presence 
of IR1072 during ageing, an increase in ERK1/2, AKT and CREB was shown, 
despite decreases in BDNF, and several HSP i.e. HSP60, 90 and 105 were 
induced. These results suggest that IR1072 treatment may be working with 
reparation mechanisms of the cell in order to restore homeostasis for optimal 
cellular function.  
 
 
Figure 7-2: Overall signalling pathways aimed to study in this investigation. Abbreviations: 
BDNF, Brain Deived Neurotrophic Factor; MEK, MAPK/ERK Kinase; ERK1/2, Extracellular 
Signal-regulated Kinase; Rsk90, 90kDa Ribosomal Protein S6 Kinases; CREB, Cyclic 
Adenosine Monophosphate (AMP) Response Element Binding; Bcl-2, B-cell Lymphoma 2; 
BAD, Bcl-2 Associated Death Factor; P, Phosphate; DNA, Deoxyribonucleic Acid AKT, 
Protein Kinase B; TRKs, Tyrosine Kinase Receptors; PI3K, Phosphatidylinositol 3-Kinase; 
BAD, Bcl-2-associated Death Promoter; TNF, Tumour Necrosis Factor; TNFR1 or 2, Tumour 
Necrosis Factor 1 or 2; JNK, c-Jun N-terminal Kinase; BIM/jBID, BH3-only proteins; 
BAX/BAK/BOK/tBID, Bcl-2 family pro-apoptotic proteins; SMAC, Second Mitochondrial-
derived Activator of Caspases; Cyto c; cytochome c; AIF, Apoptosis Inducing Factor; HSP, 
Heat Shock Protein; AMPA, α-amino-3-hydro-5-methyl-4-isoxazole Proprionate; P, 
phosphate. 
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Figure 7-3: Summary of molecular effects of ageing in CD-1 mice in the presence or absence 
of IR1072 irradiation, where blue highlights represent decrease in protein expression and pink 
represents increases in protein expression, where green represents increased acitivity. 
Dashed lines represent translocation. Abbreviations: as described in figure 7-2. 
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Figure 7-4: Summary of molecular effects of ageing in TASTPM mice in the presence or 
absence of IR1072 irradiation, where blue highlights represent decrease in protein expression 
and pink represents increases in protein expression. Dashed lines represent translocation. 
Abbreviations: as described in figure 7-2. 
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It is important to note that ageing TASTPM have increased Aβ deposition and 
increased neuronal loss compared to ageing CD-1 mice, which may go some 
way to explaining the differences in protein changes that have occurred in 
these mouse models following chronic IR1072 irradiation. 
 
It has been reported that during LILT excitation of electronic states, a fraction 
of the excitation energy is converted to heat, which causes a local increase in 
the temperature of the absorbing chromophores (Karu et al., 1995). This local 
rise in temperature may contribute to the induction of HSP and other 
molecules seen following IR1072 irradiation, however bare in mind that this 
local transient heating of absorbing molecules is not the same as average 
heating of the whole cell, which does not occur during the doses and 
intensities used in this study (Karu et al., 1995). 
 
Several studies have shown a rise in reactive oxygen species following LILT 
in cellular systems, some of which include cardiac and sperm cells with a 400-
500nm halogen lamp (Eichler et al., 2005) and in bacteria using 400-800 
white light (Lipovsky et al., 2008). Alexandratou et al. (2002) irradiated human 
foetal foreskin fibroblasts with 670nm laser and, by using specific fluorescent 
vital probes, observed a alkalinization of the cytosolic pH, an increase in 
mitochondrial membrane potential, generation of ROS and recurrent spikes of 
intracellular calcium concentration, where non-irradiated cells produced no 
such changes (Alexandratou et al., 2002). This may be an important find in 
explaining the mechanistic nature of LILT and the effects shown in this study. 
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A proposed mechanism of how IR1072 may be having an effect on certain cell 
types has been proposed (see figure 7-5). 
 
In most cell types, mitochondria appear to represent one of the major sources 
of generation of free radicals or ROS (Duchen, 2004). Complex I and 
cytochrome c oxidase of the mitochondrial ETC are the two major contributors 
to ROS production in the cell, where nitric oxide is produced in the cell by 
nitric oxide synthase (NOS) located in the inner mitochondrial membrane 
(Brookes et al., 2002).  
 
 
 
Figure 7-5: Possible mechanism of LILT. Abbreviations: LILT, Low Intensity Light Therapy; 
NO, Nitric Oxide; ATP, Adenosine Triphosphate; ROS, Reactive Oxygen Species; CAMKII, 
Calcium/calmodulin-dependent Protein Kinase II, DNA, Deoxyribonucleic Acid (Figure based 
on Huang et al., 2009). 
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Although ROS and NO are generally considered to have destructive effects, 
when present at low, physiologically relevant concentrations, they can also 
participate in initiation of redox signalling events that regulate a variety of 
molecular mechanisms, including stimulation of tyrosine residue 
phosphorylation of membrane receptors and thereby triggering cell signalling 
cascades (Salvi et al., 2005). Photosensitized generation of ROS in the 
cytoplasm of some cells induces a free-radical activation of synthesis of 
proteins, the most significant being the de novo synthesis of inducible NO-
synthase (iNOS), superoxide dismutase, and various cytokines (Vladimirov Iu 
et al., 2004). ROS can induce several redox-sensitive transcription factors, 
which in turn activates transcription of gene products involved in 
cytoprotection (Huang et al., 2009).  
 
In addition to demonstrating IR1072 being most beneficial in human 
lymphocytes, Bradford et al. (2005) showed a significant increase in iNOS 
expression following IR1072 treatment in human lymphocytes, where nitric 
oxide is a potent inhibitor of apoptosis. The up-regulation of NO in several 
reports for various wavelengths and tissue types have been confirmed, 
including endothelial and sperm cells (Ankri et al., 2009) in cardiomyocytes 
(Zhang et al., 2009) monocytes/macrophages (Novoselova et al., 2006; 
Gavish et al., 2008) and skin tissue (Glushkov et al., 2006). suggesting LILT 
may act through NO mechanisms involving the inactivation or inhibition of 
caspase-3-like protease enzyme, a key enzyme regulating apoptotic 
programmed cell death. 
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As discussed previously, a rise in ATP following LILT has been repeatedly 
reported and has been suggested to be induced in order to power metabolic 
processes such as synthesising DNA, RNA, proteins, enzymes, and other 
biological materials needed to repair or regenerate cell and tissue 
components to restore homeostasis (Enwemeka, 2004). The perinuclear 
localization of the mitochondria following LILT has been shown, which has 
been suggested to facilitate ATP access to repairing damaged nuclear 
components (Hallmann et al., 2004; Pires Oliveira et al., 2008). LILT has been 
reported to cause cAMP elevation, presumably due to increased ATP 
production following LILT, which may contribute to inducing activator protein-1 
(AP-1) activity and therefore activating transcription factors, in turn stimulating 
both DNA and RNA synthesis (Karu, 1987; Gao and Xing, 2009). This could 
be related to the changes in protein expression shown following IR1072 
treatment. 
 
Intracellular stores of Ca2+ in the mitochondrion and endoplasmic reticulum 
are thought to be regulated by multiple cellular components including ATP, 
H+, Ca2+, protein kinases, ROS and NO species (Hidalgo, 2005). Intracellular 
increases in Ca2+ can be mediated through extracellular influx (NMDA 
receptors) as well as intracellular stores (Ryanodine receptors, MPTP). 
Alexandratou (2002) suggested that their findings of intracellular spikes of 
Ca2+ following LILT may be due to the opening of the mitochondria 
permeability transition pore (MPTP) and suggested that LILT operates the 
MPTP in the low conductance state. MPTP is a channel of the inner 
mitochondrial membrane that appears to operate two distinct pathways: 1) 
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Ca2+ signalling during the lifespan of the cell (low conductance state) and 2) 
the effector signal of the apoptotic cascade during Ca2+ dependent cell death 
(high conductance state; Alexandratou et al., 2002). During the low 
conductance state, the diffusion of small ions such as Ca2+ ions is pH-
controlled, promoting spontaneous closure of the channel, whereas high 
conductance, promotes the unselective diffusion of big molecules into the 
mitochondrial matrix which in turn disrupts the mitochondrial structure and 
causes the release of cytochrome c thus initiating apoptosis (Alexandratou et 
al., 2002). Increases in intracellular Ca2+ can initiate and modulate different 
cellular events including short-term responses, such as muscle contraction 
and secretion, as well as long-term responses including cell growth and 
proliferation and the expression of genes required for memory acquisition and 
learning (Hidalgo, 2005). The increased calcium concentration activates key 
enzymes such as CaMKII, which eventually results in the modulation of AMPA 
receptors (Manabe, 2008). Calcium signalling has been implicated in the 
initiation of signalling cascades required for LTP, including ERK1/2, so if a 
change in intracellular Ca2+ has occurred following IR1072, this may 
contribute to the protein changes shown in this study.  
 
Current influx through AMPA receptors provides the depolarizing drive to 
open NMDA receptors for extracellular Ca2+ influx, and the amplitudes of 
synaptic potentials are generally thought to reflect the number of AMPA 
receptors at each synapse, where AMPA receptors are regulated by protein 
kinases and phosphatases (Carvalho et al., 2000; Bloodgood and Sabatini, 
2008), therefore the decreased AMPA receptor expression shown in this 
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study may reflect a decrease in synaptic potentials in IR1072 treated CD-1 
mice. As discussed previously, calcium excitotoxicity has been implicated as a 
major player in neuronal loss which takes place during ageing and 
neurodegenerative diseases. If IR1072 does work by restoring homeostasis to 
the cellular environment, this indirect or direct reduction in AMPA receptors 
may restore the cellular levels of intracellular Ca2+ to resting concentrations. 
Investigations into the mechanisms towards IR1072-AMPAR reduction are 
warranted. 
 
As described previously, a proton leak or uncoupling of the ETC as ageing 
occurs could lead to an increased production of ROS. This excessive ROS 
production, and therefore free radical species, may damage the nuclear DNA 
and therefore contribute to the inability of the ageing cell to transcribe 
important signalling factors involved in cell survival. In light of these results, it 
may be appropriate to suggest that varying amounts of ATP, ROS, Ca2+ and 
NO produced during various wavelength and treatment protocols in differing in 
vitro e.g. neuronal cultures, lymphocytes, and in vivo e.g. CD-1 mice, 
TASTPM mice, are determinants of the effect of LILT treatment. Future 
experiments should include a protocol for ROS, ATP, Ca2+ and NO generation 
following IR1072 treatments in order to determine a baseline of these 
products, as they are emerging as key regulators involved in LILT-induced cell 
signalling. This may help towards proposal of a mechanism for the beneficial 
effects reported following LILT treatment. 
 
 
  244 
7.1 Future work and direction 
 
Investigations into varying the frequencies of IR1072 treatments in 
chronic protocols: As this study employed a chronic in vivo IR1072 protocol 
not previously tested, it would be interesting to see whether varying 
frequencies of treatment would elicit differing effects i.e. weekly treatments, 
daily treatments. Also, if IR1072 treatments were carried out until the last day 
of behavioural experiments, short-term and long-term protein changes would 
have been observed, so this change in protocol would be beneficial in future 
experiments. 
 
Investigations in to mitochondrial photoacceptors: There is much 
published data stating that red to near-IR light at wavelengths 600-850nm is 
primarily accepted through the ETC chain in mitochondria, however there is 
very little evidence establishing the photoacceptor for IR light acceptance at 
1072nm. Extensive experiments in to the primary photoacceptor of IR1072 
are warranted, in order to achieve a basis to the mechanistic nature of LILT. 
 
Extensive investigations in to the signalling pathways and related 
receptors: Further studies into the signalling pathways, proteins and 
receptors described in this study are required, particularly into the TRKB 
receptor as BDNF expression and ERK1/2 expression do not reflect one 
another in both animal models used, suggesting the TRKB receptor may be 
altered following LILT. Also, stress pathways and anti- or pro-apoptotic 
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proteins should be investigated to get an overall picture of how IR1072 in 
influencing cellular function. 
 
ROS/NO/ATP/Ca2+ basal levels: As stated previously, basal levels of these 
ROS/NO/ATP/Ca2+ should be established as these components have been 
repeatedly reported to be increased following LILT, therefore high or low basal 
levels in differing mouse models, or parameters within a mouse model i.e. age 
or gender, may determine the therapeutic output of IR1072.  
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